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1-	ABSTRACT		
High-grade	 sarcomas	 are	 a	 heterogeneous	 group	 of	 aggressive	 tumors	 arising	 in	 bone	 and	 soft	
tissues.	They	are	usually	 treated	with	surgery	combined	 in	some	cases	with	chemotherapy.	Drugs	
active	 in	 osteosarcoma	 include	 adriamycin	 (ADM),	 cisplatin	 (CDDP),	 ifosfamide	 (IFO)	 and	
methotrexate	(MTX),	while	ADM	and	IFO	represent	standard	chemotherapy	for	synovial	sarcomas.	
The	survival	of	sarcomas	has	minimally	improved	in	the	past	decades,	and	after	relapse	treatment	
options	are	limited.		
Tumors	 grow	 within	 an	 intricate	 network	 of	 epithelial	 cells,	 vascular	 and	 lymphatic	 vessels,	
cytokines,	 chemokines	 and	 infiltrating	 immune	 cells.	 T-	 lymphocyte	 and	 antigen-presenting	 cells	
(APCs)	interactions	are	bi-directional	and	mediated	by	ligands	such	as	programmed	cell	death	ligand	
1	 (PD-L1)	 on	 APCs	 and	 PD1	 on	 lymphocytes.	 PD-L1	 is	 expressed	 also	 by	 several	 tumors.	 PD-1	
inhibitors	 such	as	pembrolizumab	or	nivolumab	have	been	approved	 for	many	 tumors	and	PD-L1	
expression	on	 tumoral	 cells	 has	been	associated	with	 response	 in	 some	of	 the	 studies.	However,	
few	data	on	the	prognostic	and	predictive	role	of	infiltrating	immune	cells	and	PD-1/PD-L1	system	in	
sarcoma	are	available.		
Stromal	cells	present	in	the	tumor	microenvironment	express	high	levels	of	CXCL12	protein,	directly	
stimulating	proliferation	and	migration	of	CXCR4-expressing	cancer	cells.	CXCR4/CXCL12	signalling	
therefore	is	an	attractive	therapeutic	target	in	cancer,	since	CXCR4	inhibition	might	sensitize	cancer	
cells	to	conventional	chemotherapy.		
Finally,	 another	 key	 element	 of	 the	 tumor	 microenvironment	 involves	 its	 vasculature.	 Tumor	
angiogenesis	 is	 related	 to	 suppression	 of	 T	 cell-mediated	 tumor	 rejection.	 There	 are	 numerous	
examples	that	demonstrate	a	simultaneous	activation	of	angiogenesis	and	immunosuppression.	The	
overall	 goal	 of	 this	 project	 is	 to	 characterize	 the	 osteosarcoma	 and	 synovial	 sarcoma	 tumor	
		 8	
microenvironment,	to	assess	how	the	infiltrating	immune	cells	can	affect	the	prognosis	of	patients	
and	to	assess	the	activity	of	immune	modulating	(anti-PD-1),	migration	inhibitors	(anti-CXCR4)	and	
antiangiogenetic	(anti-VEGFRs,	anti-PDGFRs)	compounds	in	an	in	vitro	sarcoma	model.	
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2-	INTRODUCTION	
	
2.1	-	Sarcomas	
Sarcomas	are	a	heterogeneous	group	of	mesenchymal	neoplasmas	 that	 can	be	grouped	 into	 two	
general	 types,	 primary	 bone	 sarcoma	 and	 soft	 tissue	 sarcoma.	 Most	 frequent	 primary	 bone	
sarcomas	 include	 osteosarcoma,	 Ewing	 sarcoma	 and	 chondrosarcoma;	most	 frequent	 soft	 tissue	
sarcomas	include	synovial	sarcoma,	liposarcoma,	leiomyosarcoma,	and	angiosarcoma.	The	survival	
rate	 of	 sarcoma	patients	 increased	with	 the	 emergence	of	 effective	 chemotherapy	 regimens	 and	
the	 development	 of	 surgical	 techniques.	 However,	 metastasis	 still	 occurs	 in	 20%-55%	 of	 these	
patients,	and	it	remains	the	main	cause	of	death.	Efforts	have	been	made	in	the	last	twenty	years	to	
improve	survival	outcomes	of	sarcoma	patients,	but	changes	of	the	chemotherapy	drugs,	the	doses	
and	 the	 administration	 schemes	 did	 not	 significantly	 improve	 prognosis	 (1).	 Advanced	 treatment	
methods	 are	 urgently	 needed.	 Identification	 of	 effective	 prognostic	 factors	 is	 important	 to	 get	 a	
better	 understanding	 of	 the	 pathogenesis	 of	 bone	 and	 soft	 tissue	 sarcoma,	 and	 to	 develop	 new	
effective	treatment	methods.		
2.1.1	-	Osteosarcoma	
Osteosarcoma	is	a	high-grade	malignant	tumor	composed	of	mesenchymal	cells	producing	osteoid	
and	immature	bone.	
Almost	 constantly	 intramedullary,	 rarely	 it	may	originate	at	 the	bony	 surface.	Osteosarcoma	may	
sometimes	 presents	 with	 skip	 or	 more	 distant	 skeletal	 metastases,	 but	 it	 can	 be	 also	 skeletally	
multifocal	 at	 presentation.	 There	 are,	 consequently,	 several	 varieties	 of	 osteosarcoma	 whose	
anatomo-clinical	 presentation,	 treatment	 and	 prognosis,	 however,	 are	 not	 as	 distinctive	 as	 to	
		 10	
justify	a	separate	classification.	Other	low	grade	osteosarcoma	types,	instead,	are	different	in	their	
clinical,	 pathologic	 and	 therapeutic-prognostic	 features,	 and	 are	 classified	 as	 separate	 entities	
(periosteal	OS,	parosteal	OS,	low-grade	central	OS)(Table	1,	Figure	1)	(2,3).	
Table	1.	Varieties	and	their	prevalence	on	100	cases	
High	Grade	osteosarcoma	(OS	)	varieties	 ~90	%	
§ Classic	Osteosarcoma	 75	
§ Teleangiectatic	OS	 6/7	
§ OS	of	jaw	bones	 4	
§ Secondary	OS	 4	
§ Small	cell	OS	 <1	
§ OS	of	bone	surface	 ½	
§ Multifocal	OS	 0.5	
§ Intracortical	OS	 0.05	
Low	Grade	OS	varieties	 ~10	%	
§ Parosteal	 5	
§ Central	 2.5	
§ Periosteal	 1.5	
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Figure	1.	The	Istituto	Ortopedico	Rizzoli	series:	varieties	and	their	prevalence	on	100	cases	
	
Epidemiology:	 High-grade	 osteosarcoma	 is	 the	most	 frequent	 primary	malignant	 tumor	 of	 bone,	
excluding	myeloma.	Its	prevalence	is	of	2-3	cases/million/year	(only	0.2%	of	all	malignancies).	Males	
are	more	commonly	affected	(1.5-2:1).	Most	cases	occur	between	10	and	20	years	of	age	(Figure	2).	
Older	 patients	 are	 usually	 diagnosed	with	 osteosarcoma	 secondary	 to	 radiation,	 Paget	 disease	 of	
bone,	or	develop	chondrosarcomas	or	other	primary	bone	tumors	(2).	
Localization:	70%	of	osteosarcomas	are	localized	around	the	knee	or	shoulder.	Other	locations	are	
proximal	or	mid-femur,	 ilium,	mid	and	distal	 tibia,	proximal	 fibula,	 spine,	 and	exceptionally	 in	 the	
hand	and	foot.	Osteosarcoma	usually	grows	in	the	metaphysis	or	meta-diaphysis	but	tends	to	invade	
the	epiphysis	even	in	presence	of	a	growth	plate	(2).	
Clinical:	Pain	 is	usually	 the	first	symptom,	often	referred	to	trauma.	 In	 few	weeks	 it	 increases	and	
painful	swelling	appears.	High	temperature	and	limited	joint	motion	are	advanced	signs.	Pathologic	
fracture	may	occur	in	osteolytic	forms.	Alkaline	phosphatase	is	frequently	elevated.	Less	frequently,	
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also	LDH	may	be	increased	(2).	
Figure	2.	Gender,	site	and	age	distribution	of	osteosarcoma	(1)	
	
Imaging:	 The	 plain	 x-ray	 is	 usually	 diagnostic.	 Typically,	 osteosarcoma	 starts	 intra-medullary,	 but	
breaches	the	cortex	and	expands	in	the	soft	tissues.	It	is	usually	a	combination	of	radiolucency	and	
radiodensity,	sometimes	it	is	entirely	eburneous	with	edges	always	faded.	The	pure	osteolytic	form	
is	 typical	of	 the	 teleangiectatic	variety.	The	 tumor	soft	 tissue	extension	shows	 irregular,	 cloud-like	
radiodensities,	and/or	stripes	of	density	perpendicular	to	the	cortex	(sunray	image).	Occasionally,	it	
is	 purely	 radiolucent	 and	 it	 can	be	appreciated	only	by	CT	and	MRI.	At	 the	periphery	of	 the	area	
where	the	tumor	breaches	the	cortex,	a	triangular	buttress	of	immature	bone	(Codman’s	triangle)	is	
seen.	 This	 is	 due	 to	 reactive	 bone	 acutely	 produced	 by	 the	 periosteum.	 Isotope	 bone	 scan	 is	
intensely	hot	even	beyond	the	radiographic	limits	of	the	tumor.	Rarely,	it	may	reveal	skips	or	distant	
bone	 metastases.	 CT	 demonstrates	 intraosseous	 and	 extraosseous	 extension	 of	 the	 tumor	 and	
		 13	
intratumoral	radiodensities.	With	MRI,	most	osteosarcomas	exhibit	the	usual	pattern	of	low	T1,	and	
high	T2	signal.	MRI	is	the	best	way	to	determine	medullary	tumor	borders,	epiphyseal	invasion,	skip	
metastases.	 Contrasted	 CT	 and	 MRI	 show	 the	 relationship	 with	 vessels,	 but	 in	 some	 cases,	 an	
angiogram	may	be	more	reliable	(Figure	3).	Patient	work-up	always	includes	CT	of	the	lungs	where	
metastases	may	appear	as	radiodense	round	nodules	(2,3).	
	
Figure	3.	Radiograph,	CT	and	coronal	T1W	MR	image	showing	an	high	grade	osteosarcoma	of	the	
distal	femur.	
	
	
	
	
	
	
	
	
Histopathology:	Osteosarcoma	is	fleshy-soft	in	cellular	areas	with	little	matrix,	firm	and	rubbery	in	
fibroblastic	areas	with	collagen	production,	gritty	to	stone-hard	in	osteogenic	areas,	cartilaginous	to	
myxoid	 in	chondroblastic	areas	 (2,	4-6).	Hemorrhage,	necrosis	and	cystic	alterations	are	common.	
The	 most	 relevant	 diagnostic	 feature	 is	 constant	 permeation	 of	 marrow	 spaces,	 trapping	 host	
trabecular	bone	along	 its	margins,	predominantly.	Cortex	 is	also	permeated	and	usually	breached.	
	
	
	
The	 tumor	 is	 metaphyseal,	 heterogeneous,	 forms	 bone,	 destroys	 part	 of	 the	 cortex,	 and	
invades	soft	tissues.	A	skip	metastasis	in	detected	on	MR	in	the	medullary	cavity.	
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An	endosteal	 and	periosteal	production	of	 reactive	bone	 is	 associated.	Osteosarcoma	may	 invade	
the	 joint	 capsule	 and	 ligaments.	 Rarely,	 osteosarcoma	plugs	 are	 found	 in	 the	 adjacent	 veins.	 Skip	
metastases,	usually	in	the	same	but	also	in	the	adjacent	cross-joint	bone	may	be	detected	in	a	small	
percentage	of	cases.		
Microscopically,	osteosarcoma	has	a	wide	range	of	histological	presentations,	but	the	characterizing	
feature	 is	represented	by	high-grade	sarcomatous	cells	producing	osteoid	and	woven	bone	(Figure	
4).	The	less	osteogenic	areas	of	the	tumor	(usually	the	periphery)	are	highly	cellular	and	show	more	
clear-cut	features	of	high-grade	malignancy	as	compared	to	more	osteoid	or	bone	rich	central	areas	
of	 the	 tumor.	 Cells	 are	 large,	 with	 striking	 pleomorphism,	 hyperchromia,	 prominent	 nucleoli,	
frequent	 atypical	 mitoses,	 although	 some	 10%	 of	 cases	 may	 show	 little	 anaplasia	 and	 lead	 to	
confusion	with	benign	entities	 such	 as	 osteoblastoma,	 chondroblastoma,	 giant	 cell	 tumors,	 and	 a	
few	others.	Tumor	osseous	matrix	varies	from	slender	lace-like	seams	of	osteoid	to	islands	or	dense	
sheets	of	woven	bone.	No	regular	trabeculae	rimmed	by	osteoblasts	are	produced	by	osteosarcoma	
cells.	Where	osteosarcoma	 is	 intensely	 sclerotic,	 cells	 are	 scarce,	 small,	with	no	mitoses;	 tissue	 is	
scarcely	 vascular	 and	may	be	necrotic.	 In	 these	areas,	 features	of	malignancy	may	be	absent	and	
diagnosis	of	OS	is	suggested	by	the	permeative	pattern	of	the	tumor.	Occasionally,	osteosarcoma	is	
extensively	 fibro-histiocytic	 (identical	 to	 a	 UPS),	 or	 chondroblastic	 (as	 a	 high-grade	
chondrosarcoma),	or	fibroblastic	(similar	to	a	fibrosarcoma).	The	osteoid-osseous	production,	which	
identifies	 the	osteosarcoma,	may	be	 found	only	 in	 the	microscopic	 study	of	 the	 entire	 specimen.	
Reactive	giant	cells	are	seen,	particularly	in	areas	of	hemorrhage.	Particularly	at	the	periphery	of	the	
tumor	 reactive	 osteogenesis	 associates	 and	 should	 not	 be	 confused	with	 tumorous	 osteogenesis.	
Histochemical	stains	show	a	high	content	of	alkaline	phosphatase	in	osteosarcoma	cells.	Ploidy	study	
indicates	that	most	of	osteosarcoma	are	aneuploid,	although	a	few	cases	may	be	diploid.	
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Figure	4.	High	grade	osteosarcoma	histology	
	
Sarcomatous	tissue	with	cells	producing	osteoid	and	bone.	
1- Sarcomatous	 tissue.	 The	 aspects	 of	 the	 high-grade	 malignancy	 are	 fairly	 evident:	 large,	
pleomorphic	and	hyperchromic	cells	are	seen.	
2- Neoplastic	osteoid	and	osseous	material,	 shaped	with	an	absolutely	anarchical	 architecture.	 It	 is	
nearly	impossible	to	find	trabeculae	bordered	by	a	regular	row	of	osteoblasts.	
3- Abundant	blood	 vessels.	 They	do	not	have	 their	 own	well-formed	and	 continuous	wall.	 In	 some	
areas,	vessels	are	directly	walled	by	sarcomatous	cells.		
	
	
Clinical	 Course	 and	 Staging:	 Osteosarcoma	 has	 a	 rapid	 course	 (2,	 7-12).	 At	 presentation,	 80%	 of	
patients	with	osteosarcoma	are	stage	 II-B;	only	5%	are	stage	 II-A.	About	15%	of	osteosarcoma	are	
stage	III.	 In	the	era	before	chemotherapy,	80	to	90%	of	osteosarcoma	patients	died	of	metastases,	
notwithstanding	ablation	of	the	primary	tumor.	Thus,	 it	can	be	said	that	 in	80-90%	of	cases	occult	
micrometastases	are	present	at	diagnosis.	Metastatic	spread	occurs	primarily	to	the	lungs.		
Treatment:	Treatment	of	osteosarcoma	is	based	on	chemotherapy	and	surgery	of	both	the	primary	
1 
3 
2 
2
1 
1
1 
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tumor	and	the	metastases.	Postoperative	chemotherapy	(adjuvant)	started	in	1971,	pre-	and	postop	
chemotherapy	(neoadjuvant)	was	introduced	in	1978.	Presently,	most	effective	drugs	are	Adriamycin	
(ADM),	high	dose	Methotrexate	(HDMTX),	Cisplatinum	(CDDP),	and	Ifosfamide	(IFO).	Based	on	post-
induction	 chemotherapy	 staging	 study,	 surgery	 is	 performed.	 The	 entire	 tumor	 is	 sampled	
histologically	and	examined	to	quantify	tumor	necrosis.	Good	response	is	indicated	by	necrosis	from	
90	to	100%.	Postop	chemotherapy	is	continued,	starting	1-2	weeks	after	surgery,	and	lasting	from	4	
to	6	months.	Usually,	the	same	drugs	as	used	preoperatively	are	given	in	good	responders.	In	poor	
responders,	different	drugs	are	administered	or	added	in	more	prolonged	trials.	For	the	treatment	
of	metastastic	 disease	 surgery	 and	high-dose	 ifosfamide	 or	 gemcitabine	 and	 taxotere	 have	 been	
used	 (7,8).	 In	 second	 line	 setting,	prospective	 trials	with	agents	 such	as	pemetrexed	or	 sorafenib	
and	 sorafenib/everolimus	 have	 shown	modest	 activity	 in	 osteosarcoma,	 but	 none	 were	 deemed	
worthy	of	further	development	(9-11).		
Prognosis:	 Without	 chemotherapy,	 the	 10-year	 survival	 rate	 is	 10	 to	 15%.	 With	 current	
chemotherapy	 the	 10-year	 survival	 rate	 has	 improved	 to	 about	 70%,	 for	 osteosarcoma	 non-
metastatic	at	presentation	and	involving	the	appendicular	skeleton	(2,12).	Also,	local	recurrence	rate	
after	 conservative	 surgery	 is	 is	 around	 5%	 after	 conservative	 surgery.	 Metastases	 (mainly	 to	 the	
lungs)	usually	occur	 in	the	first	2-3	years.	There	are,	however,	rare	cases	of	metsastases	occurring	
even	5	to	10	years	after	treatment.	The	second	most	frequent	site	for	metastases	is	the	skeleton	(2).	
2.1.2-	Synovial	sarcoma	
Synovial	sarcoma	is	a	malignant	tumor	whose	cells	were	once	thought	to	arise	from	synovium,	but	
their	occurrence	independent	of	any	joint	and	their	immunohistochemical	pattern	speak	to	a	tumor	
that	has	no	relationship	to	synovium	(2).		
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Epidemiology:	5-10%	of	all	sarcomas	of	soft	tissues.	Males.	15-40	years	old	(Figure	1)	(2).	
Figure	1.	Gender,	site	and	age	distribution	of	synovial	sarcoma	(ref	2)	
	
Location:	80%	extremities.	Lower	limb	(60%	-	thigh,	knee,	foot,	ankle),	upper	limb	(23%	-	forearm,	
wrist,	 shoulder).	 Only	 10%	 within	 a	 joint.	 Usually,	 close	 to	 a	 major	 joint,	 intimately	 related	 to	
tendons,	tendon	sheaths,	bursae,	beyond	the	confines	of	the	joint	capsule.		
Clinical:	 A	 palpable	 deep-seated	 mass,	 often	 with	 pain.	 Pain	 may	 be	 the	 first	 symptom	 of	 the	
disease.	 Tumor	 grows	 slowly	 and	 insiduously	 and	 the	 duration	 of	 symptoms	 ranges	 from	 2	 to	 4	
years,	although	in	some	cases	they	have	been	noted	for	as	long	as	20	years.		
Imaging:	 On	 x-ray,	 a	 round	 or	 oval,	 lobulated	 swelling	 of	 moderate	 density	 near	 a	 joint	 is	 seen.	
Usually,	bone	is	uninvolved.	Periosteal	reaction,	bone	erosion	or	bone	invasion	is	seen	in	a	minority	
of	 patients	 (15-20%).	 Multiple,	 small	 and	 spotty	 calcifications,	 or	 cloudy	 and	 faded	 shadow	 or	
massive	 and	 dense	 radiopacities	 of	 bone	 formation	 (40%).	 Radiopacities	 are	 more	
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frequent	in	the	periphery.	On	angiography,	tumors	are	richly	hypervascularized.	On	CT,	an	infiltrating	
soft	 tissue	mass	 is	 seen,	with	 slightly	higher	density	 than	muscle,	markedly	enhanced,	with	easily	
detected	calcifications,	cortical	erosion,	joint	invasion	when	tendons	or	ligaments	are	involved.		On	
MRI	–	tumors	are	nearly	always	(90%)	hypointense	on	T1,	hyperintense	on	T2,	less	commonly	with	
fluid	 levels	 (15%).	 Marked	 inhomogeneity,	 enhancement	 and	 septation	 are	 seen	 on	 T2.	 A	 triple	
signal	pattern	on	T2	 (30%):	white-like	 fluid,	 gray-like	 fat,	dark-like	 fibrous	 tissue.	 Small	high	 signal	
areas	 on	 T1	 (45%)	 are	 foci	 of	 hemorrhage.	 This	 and	 the	 triple	 pattern	 are	 suggestive	 of	 synovial	
sarcoma	(13,	14).	
Figure	2.	Radiologic	presentation	of	a	synovia	sarcoma	in	a	foot.	
	
	 	
Radiograph,	 axial	 and	 sagittal	 T1	
and	T2W	FS	MR	 images.	 The	mass	
is	 calcified,	 displaces	 the	 bones,	
and	 has	 an	 heteregoneous	 signal	
on	MR.	
	
Histopathology:	Slow-growing	lesions	are	a	firm,	lobular	mass	fairly	well	circumscribed,	attached	to	
surrounding	 tissues,	 from	 yellow	 to	 gray-white.	More	 rapidly	 growing	 lesions	 are	 a	 soft,	 globose	
mass	 poorly	 encapsulated,	 with	 a	 variegated,	 friable	 or	 shaggy	 appearance,	 from	 mottled	 pink	
yellow	to	light	brown,	with	frequent	necrosis,	hemorrhage	and	cystic	areas.	Calcifications	are	rarely	
seen.	Two	different	types	of	cells	are	seen:	epithelial	and	spindle	cells,	in	four	patterns:	1)	biphasic	
type:	 two	 cellular	 components;	 2)	 monophasic	 fibrous	 type:	 only	 spindle	 cells;	 3)	 monophasic	
epithelial	 type:	 only	 epithelioid	 cells;	 4)	 poorly	 differentiated	 type	 (20%).	 In	 the	 biphasic	 synovial	
sarcoma	there	is	a	balanced	distribution	of	the	two	components.	Epithelioid	cells	are	globose,	cubic	
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or	cylindrical,	with	 large	vescicular	nuclei,	abundant	pale	cytoplasm,	with	well-defined	limits.	They	
are	disposed	in	solid	cords,	whorls,	nests,	islands	and	border	irregular	pseudoglandular,	cleftlike	or	
cystlike	 spaces	with	 granular	 or	 homogeneous	 secretions.	 Fibrous	 cells	 are	well-oriented,	 plump,	
spindle-shape,	 have	 a	 uniform	 appearance,	 with	 scant	 and	 indistinct	 cytoplasm	 and	 oval,	 dark	
nuclei.	They	form	solid,	compact	masses	with	irregular	nodular	arrangement.	A	fine	net	of	collagen	
fibers	surrounds	the	single	cells	of	the	fibrous	component.	Mitotic	figure	are	infrequent	(1).		
Figure	 3.	 Biphasic	 synovial	 sarcoma:	 granular	 and	 spindle	 cell	 component	 intermixed	 in	 the	
same	tumor.	
	
In	monophasic/fibrous	type	synovial	sarcoma,	spindle	cells	are	the	most	prominent	 feature	of	 the	
lesion	 and	 only	 a	 minute	 focus	 of	 epithelial	 cells	 may	 be	 observed.	 Monophasic/epithelial	 type	
synovial	sarcoma	is	rare	and	presents	a	pseudoglandular	feature	with	poorly	developed	spindle	cells	
pattern	 prevalence.	 In	 poorly	 differentiated	 synovial	 sarcoma	 there	 are	 solidly,	 packed,	 oval	 or	
spindle,	poorly	differentiated	cells;	cells	are	usually	small	in	size	and	appear	neither	clearly	fibroblast	
nor	epithelioid	cell.	Mitotic	 figures	are	 frequent,	 richly	vascularized	with	hemangiopericytoma	 like	
pattern.	 Biphasic	 synovial	 sarcoma	 usually	 does	 not	 require	 immunohistochemistry	 for	 diagnosis.	
Monophasic	and	poorly	differentiated	synovial	sarcoma	show	cytokeratin	expression	in	most	cases,	
although	 it	 can	 be	 quite	 focal	 and	 confined	 to	 only	 rare	 cells	 in	 an	 entire	 section.	 EMA	may	 be	
positive	 in	 some	 cytokeratin-negative	 cases.	 S-100	protein	 expression	 is	 present	 in	 20%	of	 SS	 but	
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CD34	expression	 is	not	seen.	More	than	70%	of	synovaial	sarcomas	are	CD99	positive,	particularly	
the	 poorly	 differentiated	 asynovial	 sarcoma.	 There	 is	 nuclear	 expression	 of	 TLE-1.	 The	 balanced	
reciprocal	translocation	t(X;18)(p11.2;q11.2)	is	found	in	more	than	90%	resulting	in	fusion	of	the	SYT	
gene	on	chromosome	18	with	the	SSX1,	SSX2,	or	rarely	SSX4	gene	on	the	X	chromosome	(15).		
Course	 and	 Staging:	 Local	 recurrence	 is	 common	 even	 10	 years	 later	 if	 inadequate	 surgery	 was	
performed.	Metastases	develop	in	about	50%	of	cases.	The	tumor	usually	presents	as	AJCC	stage	IIB	
(15).			
Treatment:	 Surgery	 aims	 at	 obtaining	 wide	 margins,	 also	 sacrificing	 functionally	 important	
structures	or	amputating	the	limb.	Wide	conservative	surgery	may	be	difficult	for	the	characteristic	
growth	 of	 the	 tumor	 (16).	 It	 may	 be	 useful	 to	 associated	 adjuvant	 chemotherapy	 and	 pre-	 or	
postoperative	radiation	therapy.	Excision	of	the	regional	lymph	nodes	can	be	considered	for	selected	
patients;	sentinel	node	biopsy	may	be	worthwhile	in	slected	patients.	Overall	10-year	survival	varies	
from	 15	 to	 35%.	 Favorable	 prognostic	 factors	 are:	 <5cm,	 youth,	 women,	 distal	 extremities,	
calcifications,	<15	mits/10HPF,	degree	of	glandular	differentiation,	no	intravascular	plugs	(16).		
In	patients	with	recurrent	disease,	the	post-	relapse	survival	is	very	poor,	with	a	5-year	OS	of	about	
20–30%	 after	 lung	 recurrence,	 and	 very	 few	 patients	 live	 after	 3	 years	 in	 case	 of	 multiple	 site	
recurrences	(12,	16).	No	standard	treatment	strategies	are	defined	in	this	setting,	due	to	the	scanty	
literature	on	this	specific	subject		(17).	
Nonetheless,	 Karavasilis	 et	 al.	 (18)	 in	 a	 series	 of	 488	 advanced	 STS,	 including	 SS,	 concluded	 that	
palliative	 chemotherapy	 should	 be	 regarded	 as	 a	 standard	 treatment	 option,	 with	 approximately	
half	of	patients	deriving	benefit.		
New	target	have	been	explored	 in	 synovial	 sarcoma,	but	only	 the	pazopanib	 study	 (PALETTE)	 (19)	
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among	 all	 studies	 listed	 in	 Table	 1	 (17)	 translated	 into	 drug	 approval	 for	 metastatic	 soft	 tissue	
sarcomas	in	Europe.	
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2.2	-	Immune	system	overview	
Knowledge	 about	 the	 immune	 system	 is	 essential	 for	 understanding	 the	 principles	 underpinning	
cancer	immunotherapy.	There	are	two	types	of	immune	responses	against	microbes:	called	innate	
and	adaptive	immunity	(Figure	1)	(20).		
Figure	1.	Innate	versus	Adaptive	Immune	Response	
	
Innate	immunity,	whose	main	components	are	phagocytic	cells	(neutrophils	and	macrophages)	and	
natural	killer	cells,	provides	the	initial	defence	against	invading	microbes	during	infection	(20).	Small	
molecular	proteins	called	cytokines	mediate	many	activities	of	the	cells	involved	in	innate	immunity.	
In	addition	to	cytokines,	dendritic	cells	(DCs)	and	macrophages	play	critical	roles	in	the	activation	of	
innate	 immunity.	 These	 components	 also	 have	 a	 role	 in	 communicating	with	 acquired	 (adaptive)	
immunity	(20).	The	key	components	of	adaptive	immunity,	following	the	initial	innate	immunity,	are	
T	and	B-lymphocytes.	The	lymphocytes	play	a	central	role	in	eliminating	infectious	pathogens,	virus	
infected	cells,	and	cancer	cells	and	also	in	generating	antigen-specific	memory	cells	(99).	Adaptive	
immunity	 consists	 of	 humoral	 and	 cell- mediated	immunity.		
Innate Immunity Adaptive Immunity 
TWO ARMS OF THE IMMUNE SYSTEM 
Redgrove KA Front Immunol. 2014; DOI 10.3389/fimmu.2014.00534  
Cancer cell 
Tumor antigen 
 
Microbial antigen 
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T	 lymphocytes	 recognize	 short	 peptides	 as	 antigens	 presented	 by	 major	 histocompatibility	
complexes	 (MHCs)	 on	 the	 cell	 surface	 of	 DCs	 (21).	 CD8	 and	 CD4	 T	 cells	 recognize	 antigen	 in	 the	
context	of	MHC	class	I	and	class	II	molecules,	respectively.	Primed	and	activated	T	cells	differentiate	
into	mature	 effector	 cells	 while	 undergoing	 clonal	 expansion.	 The	 effector	 CD8	 T	 cells	 recognize	
virus	infected	cells	and	tumor	cells	and	eliminate	them	from	the	body.	The	differentiation	of	naïve	
CD8	T	cells	into	effector	and	memory	CD8	T	cells	is	mediated	by	the	“help”	of	CD4	T	cells	or	by	DCs	
(22).	DCs,	B	cells,	and	macrophages	are	professional	antigen-presenting	cells	(APCs)	(22).		
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2.3	-	The	immune	contexture	in	human	tumors	
All	immune	cell	types	may	be	found	in	a	tumor,	including	macrophages,	dendritic	cells,	mast	cells,	
natural	 killer	 (NK)	 cells,	 naive	 and	 memory	 lymphocytes,	 B	 cells	 and	 effector	 T	 cells	 (including	
various	subsets	of	T	cell:	T	helper	cells,	regulatory	T	(TReg)	cells,	T	follicular	helper	(TFH)	cells	and	
cytotoxic	T	cells).		
These	immune	cells	can	be	located	in	the	core	(the	centre)	of	the	tumour,	in	the	invasive	margin	or	
in	the	adjacent	tertiary	lymphoid	structures	(TLS).		
The	analysis	of	the	presence,	location	and	density	of	the	different	immune	cell	populations	(which	
has	been	 termed	 the	 ‘immune	contexture’)	 in	 large	annotated	collections	of	human	 tumours	has	
allowed	the	identification	of	components	of	the	immune	contexture	that	are	beneficial,	as	well	as	
those	that	are	deleterious,	to	patients	(23).		
	
2.3.1	-	The	immune	contexture:	characteristics		
Histopathological	 analyses	 of	 human	 tumours	 have	 provided	 evidence	 that	 variable	 numbers	 of	
infiltrating	immune	cells	are	found	in	different	tumours	of	the	same	type,	and	are	found	in	different	
locations	within	and	around	a	tumour	(Figure	1,	Glossary)		
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Figure	1.	Mechanisms	for	intratumoral	programmed	cell	death	ligand-1	(PD-L1)	expression.	
	
Adaptive	 focal	expression	of	PD-L1	by	macrophages	 (CD68+/CD163+)	occurs	at	 the	 interface	of	 tumor	cell	nests	with	
immune	infiltrates	secreting	pro-inflammatory	factors	such	as	interferon-γ.	The	ligation	of	PD-L1	on	macrophage	and,	in	
some	 histotypes,	 on	 tumor	 cells,	with	 programmed	 cell	 death	 protein	 1	 (PD-1)	molecules	will	 down-modulate	 T	 cell	
function,	essentially	creating	a	negative	 feedback	 loop	 that	 reduces	antitumor	 immunity	 (the	so	called	 ‘tumor	shield’	
effect),	eventually	reducing	CD8	tumoricidal	function.	
Macrophages,	mast	cells,	granulocytes	and	myeloid-	derived	suppressor	cells	(MDSCs)	are	found	in	
most	cases	infiltrating	or	surrounding	tumour	beds	both	in	the	core	and	at	the	invasive	front	of	the	
tumour.	 It	 is	 well	 established	 that	 chronic	 inflammation	 and	 the	 presence	 of	 M2	 macrophages	
favour	 tumour	 growth	 and	 spreading	 (24).	 Lymphocytes	 are	 not	 randomly	 distributed	 but	 are	
located	 in	 specific	areas.	Therefore,	NK	cells	are	 found	 in	 the	stroma	and	are	not	 in	contact	with	
tumour	cells.	B	cells	are	mostly	found	in	the	invasive	margin	of	growing	tumours	and		in	TLS	that	are	
particularly	 CD8+	 T	 cells,	may	 be	 located	 in	 the	adjacent	 to	 tumour	 beds	 (25).	 T	 cells,	
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invasive	margin	but	can	also	be	in	the	tumour	core.	Immature	dendritic	cells	are	distributed	in	the	
tumour	 core,	 in	 contact	 with	 tumour	 cells	 or	 in	 the	 surrounding	 stroma.	 Mature	 dendritic	 cells	
concentrate	in	TLS,	in	close	contact	with	naive	T	cells	(25).		
The	fact	that	functional	populations	of	immune	cells	are	located	in	different	areas	of	a	tumour,	and	
that	this	distribution	varies	between	cancer	types,	suggests	that	different	immune	cell	populations	
may	have	different	 roles	 in	 tumour	 control.	Moreover,	 the	variable	density	and	 location	of	 these	
immune	 cells	 between	 tumours	 in	 different	 individuals	with	 the	 same	 cancer	 type	prompted	 the	
investigation	of	whether	the	immune	context	might	affect	clinical	outcome.		
	
	
	
	
	
During the past decade, work that began 
with the mouse studies by R. D. Schreiber 
and colleagues1–4, and that culminated with 
the demonstration that infiltrating T cells 
have a major effect on the clinical attributes 
of human cancer5,6, has changed the field of 
tumour immunology. Indeed, a recent 
review by Hanahan and Weinberg included 
“avoiding immune destruction” (REF. 7) as 
an emerging hallmark of cancer, in addi-
tion to the previously established hallmark 
of tu our-promoting inflammation. The 
potential effect of a patient’s immune system 
on clinical outcome is not only of academic 
inter st but it also has important implica-
tions for the identification of prognostic 
markers, and markers that predict responses 
to chemotherapy and radiotherapy.
A demonstration of the effect of the host 
immune response on tumour invasion, 
recurrence and metastasis has come from 
analyses of the in situ immune components 
and how these are organized within human 
tumours. Indeed, immune infiltrates ar  
heterogeneous between tumour types, and 
are very diverse from patient to patient. 
All immune cell types may be found in a 
tumour, including macrophages, dendritic 
cells, mast cells, natural killer (NK) cells, 
naive and memory lymphocytes, B cells and 
effector T cells (including various subsets  
of T cell: T helper cells, T helper 1 (TH1) cells, 
TH2 cells, TH17 cells, regulatory T (TReg) cells, 
T follicular helper (TFH) cells and cytotoxic 
T c lls). These immune cells can be located 
in the core (the centre) of the tumour, in the 
invasive margin or in the adjacent tertiary 
lymphoid structures (TLS). The analysis of the 
location, density and functional orientation 
of the different immune cell populations 
(which we have termed the ‘immune contex-
ture’ (REF. 8)) in large annotated collections 
of human tumours has allowed the identifi-
cation of components of the immune con-
texture that are beneficial, as well as those 
that are deleterious, to patients. In addition, 
bioinformatics tools9,10 have permitted the 
identification of chemokines and cytokines 
that are involved in shaping the immune 
contexture11.
The immune contexture: characteristics
Histopathological analyses of human 
tumours have provided evidence that vari-
able numbers of infiltrating immune cells  
are found in different tumours of the same 
type, and are found in different locations 
within and around a tumour (FIG. 1). Macro-
phages, mast cells, granulocytes and myeloid-
derived suppressor cells (MDSCs) are found 
in most cases infiltrating or surrounding 
tumour beds both in the core and at the 
nvasive front of the tumour. It is well estab-
lished that chronic inflammation and the 
presence of M2 macrophages favour tumour 
growth and spreading12. Lymphocytes are 
not randomly distributed but are located in 
specific areas. Therefore, NK cells are found 
in the stroma and are not in contact with 
tumour cells. B cells are mostly found in the 
invasive margin of growing tumours and 
in TLS that are adjacent to tumour beds13. 
T cells, particularly CD8+ T cells, may be 
located in the invasive margin but can also 
be in the tumour core. Few CD8+ T cells are 
seen in TLS, which are similar to secondary 
follicles in lymph nodes that contain naive 
T cells and memory T cells, B cells and mature 
dendritic cells. Indeed, immature dendritic 
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Abstract | Tumours grow within an intricate network of epithelial cells, vascular and 
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Different types of infiltrating immune cells have different effects on tumour 
progression, which can vary according to cancer type. In this Opinion article we 
discuss how th  co text-spe ific nature of infiltrating immu e cells can affect the 
prognosis of patients.
Glossary
Cytotoxic T cells
CD3+CD8+ effector T cells with cytotoxic granules that 
contain perforin and granzymes, which are released on 
interaction with target cells expressing cognate antigen. 
This leads to the death of target cells by apoptosis.
Dendritic cells
Cells that capture microorganisms or dead tumour cells 
and that process them to present antigen to T cells in 
secondary or tertiary lymphoid organs. They express high 
levels of co-stimulatory molecules, which allows them to 
activate naive T cells.
High endothelial venules
Specialized venules that occur in secondary lymphoid 
organs, except the spleen. They allow continuous 
transmigration of lymphocytes as a consequence of the 
constitutive expression of adhesion molecules and 
chemokines at their luminal surface.
Macrophages
Can be subdivided according to their cellular properties 
and cytokine secretion profiles. M1 macrophages secrete 
pro-inflammatory cytokines (IL-1, IL-6 and TNF), release 
reactive oxygen and reactive nitrate species and have a 
pro-inflammatory role. M2 macrophages secrete IL-4, 
IL-10, IL-13 and TGFβ and have an anti-inflammatory role, 
promote angiogenesis and favour tumour progression.
Memory T cells
CD3+CD4+CD45RO+ and CD3+CD8+CD45RO+ cells that 
have encountered antigen and that respond faster and with 
increased intensity on antigenic stimulation compared  
with naive T cells.
Myeloid-derived suppressor cells
(MDSCs). Heterogeneous population of polymorphonuclear 
and monocytic CD11b+GR1+ cells that inhibit T cell 
activation.
Naive T cells
CD3+CD4+ and CD3+CD8+ cells that differentiate into 
effector T cells (CD4+ T helper cells or CD8+ cytotoxic 
T cells) in secondary lymphoid organs or TLS after 
stimulation with three signals: antigen, co-stimulatory 
molecules and cytokines.
Regulatory T (TReg) cells
Population of CD3+CD4+ T cells that inhibit effector B and 
T cells. Some produce cytokines with immunosuppressive 
activities; for example, IL-10 and TGFβ. They have a central 
role in suppressing anti-self immune responses to prevent 
autoimmune diseases.
Tertiary lymphoid structures
(TLS). Ectopic lymphoid aggregates that are generated 
during the process of chronic immune stimulation and  
that exhibit the structural characteristics of secondary 
lymphoid organs.
T helper cells
Populations of CD3+CD4+ effector T cells that secrete 
cytokines with differential activities. TH1 cells produce IL-2 
and IFNγ and favour cellular immunity (acting on CD8+ 
cytotoxic T cells, NK cells and macrophages). TH2 cells 
produce IL-4, IL-5 and IL-13 and favour humoral immunity 
(acting on B cells). TH17 cells produce IL-17A, IL-17F, IL-21 
and IL-22 and favour anti-microbial tissue inflammation 
(acting on epithelial and endothelial cells, fibroblasts and 
immune cells).
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2.3.2	-Clinical	impact	of	the	immune	contexture	
2.3.2.1	-	Intratumoural	lymphoid	infiltrates		
Virchow	commented	on	the	interaction	between	leukocytes	and	tumour	cells	in	his	monograph	of	
1863	 (26).	Today,	we	are	 still	unravelling	 the	complexities	of	 the	 interaction	between	cancer	and	
the	 host	 immune	 system.	 Different	 components	 of	 the	 immune	 system	 can	 either	 promote	 or	
combat	 tumour	 growth.	 The	 potential	 for	 the	 immune	 system,	 in	 particular	 CD8+	 cytotoxic	 T	
lymphocytes,	to	control	or	eradicate	tumours	has	been	shown	in	 laboratory	models.	 In	a	study	of	
human	colorectal	carcinoma	(CRC)	specimens	detailing	the	relationship	between	T	cell	densities	at	
the	 invasive	 tumour	 margin	 and	 those	 in	 the	 centre	 of	 the	 tumour,	 high	 densities	 of	
CD3+CD8+CD45RO+granzyme+	 T	 cells	 (that	 is,	 antigen-experienced	 cytolytic	 Teff	 cells)	 were	
associated	with	a	lower	likelihood	of	tumour	relapse	and	improved	overall	survival	(27).	Moreover,	
coordinated	 pathological	 analysis	 of	 CD3+	 T	 cell	 densities	 outperformed	 internationally	 accepted	
clinical	 staging	 criteria	 (Union	 for	 International	Cancer	Control	 (UICC)-TNM)	 in	predicting	disease-
free	 survival	 and	overall	 survival	 in	multivariate	analysis	 (27).	 In	a	 survey	of	 the	 literature	on	 the	
prognostic	importance	of	T	cell	infiltrates	in	different	tumour	types,	the	association	of	CD8+		T	cells	
with	improved	prognosis	was	seen	in	97%	(58/60)	of	the	reports	analysed	(28).			
Table	 1	 summarizes	 the	 effect	 of	 T	 cells	 on	 solid	 tumor	 clinical	 outcome	 (29-53).	 A	 strong	
lymphocytic	 infiltration	 has	 been	 reported	 to	 be	 associated	 with	 good	 clinical	 outcome	 in	many	
different	 tumour	 types,	 including	 melanoma,	 and	 head	 and	 neck,	 breast,	 bladder,	 urothelial,	
ovarian,	colorectal,	renal,	prostatic	and	lung	cancer.	
On	 the	 other	 hand	most	 of	 the	 studies	 in	 sarcomas	 either	 failed	 to	 demonstrate	 any	 correlation	
		 29	
(51,52),	or	were	inhomogenous	for	stage	of	the	patients	included	(53).	
Table	1.	Immune	infiltrate	and	cancer	outcome	
Cells	 CD8+	T	cells	 TReg	cells	
Melanoma	 Good29,30	 None31,	Poor32	
Head	and	neck	cancer	 Good
33	 Good33	
Breast	cancer	 Good34	 None35	,	Poor36	
Bladder	cancer	 Good37	 Good38	
Ovarian	cancer	 Good39	 Good40,	Poor41	
Oesophageal	cancer	 Good42	 	
Colorectal	cancer	 Good27	 Good43	
Renal	cell	carcinoma	 Good44,	Poor44	 Poor
45
	
Prostatic	
adenocarcinoma	 Good
46	
	
Lung	carcinoma	 Good
25	 Poor
47	
Pancreatic	cancer	 Good
48
	 Poor49	
Brain	cancer	 	 None
50	
Soft	tissue	sarcoma	 None51	 	
Osteosarcoma	 None52,	53	 	
CD8+	 T	 cell	 infiltrate	 was	 also	 among	 the	 first	 predictive	 biomarkers	 explored	 for	 immune	
checkpoint-blocking	therapies.	Specifically,	in	the	context	of	anti-PD1	therapy	for	melanoma,	CD8+	
T	cell	density	at	the	invasive	tumour	edge	has	been	correlated	with	response	to	anti-PD1	treatment	
(54)		
2.3.2.2	-	Intratumoural	PD-L1	expression	
		 30	
Beyond	 enumerating,	 localizing	 and	 phenotyping	 CD8+	 Teff	 cells	 and	 other	 tumour-infiltrating	
immune	 cell	 types,	 the	 next	 layer	 of	 biomarker	 investigation	 involves	 examining	 specific	 defence	
mechanisms	that	tumours	can	use	to	guard	against	immune	attack.	A	dominant	mechanism	that	is	
relevant	to	anti-PD1	drug	response	is	PD-L1	expression.	PD-L1	is	normally	expressed	by	a	subset	of	
macrophages	and	can	be	induced	on	activated	lymphocytes	(T,	B	and	NK	cells),	endothelial	cells	and	
other	 non-malignant	 cell	 types	 in	 an	 inflammatory	 microenvironment,	 as	 part	 of	 a	 physiological	
process	to	down-modulate	ongoing	host	immune	responses	in	peripheral	tissues	(52-57).	However,	
tumour	cells	and	associated	stromal	cells	can	also	express	PD-L1,	thereby	turning	off	Teff	cells	(56).	
In	 some	 cancers,	 PD-L1	 expression	 is	 constitutively	 driven	 by	 aberrant	 signalling	 pathways	 or	
chromosomal	alterations.	For	example,	PTEN	mutations	causing	PI3K–AKT	pathway	activation	 in	a	
subset	of	 glioblastoma	 cases	 (58),	 	 can	 result	 in	broad	expression	of	 PD-L1	on	 the	 surface	of	 the	
majority	of	the	tumour	cells.		
PD-L1	may	also	be	expressed	in	the	TME	by	a	mechanism	termed	adaptive	immune	resistance	(59)	a	
phenomenon	 in	 which	 tumour	 and	 stromal	 cells	 adapt	 to	 attack	 from	 infiltrating	 T	 cells	 by	
expressing	 the	 immune	 inhibitory	 ligand	 PD-L1.In	 this	 scenario,	 PD-L1	 expression	 is	 driven	 by	
inflammatory	cytokines	such	as	interferon-γ	secreted	by	tumour	antigen-specific	T	cells.		
The	first	scientific	support	 for	 the	concept	of	adaptive	 immune	resistance	was	provided	by	Taube	
and	 colleagues	 in	 a	 study	 focused	 on	 human	melanoma	 samples	 (60).	 In	 this	 study,	 four	 distinct	
archetypes	of	tumour–host	 interaction	were	demonstrated:	1)	broad,	constitutive	tumour	cell	PD-
L1	 expression	 in	 the	 absence	 of	 a	 substantial	 host	 immune	 response,	 consistent	 with	 the	 afore	
mentioned	 genetically	 driven	 constitutive	 PD-L1	 upregulation;	 2)	 PD-L1	 expression	 focally	 and	
geographically	 associated	 with	 the	 host	 anti-	 tumour	 immune	 response;	 3)	 tumours	 that	 had	
immune	cell	 infiltrates	but	 lacked	PD-L1	expression;	and	4)	 tumours	 that	 lacked	both	an	 immune	
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response	and	PD-L1	expression.		
Notably,	 intratumoural	 PD-L1	 expression	 was	 associated	 with	 improved	 overall	 survival	 in	 this	
melanoma	 study,	 contrary	 to	expectations	based	on	 its	 known	 immunosuppressive	 function	 (60).	
This	 paradox	 is	 explained	 by	 a	 mechanism	 in	 which	 cytotoxic	 T	 lymphocytes	 upregulate	 PD-1	
expression	when	they	encounter	tumour	antigens	(adaptive	response	to	IFNγ):	PD-L1	in	this	context	
may	be	considered	as	a	marker	of	active	immune	response.		
Further	 complexity	 has	 arisen	 with	 regard	 to	 the	 cell	 type	 (or	 types)	 expressing	 PD-L1.	 Certain	
cancers,	such	as	melanoma,	SCCHN,	and	breast	cancer,	frequently	express	PD-L1	on	the	surface	of	
tumour	cells	as	well	as	on	 infiltrating	 immune	cells	 (60-62).	 In	contrast,	 in	other	 tumours	such	as	
CRC	 and	 gastric	 carcinoma,	 PD-L1	 is	 observed	 almost	 exclusively	 on	 tumour-	 infiltrating	 immune	
cells	and	 is	only	rarely	expressed	on	tumour	cells	themselves	(63-65).	Such	differential	expression	
may	reflect	the	variable	susceptibility	of	tumour	cells	and	infiltrating	immune	cells	to	cytokines	and	
other	stromal	factors	in	the	tumour	milieu	(666).		
PD-L1	in	sarcomas	
In	a	study	by	Kim	JR	et	al,	there	were	58%	of	PD-1	and	65%	PD-L1	positive	expression	in	a	series	of	
105	 soft	 tissue	 sarcoma	 patients	 with	 localized	 disease	 (67).	 PD-1	 expression	 was	 measured	 in	
lymphocytes	and	PD-L1	in	tumor	cells.	Interestingly,	the	authors	found	a	significant	correlation	with	
survival,	with	 a	5-year	event	–free	 survival	 (EFS)	 rates	 for	PD-1-/PD-L1-,	 PD-1+/PD-L1-	 or	PD-L1+	of	
90%,	74%	and	13%	respectively	(64).	By	contrast,	in	a	study	from	MSKCC,	reporting	on	a	series	of	50	
soft	tissue	sarcoma,	only	12%	and	22%	of	tumors	had	PD-L1	and	PD-1	positivity	respectively	and	no	
significant	association	with	clinical	end	points	was	detected	(68).	Movva	S	et	al	reported	50%	of	PD-
L1	positivity	in	a	large	series	including	2539	sarcoma	cases	(69).	Last,	Toulmonde	et	al,	among	328	
		 32	
localized	soft	tissue	sarcomas	with	genomic	complexity,	including	low	grade	tumor,	reported	a	PD-
L1	rate	of	19.5%,	with	no	survival	implication	(51).	
Collectively,	 in	these	studies,	the	range	of	PD-L1	positivity	in	STS	is	wide	(12-58%)	reasons	such	as	
the	inclusion	of	different	histotypes		(large	prevalence	of	GIST	in	the	study	by	MSKCC)	the	different	
methodology	 used	 (namely,	 the	 antibodies	 used:	 Dako	 in	 MSKCC	 series	 (68),	 Santa	 Cruz	 in	 Kim	
series	(64),	Pharmingen	in	Movva	series	(69),	Ventana	clone	SP142	in	the	study	by	Toulmonde	(51);	
and	also	different	scoring	or	procedure	such	as	TMA	or	whole	section)	might	explain	it.		
Dealing	with	bone	tumors,	a	74%	PD-L1	positive	expression	on	tumor	cells	was	demonstrated	in	a	
series	of	38	osteosarcoma	patients	with	 localized	and	metastatic	disease	 (70).	 In	 this	study	PD-L1	
gene	expression	by	RT-PCR	assay	was	performed	on	 total	 RNA	of	 the	 same	 samples:	 the	median	
overall	 survival	 for	 PDL1-low	 patients	 was	 89	 months	 (29	 cases),	 and	 28	 months	 for	 PDL1-high	
patients	 (9	 cases)	 (P	 =	 0.054)	 (70).	 Another	 study	 on	 localized	 and	 metastatic	 osteosarcoma	
demonstrated	 an	 expression	 of	 PD-L1	 in	 7%	 and	 25%	 of	 TMA	 or	whole	 sample	 respectively	 in	 a	
series	of	54	patients	(52).	The	event	free-survival	(EFS)	in	this	series	was	significantly	improved	for	
PD-L1	negative	cases,	but	no	clinical	information,	included	stage,	of	patients	analysed	was	provided.	
Moreover,	PD-L1	expression	was	assessed	in	a	large	series	of	conventional,	mesenchymal,	clear	cell	
and	dedifferentiated	chondrosarcomas	using	tissue	microarrays:	 interestling	PD-L1	expression	was	
absent	 in	conventional	 (n	=	119),	mesenchymal	 (n	=	19)	and	clear	cell	 (n	=	20)	chondrosarcomas,	
while	 9/22	 (41%)	 dedifferentiated	 chondrosarcomas	 displayed	 PD-L1	 positivity:	 PD-L1	 expression	
was	not	prognostic	in	this	series	(71).	
2.4	-	VEGFR,	neoangiogensis	and	immunotherapy	
The	 dynamic	 interactions	 between	 tumour	 cells	 and	 immune	 cells	 are	 dependent	 on	 the	 local	
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network	of	blood	and	lymphatic	vessels.	A	dense	vascular	network	may	allow	potential	metastatic	
cells	 to	 escape	 the	primary	 tumour	but,	 conversely,	 could	 also	 favour	 the	 infiltration	by	 immune	
cells	 provided	 that	 the	 relevant	 chemokines	 are	 produced.	 Vascular	 endotheial	 growth	 factor	 A	
(VEGFA),	 a	 cytokine	 that	 is	 produced	 by	 tumour	 cells,	 is	 a	 major	 inducer	 of	 tumour-associated	
neovascularization,	which	present	specific	features	as	compared	with	normal	vascularization	(Table	
1).	
Table	1.	Normal	vs.	Tumor	Vasculature	
	
Angiogenesis	 is	 involved	 in	 tumor	development	 from	the	 initial	 stages	of	cancer	 formation	 to	 the	
growth	of	distant	metastases.	Importantly,	VEGF	is	overexpressed	not	only	by	tumor	cells,	but	also	
by	 any	 hypoxic	 cells	 in	 the	 tumor,	 including	 tumor	 stromal	 cells,	 fibroblasts,	 and	 macrophages,	
which	are	particularly	responsive	to	hypoxia	(72).	A	tumor	that	is	not	yet	hypoxic	is	usually	avascular	
and	dormant.	When	it	undergoes	the	“angiogenic	switch,”	VEGF	expression	is	elevated,	vasculature	
is	 established	 via	 capillaries,	 and	 the	 tumor	 begins	 an	 exponential	 growth	 phase.	 This	 phase	 is	
associated	with	greatly	increased	metastatic	potential	because	platform	metastasis	can	easily	occur	
via	the	newly	generated	blood	vessels	(72).	
VEGF	 is	also	 important	 in	the	metastatic	process.	When	tumor	cells	gain	entry	 into	blood	vessels,	
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they	travel	to	other	tissues	and	form	metastatic	nodules.	However,	these	nodules	are	initially	poorly	
vascularized	 until	 they	 undergo	 a	 similar	 angiogenic	 switch,	 when	 they	 develop	 vasculature	 and	
start	 to	 grow	 exponentially.	 Anti-VEGF	 monoclonal	 antibodies	 have	 been	 developed	 that	 target	
VEGF-D,	VEGF-C,	and	VEGF	receptors	(VEGFR).	Anti-VEGFR	antibodies	are	currently	in	phase	I	and	II	
clinical	trials,	and	anti-VEGFR3	antibodies	appear	to	inhibit	some	forms	of	angiogenesis.	
More	 recently,	 it	 has	 been	 speculated	 that	 anti-VEGF	 treatments	 might	 represent	 an	 important	
actors	in	the	Cancer-Immunity	Cycle	(Figure	1)	(73).	
Figure	1.	Therapies	that	Might	Affect	the	Cancer-Immunity	Cycle	
	
Our	institution,	in	collaboration	with	the	Italian	Sarcoma	Group,	and	Spanish	Sarcoma	Group	(GEIS),	
has	recently	activate	the	first	trial	using	sunitinb,	an	anti-TKI,	including	VEDFR,	as	immunomodulator	
in	sarcomas:		‘Phase	I-II	trial	of	sunitinib	plus	nivolumab	after	standard	treatment	in	advanced	soft	
issue	and	bone	sarcomas	(EudraCT	Number:	2016-004040-10).	The	aim	of	this	project	is	to	assess	in	
vitro	the	potential	immunomodoluation	properties	of	this	approach.	
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2.4.1	–	VEGFR	inhibitors	as	immune-modulators	in	sarcomas	
VEGF,	v-akt	murine	thymoma	viral	oncogene	homolog	(AKT),	platelet-derived	growth	factor	(PDGF),	
mitogen-activated	protein	kinase	(MAPK),	are	variably	expressed	in	osteogenic	sarcoma,	and	VEGF	
pathway	was	found	to	be	a	critical	signaling	pathway	in	osteogenic	sarcoma	(74).		
Sunitinib	is	a	small	molecule	receptor	tyrosine	kinase	(RTK)	inhibitor	that	blocks	signaling	of	multiple	
RTKs,	including	vascular	endothelial	growth	factor	receptor	(VEGFR),	platelet-derived	growth	factor	
receptor	(PDGFR),	Kit,	and	Flt-3,	colony	stimulating	factor	receptor	type	1	(CSF-1R)	and	the	glial	cell-
line	derived	neurotropic	factor	receptor	(RET)	(75).		
Sunitinib	is	approved	by	the	FDA	for	the	treatment	of	patients	with	gastrointestinal	stromal	tumors	
after	disease	progression	on	or	intolerance	to	imatinib,	for	the	treatment	of	patients	with	advanced	
renal	cell	carcinoma,	and	for	the	treatment	of	pancreatic	neurendocrine	tumors	(pNET)	(76).		
The	approved	dose	for	these	indications	is	50	mg	orally	daily	for	4	weeks,	followed	by	2	weeks	off.	
This	 compound	 has	 been	 also	 shown	 effective	 in	 soft	 tissue	 sarcomas,	 with	 partial	 responses	
described	 in	 synovial	 sarcomas,	 leiomyosarcoma,	 angiosarcoma	 (77)	 and	 activity	 described	 for	
desmoplastic	 sarcomas	 (78),	 alveolar	 soft	 part	 sarcomas	 (79)	 and	 extraskeletal	 myxoid	
chondrosarcomas	 (80).	 There	 are	no	published	 studies	 on	 the	use	of	 sunitinib	 in	 bone	 sarcomas,	
with	 limited	 pre-clinical	 evidence	 of	 sunitinib	 potential	 for	 effective	 treatment	 of	 metastasizing	
osteosarcoma	(81).	
Sunitinib	 might	 exert	 immunostimulatory	 activity	 through	 the	 modulation	 of	 the	 ratio	 of	
immunostimulatory	 versus	 immunoregulatory	 cells.	 In	 fact,	 In	 addition	 to	 its	 pro-angiogenic	
function,	 VEGF	 has	 immune	 modulating	 properties,	 which	 include	 increasing	 the	 influx	 of	
lymphocytes	and	DCs	into	the	tumour,	while	decreasing	the	intratumoural	frequencies	of	TReg	cells	
		 36	
and	 myeloid-derived	 suppressor	 cells	 (MDSCs)	 (82-84).	 Furthermore,	 high	 expression	 of	 VEGFA	
counteracts	the	beneficial	effects	of	TH1	cells	or	cytotoxic	T	cells	by	suppressing	the	expression	of	
interferon	regulatory	factor	1	(IRF1)	and	granulysin	(GNLY),	respectively	(85).	In	addition,	VEGFA	is	
known	to	 inhibit	dendritic	cell	maturation,	which	may	result	 in	the	 induction	of	suppressor	rather	
than	of	 effector	 cells,	which	 hampers	 the	 necessary	 balance	 of	 immune	 cells	 at	 the	 tumour	 site.	
Indeed,	 treatment	 with	 anti-VEGFA	 chemotherapy	 drugs,	 such	 as	 sunitinib,	 sorafenib	or	
bevacizumab,	 results	 in	 a	 decrease	 of	 TReg	 cells	 and	 MDSCs	 both	 in	 the	 periphery	 and	 in	 the	
tumours	of	some	patients	(86).	The	analysis	of	a	cohort	of	patients	with	metastatic	renal	cell	cancer	
who	 were	 treated	 with	 sunitinib	 or	 bevacizumab	 revealed	 that	 patients	 with	 a	 decrease	 in	
circulating	TReg	cells	after	two	or	three	treatment	cycles	had	a	significantly	longer	overall	survival	
than	patients	with	no	decrease	in	circulating	T	cells	(87).		
Some	of	the	immunomodulatory	treatments,	including	VEGFR	inibitors	are	summarized	below	(Box	
1).	
	
Box	1		Immunomodulatory	treatments	that	modify	the	immune	context	
	
	
	
		
		
	
	
Immunogenic	chemotherapies,	such	as	oxaliplatin,	which	induce	calreticulin	expression	on	the	
tumour	cell	membrane,	result	in	an	increased	uptake	of	the	tumour	cell	by	phagocytic	cells	and	
improved	antigen	presentation,	which	helps	to	clear	cancer	cells90,	91	
Anti-angiogenic	drugs	decrease	the	levels	of	myeloid-derived	suppressor	cells	(MDSCs),	as	well	as	
circulating	and	intratumoural	regulatory	T	(TReg)	cells,	which	modulate	anti-tumour	
immunity87,88,89.		
Immune	checkpoint-blocking	antibodies	(which	target	cytotoxic	T	lymphocyte-associated	antigen	
4	(CTLA4),	programmed	cell	death	protein	1	(PD1),	PD1	ligand	1	(PDL1)	and	CD137,	for	example)	
and	specific	depletion	of	T	Reg		cells92	increase	the	infiltration	of	the	tumour	microenvironment	by	
T	cells,	particularly	CD8+	T	cells,	which	increases	immune	responses	to	tumour	cells93,94	
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Emerging	 data	 on	 chemotherapy/TKIs	 and	 immunotherapy	 combination,	 showed	 that	 the	 drugs	
schedule	may	play	a	role,	with	best	responses	observed	in	sequential	versus	concurrent	approach	
(59,	95,	96).		
	
2.4.2	-	Immunotherapy	in	sarcomas	
Historically,	 Coley	 reported	 a	 case	 of	 unresectable	 small-cell	 sarcoma	 of	 the	 neck	 in	 1891.	 The	
sarcoma	 completely	 regressed	 after	 a	 severe	 episode	 of	 erysipelas.	 He	 reported	 that	 a	 systemic	
response	against	erysipelas	influenced	the	patient's	tumor	(97).	The	mechanism	by	which	erysipelas	
caused	tumor	regression	was	unclear	at	that	time.		
However,	 it	 is	now	understood	 that	 the	activation	of	 innate	 immunity	 through	Toll-like	 receptors	
(TLRs)	by	erysipelas	followed	by	activation	of	acquired	immunity	specific	to	sarcoma	may	contribute	
to	the	underlying	mechanism	(98).	Thus,	the	case	described	by	Coley	was	the	first	to	demonstrate	
that	 the	 immune	 system	might	be	 involved	 in	 the	 spontaneous	 regression	of	 sarcomas.	Over	 the	
past	100	years,	his	work	encouraged	many	scientists	to	work	on	cancer	immunology,	in	an	attempt	
to	find	a	cure	for	cancers	(99,	100).	
The	myriad	 of	 genetic	 and	 epigenetic	 alterations	 that	 are	 characteristic	 of	 all	 cancers	 provide	 a	
diverse	 set	 of	 antigens	 that	 the	 immune	 system	 can	 use	 to	 distinguish	 tumour	 cells	 from	 their	
normal	counterparts.		
Tumor	 antigens	 recognized	 by	 the	 immune	 system	 are	 categorized	 into	 cancer	 testis	 antigens	
(CTAs),	 melanocyte	 differentiation	 antigens,	 mutated	 proteins,	 overexpressed	 proteins,	 and	 viral	
antigens	(101).	Several	types	of	CTAs	have	been	identified	in	patients	with	sarcomas	(Table	1).		
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Table	1.	Cancer	testis	antigens	in	bone	and	soft	tissue	sarcomas	(101)	
	
	
	
Because	 tumor	 antigens	 are	 potential	 targets	 that	 induce	 cytotoxic	 immune	 responses,	 many	
clinical	trials	have	utilized	tumor	antigens	as	vaccines	for	decades.		
In	 2011	 Robbins	 et	 al	 published	 the	 first-in-human	 clinical	 trial	 utilizing	 the	 adoptive	 transfer	 of	
autologous	 peripheral	 blood	 mononuclear	 cells	 (PBMC),	 transduced	 with	 a	 high-affinity	 TCR	
directed	 against	 an	 HLA-A*0201–restricted	 NY-ESO-1	 epitope,	 in	6	 cases	 with	 NY-ESO-1	 positive	
synovial	 sarcomas.	 This	 trial	 demonstrated	 a	 good	 response	 in	 terms	 of	 response	 rate	 (102).	
However,	results	are	preliminary	(18	cases	treated	so	far	 in	the	up-date	publication,	103)	and	the	
procedure	 cannot	 be	 adopted	 in	 all	 patients	 (HLA-A*02:01	 and	 NY-ESO-1	 restricted	 trial).	 	 Figure	 2	
shows	the	progression-free	survival	(PFS)	and	overall	survival	(OS)	curves	(103).		
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Table 1: Cancer testis antigens in bone and soft tissue sarcomas.
Sarcoma subtypes Expression of cancer testis antigens
NY-ESO LAGE MAGE-A3 MAGE-A4 MAGE-A9 PRAME SSX-2
Bone sarcomas
Osteosarcoma [14] + + + +
Ewing’s sarcoma [14] + + + +
Chondrosarcoma [14] + + + +
Soft tissue sarcomas
Synovial sarcoma [15] + + + + + + +
Malignant fibrous histiocytoma,
pleomorphic spindle cell sarcoma [15] + + + + +
Liposarcoma [15] + + + + + +
Leiomyosarcoma [15] + + + + +
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Figure 1: An overview of tumor immunology. Tumor cells are initially attacked by the innate immune ystem. DC capture tumor antigens
at the tumor site and migrate to the tumor draining lymph nodes. DCs present the tumor antigen to T cells within the lymph node. Antigen-
specific CD4 and CD8 T cells are stimulated by DCs. After stimulation, T cells differentiate into effector cells and activate at the tumor site.
Effector CD8 T cells kill tumor cells, although their function is regulated by the immune check oint m chanism. NK: natural killer cell; MP:
macrophage; DC: dendritic cell.
3. Outcomes of Clinical Trials for Bone and
Soft Tissue Sarcomas
Treatments for bone and soft tissue sarcomas include surgery,
chemotherapy, and radiotherapy. To date, clinical results of
combined therapies have been more successful than those
of surgical approaches. However, as described above, the
prognosis of bone and soft tissue sarcomas has plateaued
since the 1990s. In these recent years, immunotherapies are
expected to further improve the prognosis of patients, and
several clinical trials have been performed (Tables 2 and 3).
3.1. Cytokine Therapies. Cytokines are proteins that regulate
the immune system. Interleukin-2 (IL-2) and interferons
(IFNs) have been used in the immunotherapy for sarcomas
[77], and clinical results are evident. IL-2 leads to the activa-
tion and expansion of CD4 and CD8 T cells [78]. Rosenberg
et al. established a tumor regression model involving recom-
binant IL-2 injection for murine melanoma and sarcomas
[32].Then, several studies described the effectiveness of high-
dose IL-2 therapy for patients with metastatic melanomas
[79, 80]. Therefore, recombinant IL-2 was administered to
patients with bone and soft tissue sarcomas [16]. Schwinger
et al. reported a positive clinical result using a high-dose IL-
2 treatment in two patients with Ewing’s sarcomas and four
patients with metastatic osteosarcomas. Patients had already
been treated with surgery (1–5 times), chemotherapy (7–43
cycles), and radiation therapy (for patients with Ewing’s sar-
coma). Although one patient with metastatic osteosarcoma
progressed during the treatment period, two patients with
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Figure	2.	Progression-free	survival	(PFS)	and	overall	survival	(OS)	in	synovial	sarcoma	
	
	
	
Although	antitumor	immunity	is	induced	in	patients	with	cancer	vaccines,	recent	advancements	in	
cancer	immunity	have	revealed	the	presence	of	immune-inhibitory	mechanisms.	
In	fact,	the	ultimate	amplitude	and	quality	of	the	T	cells	response,	which	is	initiated	through	antigen	
recognition	 by	 the	 T	 cell	 receptor	 (TCR),	 is	 regulated	 by	 a	 balance	 between	 co-stimulatory	 and	
inhibitory	signals	(that	is,	immune	checkpoints)	(Figure	3)	(104).		
	
	
	
protected. The adoptive transfer of an in vitro sensitized autolo-
gous CD4þ T-cell clone that recognized an HLA-DP"04 restricted
NY-ESO-1 peptide mediated regression of metastatic melanoma
in 1 of 9 patients (16, 18). In 2010, we presented preliminary
results of the ﬁrst adoptive cellular immunotherapy trial for solid
cancers to utilize the transfer of autologous PBMC transduced
with a CG-reactive TCR. In that study as well as the current one,
patients received autologous PBMCs that were transduced with a
TCR, termed 1G4-aLY, that possessed a high avidity for the HLA-
A"0201–restricted NY-ESO-1:157-165 epitope (11). Response
rates of 45% and 67% were observed in the initial cohorts of
melanoma and synovial cell sarcoma patients, respectively, all of
whom had progressive disease after extensive prior treatment.
Clinical responses to therapy were not associated with the per-
sistence of adoptively transferred T cells, as determined either
using NY-ESO-1 tetramer binding or antigen-speciﬁc ELISPOT to
evaluate TCRs, although only 6 patients with synovial sarcoma, as
well as 11patientswithmelanoma,were evaluated in the previous
study. The current study was carried out on 18 patients with
synovial cell sarcoma and 20 patients with melanoma, including
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Figure 2.
Kaplan–Meier curve of overall survival
and progression-free survival. The
overall and progression-free survival of
heavily pretreated patients with
synovial cell sarcoma (A) and patients
with melanoma (B) in response to
therapy with NY-ESO-1 TCR-transduced
T cells is presented.
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Figure	 3.	 Co-stimulatory	 and	 inhibitory	 signals	 (immune	 checkpoints)	 in	 cancer	 immunotherapy	
(adapted	from	Pardoll	et	al,	ref	104).	
	
Under	normal	physiological	conditions	immune	checkpoints	are	crucial	for	the	maintenance	of	self-
tolerance	(that	is,	the	prevention	of	autoimmunity)	and	also	to	protect	tissues	from	damage	when	
the	immune	system	is	responding	to	pathogenic	infection.		
Cancer,	 are	 able	 to	 deregulate	 the	 expression	 of	 immune-checkpoint	 proteins,	 such	 as	 PD1	
Figure 1. Multiple co-stimulatory and inhibitory interactions regulate T cell responses
Depicted are various ligand–receptor interactions between T cells and antigen-presenting 
cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide–
m jor histocompatibility c mplex (MHC) molecule c mplexes that ar  recognized by the T 
cell receptor (TCR)). These responses can occur at the initiation of T cell responses in 
lymph nodes (where the major APCs are dendritic cells) or in peripheral tissues or tumours 
(where effector responses are regulated). In general, T cells do not respond to these ligand–
receptor interactions unless they first cog ize their cognat  antigen through the TCR. 
Many of the ligands bind to multiple receptors, some of which deliver co-stimulatory signals 
and others deliver inhibitory signals. In general, pairs of co-stimulatory–inhibitory receptors 
that bind the same ligand or ligands — such as CD28 and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) — display distinct kinetics of expression with the co-
stimulatory receptor expressed on naive and resting T cells, but the inhibitory receptor is 
commonly upregulated after T cell activation. One important family of membrane-bound 
ligands that bind both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 
family members and their known ligands belong to the immunoglobulin superfamily. Many 
of the receptors for more recently identified B7 family members have not yet been 
identified. Tumour necrosis factor (TNF) family members that bind to cognate TNF receptor 
family molecules represent a second family of regulatory ligand–receptor pairs. These 
receptors predominantly deliver co-stimulatory signals when engaged by their cognate 
ligands. Another major category of signals that regulate the activation of T cells comes from 
soluble cytokines in the microenvironment. Communication between T cells and APCs is 
bidirectional. In some cases, this occurs when ligands themselves signal to the APC. In other 
cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on 
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(programmed	 cell	 death	 protein	 1)	 and	 its	 ligand	 (PD-L1)	 or	 T-lymphocyte-	 associated	 antigen	 4	
(CTLA-4),	a	protein	receptor	expressed	on	T	cells,	that	downregulates	T	cell	activation.	
Tumor	 cells	 upregulate	 the	 expression	 of	 PD-L1,	 and	 the	 interaction	 of	 PD1	 with	 PD-L1	
downregulates	the	function	of	T	cells	within	the	tumor	microenvironment.	Therefore	these	immune	
checkpoints	represent	an	important	immune	resistance	or	tolerance	mechanisms	for	tumor	cancer	
escape	and	are	emerging	as	an	important	therapeutic	target	for	many	tumors.		
In	 the	 last	 years	many	 studies	with	 immune	 checkpoints	 inhibitors	were	 performed	 in	 sarcomas	
with	 pembrolizumab	 (anti-PD1)	 (105),	 which	 was	 considered	 active	 in	 some	 histologic	 subtypes	
(liposarcoma	 dedidiffernetiated	 and	 UPS),	 nivolumab	 (anti-PD-1)	 (combined	 with	 pazopanib,	 an	
anti-VEGFR/PDGFR	in	some	case)	(106)	and	ipilimumab	(anti-CTLA4)	(considered	negative)	(107).		
Last,	CMB305,	a	prime-boost	vaccine	approach	against	NY-ESO-1-expressing	tumors,	was	combined	
with	 anti-PD1	 compound	 (atezolizumab)	 in	 36	 patients	 with	 NY-ESO-1+	synovial	 sarcoma	 or	
myxoid/round-ell	 liposarcoma:	 the	 combination	 had	 an	 increase	 PFS	 as	 compared	 with	
atezolizumab	alone	but	the	duration	of	the	response	was	short	(2.6	months	median	PFS)	(108).	
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2.5	-	CXCR-4	and	tumor	microenvironment	
	
Tumor	progression	is	a	multistep	process	during	which	tumor-	associated	stromal	cells	perform	an	
intricate	cross-talk	with	tumor	cells	to	supply	appropriate	signals	that	may	promote	tumor	survival,	
proliferation	and	aggressiveness.		
An	 increasing	 number	 of	 preclinical	 cancer	 studies	 underscore	 the	 importance	 of	 the	
microenvironment	in	tumourigenic	potential	of	epithelial	cells	(109)	The	tumour	microenvironment	
consists	of	resident	non-cancerous	cells	(stromal	fibroblasts,	endothelial	cells	and	immune	cells),		
	
connective	 tissue	 and	 extracellular	 matrix,	 altogether	 supporting	 tumour	 structure,	 angiogenesis	
and	growth	(110).	
A	 tumor	 can	 influence	 its	 microenvironment	 by	 releasing	 extracellular	 signals,	 promoting	 tumor	
angiogenesis	 and	 inducing	 the	 inflammatory	 response,	 while	 the	 immune	 cells	 in	 the	
microenvironment	 can	 affect	 the	 growth	 and	evolution	of	 cancer	 cells.	 The	 relationship	between	
cancer	cells	and	their	microenvironment	contributes	to	tumor	heterogeneity		(111).		
Mesenchymal	stem	cells	(MSCs)	are	non-hematopoietic	multipotent	stromal	cells	that	are	involved	
in	 tissue	 homeostasis	 and	 regeneration.	 Early	 studies	 demonstrated	 that	 bone	 marrow-derived	
mesenchymal	 stem	 cells	 (BM-MSCs)	 possess	 a	 remarkable	 ability	 to	 home	 in	 to	 tumor	 sites	 and	
putative	 immune-	 privileged	 status	 that	 renders	 them	 suitable	 carriers	 for	 delivering	 anti-tumor	
agents	to	the	tumor	microenvironment	(112).	However,	BM-MSCs	have	also	been	identified	as	pro-
active	 tumor	 stroma-associated	 cells	 that	 are	 implicated	 in	 promoting	 cell	 survival,	 angiogenesis,	
invasion,	and	metastasis	in	addition	to	the	evasion	of	the	immune	system	(113).		
The	 cross-talk	 between	 tumor	 cells	 and	 stromal	 cells	 induced	 the	 production	 of	 growth	 factors,	
cytokines	 and	 chemokines	 that	 can	 specifically	 attract	 BM-MSCs	 to	 invade	 the	 tumor	
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microenvironment,	as	has	been	shown	in	breast	(114)	and	other	solid	tumors.	
BM-MSC-derived	chemokines,	such	as	chemokine	ligand	1	(CXCL1),	CXCL2	or	CXCL12	(also	known	as	
stromal	 cell-derived	 factor	 1	 (SDF-1)),	have	 been	 shown	 to	 promote	 cancer	 cell	 proliferation	
through	the			related	receptors	chemokine	receptor	2	(CXCR2)	and	4	(CXCR4)	in	a	number	of	cancer	
models	(115,	116).	
The	CXCR4	belongs	to	the	large	superfamily	of	G	protein-coupled	receptors	and	has	been	identified	
to	play	a	crucial	role	in	a	number	of	biological	processes,	including	the	trafficking	and	homeostasis	
of	immune	cells	such	as	T	lymphocytes	(Figure	1)	(117)	
Figure	1.	CXCR4	intrcellular	signaling	pathways	
	
	
CXCR4	has	been	found	to	be	a	prognostic	marker	in	various	types	of	cancer,	including	leukemia	and	
breast	 cancer,	 and	 recent	 evidence	 has	 highlighted	 the	 role	 of	 CXCR4	 in	 prostate	 cancer	 (117).	
Furthermore,	CXCR4	expression	is	upregulated	in	cancer	metastasis,	 leading	to	enhanced	signaling	
(117).	
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The	CXCR4/CXCL12	 (SDF-1)	axis	has	additionally	been	 identified	to	have	a	role	 in	normal	stem	cell	
homing.	 	 In	 fact	 BM-MSCs	 express	 CXCR4,	 indicating	 that	 the	 CXCR4/SDF-1	 axis	 may	 direct	 the	
trafficking	 and	metastasis	 of	 these	 cells	 to	 organs	 that	 express	 high	 levels	 of	 SDF-1,	 such	 as	 the	
lymph	nodes,	lungs,	liver,	and	bone	(117).	
High	 levels	 of	 CXCL12	 expressed	 by	 cancer	 cells	 and	 tumor-associated	 stromal	 cells	 directly	
stimulated	 the	proliferation	and	 invasiveness	of	breast	 cancer	 cells	 in	an	autocrine	and	paracrine	
manner	 (118).	 Moreover,	 in	 mouse	 models	 of	 human	 breast	 cancer	 (118),	 and	 prostate	 cancer	
(119),	high	CXCL12	levels	in	the	tumour	attract	CXCR4-positive	inflammatory,	vascular	and	stromal	
cells	 into	 the	 tumour	mass,	 where	 they	 will	 eventually	 support	 the	 tumour	 growth	 by	 secreting	
growth	factors,	cytokines,	chemokines	and	pro-angiogenic	factors.	CXCL12	is	physiologically	mainly	
expressed	 by	 mesenchymal	 stromal	 cells	 in	 various	 organs	 and	 tissues,	 such	 as	 the	 liver,	 lungs,	
lymphatic	tissues	and	bone	marrow	(119).		
Preclinical	 mouse	 models	 of	 human	 multiple	 myeloma,	 acute	 lymphocytic	 leukaemia,	 chronic	
lymphocytic	 leukaemia	 and	 non-Hodgkin	 B-cell	 and	 T-cell	 lymphoma	 have	 shown	 that	 CXCR4	
positive	cancer	cells	can	be	recruited	to	CXCL12-rich	mesenchymal	stroma	niches	(119,120).		
	
2.5.1	-	CXCR4	expression	in	sarcomas		
Several	 studies	have	 reported	 that	BM-MSCs	promoted	 the	progression	of	osteosarcoma	through	
different	mechanisms	involving		CXCR4	(121,	122).		Furthermore	a	metanalysis	on	CXCR4	expression	
in	 samples	 of	 patients	 with	 bone	 and	 soft	 tissue	 sarcomas	 was	 recently	 published	 (11	 articles	
published	 from	 2005	 to	 2015)	 (123).	 Baseline	 characteristics	 of	 the	 included	 11	 studies	 are	
summarized	in	Table	1	(124	–	135).	
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Table	1.	Characteristics	of	eligible	studies	included	in	CXCR4	in	sarcoma	meta-analysis	
	
	
The	sample	size	of	the	studies	included	in	the	meta-analysis	ranged	from	30	to	159	patients,	and	a	
total	of	901	sarcoma	patients	were	included.		
Overall	 455/901	 (50%)	 of	 patients	 presented	 CXCR4	 overexpression,	 but	 the	 rate	 of	 CXCR4	
overexpression	was	wide	(ranging	from	33.3%	to	69.6%),	possibly	due	to	the	different	stage	of	the	
patients	included	in	the	different	series	(123).		
A	total	of	9	studies	with	635	patients	were	included	in	the	analysis	of	overall	survival.	Under	fixed-
effect	model,	the	pooled	HR	was	2.28	(95%	CI:	1.79–2.92,	P	<	0.001),	suggesting	that	overexpression	
of	CXCR4	was	an	indicator	for	poor	overall	survival	(Figure	2).	
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Figure	2.	Meta-analysis	of	the	effect	of	CXCR4	overexpression	on	overall	survival	(ref	123)	
	
When	the	analysis	was	stratified	by	histological	subtypes	(bone	sarcoma	comprising	osteosarcoma	
and	Ewing	sarcoma,	and	soft	 tissue	sarcoma	 including	synovial	sarcoma	and	rhabdomyosarcoma),	
statistical	 analysis	 method	 (multivariate	 analysis	 and	 univariate	 analysis)	 and	CXCR4	measuring	
method	 (IHC	 or	 RT-PCR),	 the	 significant	 correlation	 to	 poor	 overall	 survival	 was	 also	 observed	
except	for	that	in	Ewing	sarcoma	and	RT-PCR	groups	(123).		
Furthermore,	 in	 the	 study	 by	 our	 group	 including	 only	 patients	 with	 synovial	 sarcoma	 and	 no	
metastases	at	diagnosis,	the	CXCR4	impact	on	survival	was	specifically	observed	in	the	subgroup	of	
patients	undergoing	chemotherapy,	suggesting	CXCR4	role	in	resistance	to	chemotherapy	(Figure	3)	
(124).	
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2.5.2-	CXCR4	mechanism	of	action	and	‘chemosensitizer’	potential	
The	recruitment	of	CXCR4	positive	cancer	cells	mimics	the	homing	of	normal	stem	cells	to	the	bone	
marrow	(Figure	4).	
Various	mechanisms	of	action	of	CXCR4/CXCL12	axis	in	tumor	biology	have	been	proposed	(135):	
A.	 CXCR4/CXCL12	 regulation	 of	 primary	 tumor	 growth	 and	metastasis.	 Tumor	 associated	 stromal	
cells	 (pink)	constitutively	express	CXCL12.	This	paracrine	signaling	stimulates	the	proliferation	and	
survival	of	CXCR4-positive	tumor	cells	(grey).	Moreover,	CXCR4-expressing	tumor	cells	migrate	along	
the	CXCL12	gradient	to	distant	organs	showing	peak	levels	of	CXCL12	expression,	eventually	leading	
to	metastases	(118).		
B.	Tumor	cells	utilize	CXCR4	to	access	the	CXCL12-rich	bone	marrow	microenvironment	that	favors	
Figure	3.	5-year	overall	
survival	in	patients	with	
localised	synovial	sarcoma	
according	to	CXCR4	
expression:	
CXCR4	negative	
CXCR4	positive	
a)	immunohistochemical	
expression	of	CXCR4;	
b)	patients	undergoing	surgery	
and	chemotherapy;		
c)	patients	undergoing	surgery	
alone	
	
a.	
	
1
b.	
2
c.	
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their	 growth	 and	 survival.	 High	 levels	 of	 CXCL12	 secretion	 by	 bone	 marrow	 stromal	 cells	 are	
essential	for	homing	of	CXCR4-expressing	tumor	cells.	CXCR4	antagonists	can	inhibit	the	cross-talk	
between	tumor	and	stromal	cells	and	mobilize	cancer	cells	from	this	protective	microenvironment,	
making	 them	 more	 sensitive	 to	 conventional	 drugs	 (standard	 chemotherapy):	 ‘chemosentitizer	
effect’	(120).	
C.	 High	 expression	 of	 CXCL12	 by	 tumor	 cells	 and	 tumor-associated	 stromal	 cells	 forms	 a	 local	
gradient	of	the	chemokine	in	the	tumor	region.	CXCR4-expressing	bone	marrow	derived	progenitor	
cells	 are	 thus	 recruited	 to	 the	 tumor,	where	 they	 contribute	 to	 the	process	 of	 vasculogenesis	 by	
supporting	newly	formed	blood	vessels	and	by	releasing	other	pro-angiogenic	factors	(136).	
Figure	4.	Multiple	functions	of	chemokine	receptor	4	(CXCR4)/chemokine	ligand	(CXCL12)	axis	in	
tumor	biology	
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As	 initially	 shown	 in	 an	 acute	 promyelocytic	 leukaemia	mouse	model,	 cancer	 cells	 that	 home	 to	
bone	marrow	 reside	 in	a	microenvironment,	which	protects	 them	 in	a	CXCR4-dependent	manner	
from	chemotherapy	(120).		 In	other	words,	CXCR4/CXCL12	mediated	invasion	of	tumor	cells	 in	the	
stromal	layer	allows	their	direct	attachment	to	stromal	cells.	Activated	adhesion	molecules,	such	as	
avb3	integrins,	provide	malignant	cells	with	pro-survival	signaling	in	vitro.
	This	is	thought	to	lead	to	
adhesion-mediated	 drug	 resistance	 (137),	 with	 the	 acquisition	 of	 a	 quiescent	 phenotype	 that	 is	
thought	to	be	a	feature	that	allows	cancer	cells	to	avoid	chemotherapeutic	toxic	activity	(quiescent	
=	chemoresistant	phenotype)	(138,	139).		
The	above	findings	indicate	that	CXCR4/CXCL12	signaling	events	present	in	the	bone	marrow	niche	
can,	 directly	 or	 indirectly,	 contribute	 to	 resistance	 to	 chemotherapy	 in	 leukaemia	 (140)	 and	 solid	
tumors	(141).	
Since	 the	 CXCL12-CXCR4	 interaction	 is	 considered	 crucial	 for	 attracting	 tumor	 cells	 to	 the	 bone	
marrow	 niche,	 CXCR4	 inhibitors	 have	 been	 explored	 as	 chemosensitising	 agents	 in	 the	 field	 of	
leukaemia	tretment	(140-142).	
Most	 results	 on	 chemosensitisation	 by	 CXCR4	 inhibition	 have	 been	 obtained	 in	 haematological	
mouse	 models.	 Therefore	 the	 findings	 in	 these	 models	 might	 not	 directly	 be	 applicable	 to	 the	
situation	of	solid	tumours.	Nonetheless,	there	is	growing	evidence	that	CXCR4-positive	solid	tumour	
cells,	 analogous	 to	 leukaemic	 cells,	 also	 interfere	 with	 the	 microenvironment	 that	 favours	 their	
survival	during	anticancer	therapy	(144,	145).	In	an	in	vivo	mouse	model	of	human	melanoma	lung	
metastases,	 the	 CXCR4	 antagonist	 T22	 was	 able	 to	 sensitize	 melanoma	 cells	 for	 immune-
augmenting	low	dose	cyclophosphamide	and	anti-CTLA4	monoclonal	antibody	therapy,	resulting	in	
70	and	50%	 fewer	 lung	metastases,	 respectively,	when	compared	 to	 cyclophosphamide	and	anti-
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CTLA4	monoclonal	antibody	alone	(144).	
In	 conclusion,	 numerous	 preclinical	 studies	 support	 the	 usage	 of	 CXCR4	 antagonists	 in	 cancer,	 in	
order	 to	 sensitize	 tumour	 cells	 to	 current	 chemotherapeutic	 therapies	 by	 disrupting	 CXCR4-
dependent	tumour-stroma	interactions	(140-145).	
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3	-	AIM	OF	THE	STUDY	
	
The	 overall	 aim	of	 this	 project	 is	 to	 analyse	 current	 evidence	 on	 tumor	microenvironment	 and	
immune-infiltrate	 role	 in	 sarcomas,	 and	 to	provide	 some	 insights	 in	 this	 field	with	both	patient-
derived	tissue	studies	and	in	vitro	studies	of	tumor	microenvironment–targeted	agents	activity	on	
osteosarcoma	and	synovial	sarcoma	cell	lines.	
	
3.1	–	AIM	1:	Immune	context	in	osteosarcoma	and	synovial	sarcoma	
PD-1/PD-L1	immune	checkpoint	blockade	provides	clinical	benefits	in	a	variety	of	solid	tumors.		
We	 hypothesized	 that	 immune	 infiltrates	 were	 associated	 with	 superior	 survival,	 and	 examined	
primary	osteosarcoma	and	synovial	sarcoma	tissue	microarrays	(TMAs)	to	test	this	hypothesis.	Also,	
we	analysed	the	role	of	the	PD-1/PD-L1	expression	in	tumor	microenvironement	of	sarcomas.	
	
3.2	–	AIM	2:	Anti-VEGFR	and	anti-PD-1	activity	in	osteosarcoma	and	synovial	sarcoma	cell	lines	
We	 hypothesized	 that	 the	 ability	 of	 PD-1/PD-L1	 immune-checkpoint	 inhibitors	 to	 reduce	 cancer	
immunological	 tolerance	 might	 be	 increased	 by	 immunomodulators.	 Therefore,	 by	 using	 a	 co-
culture	system	with	sarcoma	cell	 lines,	 lymphocytes	and	dendritic	cells,	we	assessed	the	effect	of	
anti	-VEGFR/PDGFR	inhibitors	(sunitinib)	in	combination	with	anti-PD1	agents	(nivolumab).	
	
	3.3	–	AIM	3:	Anti-CXCR4	activity	in	osteosarcoma	and	synovial	sarcoma	cell	lines		
Based	 on	 the	 fact	 that	 the	 anti-tumor	mechanism	of	 CXCR4	 inhibitors	 (AMD3100	 and	MDX1338)	
alone	or	 in	combination	with	chemotherapy	were	not	assessed	 in	sarcoma,	we	hypothesized	that	
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AMD3100	 and	 MDX1338	 were	 more	 effective	 than	 chemotherapy	 alone	 in	 the	 treatment	 of	
sarcoma.		
Here,	we	measured	the	expression	of	CXCR4	and	SDF-1	on	osteosarcoma	and	synovial	sarcoma	cell	
lines	 and	 then	 evaluated	 the	 effect	 of	 combined	 treatment	 of	 AMD3100	 and	 MDX1338	 and	
adriamyicin	on	the	migration,	proliferation	and	apoptosis	of	sarcoma	cells	in	vitro.	
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4	-	MATERIALS	AND	METHODS		
	
4.1	-	Aim	1:	Immune	context	in	osteosarcoma	and	synovial	sarcoma	
4.1.1	-	Osteosarcoma	
4.1.1.1	-	Pre-treatment	(bioptic	samples)	
After	 EC	 approval,	 tissue	 samples	 obtained	 from	 biopsies	 performed	 prior	 chemotherapy	 in	 129	
patients	 were	 collected.	 Patients	 were	 prospectively	 treated	 at	 Istituto	 Ortopedico	 Rizzoli	 from	
04/2001	 to	 11/2006	 within	 protocol	 ISG-OS1,	 with	 surgery	 and	 a	 chemotherapy	 based	 on	
methotrexate,	cispaltin,	adriamicyn	and	ifosfamide	as	described	(146),	were	collected.	
The	clinical	characteristics	of	the	patients	were	the	following:	the	median	age	was	16	years	(range	
4-39	 years),	 with	 paediatric	 patients	 (59/86,	 67%)	 and	 male	 gender	 (53/86,	 62%)	 being	 most	
represented.	High	LDH	levels	and	high	AP	at	baseline	were	detected	in	36/86	(42%)	and	18/86	(21%)	
of	 patients	 respectively.	 All	 patients	 underwent	 neo-adjuvant	 chemotherapy	 and	 surgery	 as	 per	
protocol.	A	good	pathologic	response	(≥90%	necrosis)	was	achieved	by	45/86	(52%)	of	the	patients.			
All	 samples	 underwent	 decalcification	 as	 previously	 described	 (147).	 For	 tissue	microarray	 (TMA)	
construction,	 a	 slide	 stained	with	 hematoxylin	 and	 eosin	was	 prepared	 from	each	 formalin-fixed,	
paraffin-embedded	 (FFPE),	and	 representative	 tumor	 regions	were	morphologically	 identified	and	
marked	on	each	slide.	Tissue	cylinders	with	a	diameter	of	1.0	mm	were	punched	from	the	marked	
areas	of	each	block	and	brought	into	a	recipient	paraffin	block.	Five	TMAs	were	constructed.	Each	
tumor	sample	was	represented	by	a	minimum	of	1	core	to	a	maximum	of	5	cores.			
From	 TMA	 blocks,	 4	 micron-sections	 were	 cut.	 This	 histological	 sections	 were	 coloured	 with	
haematoxylin	 eosin	 and	 the	 tumor	 microenvironment	was	characterized	by	applying	
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antibodies	 directed	 against	 fixation	 resistant	 epitopes	 of	 CD68	 (tumor	 associated	 macrophages:	
TAM),	CD3,	CD8,	CD20	(T	tumor	infiltrating	lymphocytes:	TILs),	FOXP3	(T	regulatory	lymphocytes:	T-
regs),	 Tia-1	 (cytotoxic	 T	 cell),	 BDCA-2/CD303	 (plasmacytoid	 dendritic	 cells:	 pDC),	 Arginase-1	
(myeloid	derived	suppressor	cells:	MDSC)	proteins.	PD-1	expression	on	immune-cells	(IC),	and	PD-L1	
on	both	tumour	cells	(TC)	and	IC	was	also	investigated.	The	antibody	reactivity,	source	as	well	as	the	
antigen	retrieval	protocols	were	reported	in	Table	1.	
Table	 1.	 Immunohistochemistry	 antibody	 reactivity,	 sources	 as	 well	 as	 the	 antigen	 retrieval	
protocols,	dilutions	and	revelation	systems.	
	
	
A	semi-quantitative	score	from	0	to	3	was	assigned	to	immune	infiltrates:	0	=	"none":	no	immune	
infiltrates;	 1	 =	 "focal":	 mostly	 perivascular	 in	 tumor	 with	 some	 intra-tumoral	 extension;	 2	 	 =	
antibody	 clone	 Origin	 dilution	 antigen	retrieval	 revelation	system	
CD3	 SP7	 Neomarkers	 1:60	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
CD8	 144B	 Dako	 1:100	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
CD20	 L26	 Dako	 1:300	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
FOXP3	 Sp97	 Abnova	 1:100	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
TIA-1	 2G9	 Immunotech	 1:300	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
BDCA-
2/CD303	
124B3.13	 Dendritics	 1:100	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
Arginase-1	 polyclonal	 GeneTex	 1:3200	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
PD-1	 NAT-1	 Prof.	Roncador	(Madrid)	 1:4	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
PD-L1	 SP263	 Ventana,	Roche	 RTU	 Ventana	 Cell	
Conditioning	 1	
(CC1)	
Ventana	 OptiView	
Detection	system	
CD68	 PGM1	 Prof.	Falini	(Perugia)	 1:5	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
CD163	 10D6	 Leica	 1:100	 PT-link	 EnVision	
Flex	
Dako	 Real	 Detection	
system	
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"moderate":	prominent	extension	of	immune	infiltrates	away	from	perivascular	areas	and	amongst	
tumor	cells);	3	=	"strong"	(immune	infiltrates	obscuring	tumor)	(148).	Pathologists	were	blinded	to	
clinical	information.	
Only	cores	with	tumoral	component	were	included	in	the	analysis.	The	immunehistochemical	scores	
were	generally	concordant	among	cores	of	the	same	patient,	 in	case	of	heterogeneity	the	highest	
score	was	considered	for	the	analysis.	
For	 survival	 analysis	 samples	 were	 classified	 as	 negative	 (immunostaining	 =	 0)	 or	 positive	
(immunostaining	=	1	to	3)	for	all	markers	except:	CD68+	cases	that	were	classified	in	high	expressing	
(severe	 and	 moderate	 expression)	 and	 low	 expressing	 (focal	 expression).	 	 Score	 for	 PD-L1	
expression	in	TC:	specimens	with	>5%	membranous	expression	were	considered	positive.	
4.1.1.2	-	Post-induction	chemotherapy	(surgical	samples)	
In	86/129	patients,	FFPE	from	tumoral	masses	surgically	resected,	after	neoadjuvant	chemotherapy,	
were	collected.	The	full	slides	sections	from	FFPA	were	 investigated	by	 immunohistochemistry	for	
CD8+	and	Tia1	expression.	
4.1.1.3	-	Statistical	analysis	
The	following	factors	were	correlated	with	overall	survival	(OS)	in	all	samples	obtained	at	diagnosis:	
age	(pediatric	<	18	years	vs.	adult	≥	18	years),	gender,	LDH	and	phosphatase	alkaline	(PA)	levels	at	
baseline	 (normal	 vs.	 high),	 pathologic	 response	 (good:	 chemotherapy-induced	 tumor	 necrosis	 ≥	
90%;	 poor:	 chemotherapy-induced	 tumor	 necrosis	 <	 90%)	 (147),	 tumoral	 microenvironment	
components,	PD-1	expression	on	IC,	and	PD-L1	both	on	TC	and	IC.	
In	 the	 analysis	 on	 post-induction	 chemotherapy	 changes,	 CD8	 and	 Tia1	 expression	 were	 with	
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correlated	 with	 OS.	 OS	 was	 estimated	 according	 to	 the	 Kaplan	 and	 Meier	 method	 with	 their	
respective	 95%	 confidence	 intervals	 (CI)	 and	 calculated	 from	 the	 first	 day	 of	 chemotherapy	
administration	to	death	or	last	follow-up	visit.	
4.1.2	-		-	Synovial	sarcoma	
4.1.2.1	-	Design	and	patients	
This	study	is	a	systematic	mono	institutional	retrospective	analysis.	From	the	previous	series	of	250	
patients	(149)	referred	to	our	Institute	from	1976	to	2008,	we	selected	patients	admitted	for	first	
diagnosis;	therefore,	metastatic	and	recurrent	patients	at	presentation	were	excluded.	All	patients	
with	 incomplete	clinical	and	 follow-up	data	were	also	excluded.	General	 informed	consent	 to	 the	
use	 of	material	 was	 obtained	 from	 all	 adult	 patients	 or	 from	 parents/guardians	 for	minors	 from	
2004.	The	research	protocol	was	approved	by	Rizzoli	Orthopedic	Institute	ethics	committee.		
4.1.2.2	-	Data	collection	
Demographic	 data	 (age	 at	 onset,	 gender,	 follow-up	 duration),	 clinical-histological	 presentation	
(biphasic,	monophasic/poorly	differentiated,	tumor	size,	site),	treatment	(R0/R1	resection,	adjuvant	
chemotherapy,	adjuvant	radiotherapy),	and	outcome	(overall	survival	(OS),	were	collected.	Follow-
up	was	obtained	from	hospital	charts,	or	if	necessary,	by	a	phone	call.	
4.1.2.3	-	Histology	and	molecular	studies	
The	diagnosis	was	 confirmed	by	pathologists	with	expertise	 in	 soft	 tissue	and	bone	 tumors,	 after	
revision	 of	 histological	 slides	 according	 to	 histopathological	 and	 immunohistochemical	 criteria	
(150).	 The	 presence	 of	 SS18	 (SYT)	 gene	 rearrangement	 and	 fusion	 transcripts	 was	 assessed	 by	
Fluorescence	in	situ	hybridization	(FISH)	and	Reverse	Transcriptase-Polymerase	Chain	Reaction	(RT-
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PCR)	analysis	for	diagnosis	confirmation.	
4.1.2.4	-	FISH	analysis	
FISH	was	 performed	 using	 the	 SS18(SYT)	 (18q11.2)	 VYsis	 LSI	 Dual	 Color	 Break-apart	 DNA	 probes	
(Abbott	Molecular,	Des	Plaines,	 IL,	USA)	according	 to	 the	manufacturer’s	protocol.	A	minimum	of	
100	tumor	cell	nuclei	with	intact	morphology	as	determined	by	DAPI	counterstaining	were	counted	
in	the	previously	marked	neoplastic	area.	A	positive	result	was	defined	as	the	presence	of	a	visible	
translocation	 (separation	 of	 red	 and	 green	 signals > 3	 signal	 diameters)	 in	more	 than	 10%	of	 the	
cells	(151).	
4.1.2.5	-	RT-PCR	analysis	
RNA	was	extracted	from	fresh	tissue	using	a	modified	method	including	Trizol	Reagent	(Invitrogen,	
Carlsbad,	CA)	and	the	column	of	RNeasy	Mini	Kit	(Qiagen	GmbH,	Hilden	Germany).	2	μg	of	RNA	was	
reverse	transcribed	using	High	Capacity	cDNA	Archive	Kit	(Applied	Biosystems,	Foster	City,	CA).	The	
primers	 used	 for	 detection	 of	 t(X;18)	 SS18(SYT)-SSX1	 and	 t(X;18)	 SS18(SYT)-SSX2	 by	 PCR	
amplification	was:	 forward	 SS18	 5ʹGGA	 CAA	GGT	 CAG	 CAG	 TAT	GGA3ʹ;	 reverse	 primers	 for	 SSX1	
5ʹTTG	GGT	CCA	GAT	CTC	TTA	TT3ʹ;	and	reverse	for	SSX2	5ʹTTGGGTCCAGATCTCTCGTG3ʹ	(152).	
4.1.2.6	-	Immunohistochemistry	staining	
The	 immunohistochemistry	 staining	 for	 synovial	 sarcoma	 are	 the	 same	 of	 osteosarcoma	 (see	
paragraph.	4.1.1.1).		
This	histological	sections	were	coloured	with	haematoxylin	eosin	and	the	tumor	microenvironment	
was	characterized	by	applying	antibodies	directed	against	fixation	resistant	epitopes	of	CD3,	CD8		(T	
tumor	infiltrating	lymphocytes:	TILs),	FOXP3	(T	regulatory	lymphocytes:	T-regs),	PD-1	expression	on	
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immune-cells	(IC),	and	PD-L1	on	both	tumour	cells	(TC)	and	IC	was	also	investigated.		
	
4.1.2.7	-	Statistical	analysis	
The	following	parameters	were	examined	for	statistical	prognostic	correlations:	total	expression	of	
PD-L1	(IC),	PD-L1	(TC),	CD8,	CD3.	The	following	categories	were	compared:	patients	age	(adolescent	
and	 young	 adults	 (AYA)	 with < 30	years	 versus	 adults	 with	 ≥30	years);	 tumor	 size	 (≤5	cm	 versus	
>5	cm);	 surgical	 margins	 (adequate	 including	 wide	 or	 radical	 versus	 inadequate	 including	
intralesional,	 marginal	 or	 contaminated	 margins,	 according	 to	 Enneking’s	 classification)	 (153);	
histology	 (biphasic	 versus	 other	 histotypes);	 adjuvant	 treatments	 (chemotherapy	 or	 radiotherapy	
performed	within	3	months	after	 tumor	excision).	Chi-square	 (χ2)	 test	with	Fisher’s	exact	p	value	
was	used	 to	 correlate	 protein	 expression	with	 clinical	 parameters.	Overall	 survival	 (OS)	 time	was	
calculated	from	the	time	of	admission	at	our	 Institute	to	death	or	 last	 follow-up	visit.	All	 time-to-
event	end	points	were	modelled	using	 the	method	of	Kaplan	and	Meier	and	analysed	by	 the	 log-
rank	 test.	 The	 results	 of	 the	 Cox	 model	 analysis	 were	 reported	 as	 relative	 risks	 (RRs)	 and	 95%	
confidence	intervals	(CIs).	
	
4.2	-	Aim	2:	Anti-VEGFR	and	anti-PD-1	activity	in	osteosarcoma	and	synovial	sarcoma		
4.2.1	-	Human	Cells	
Peripheral	blood	mononuclear	cells	 (PBMCs)	were	 isolated	 from	buffy	coats	of	healthy	donors	by	
Ficoll-Hypaque	 centrifugation	 (Amersham,	USA).	 CD3+	 and	 CD14+	 cells	were	 purified	 by	magnetic	
separation	 (MiltenyiBiotec,	 Germany),	 according	 to	 manufacturer’s	 instructions.	 Purity	 of	 cell	
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populations	was	always	>	90%.			
4.2.1-	Cell	lines		
Human	osteosarcoma	cell	 line	SaOS-2	and	MG-63	were	obtained	by	Dr	Massimo	Serra	Laboratory	
(Istituto	 Ortopedico	 Rizzoli,	 Bologna,	 Italy)	 and	 cultured	 in	 Dulbecco's	 modified	 Eagle's	 medium	
(DMEM)	 supplemented	 with	 10%	 Fetal	 Bovin	 Serum	 (FBS)	 and	 antibiotics	 in	 37	 C°	 humidified	
atmosphere	with	5%	CO2.	Synovial	sarcoma	cell	lines	SYO-1,	bearing	the	pathogenetic	translocation	
(X;18)(p11.2;q11.2),	was	obtained	by	Dr	Akira	Kawai	(National	Cancer	Center,	Tokyo,	Japan)	and	Dr.	
Aki	Yoshida	Laboratories	(Okayama	University,	Tokyo,	Japan)	and	cultured	alfaMEM	supplemented	
with	10%	FBS,	or	10%	fetal	calf	serum	(FCS)	and	antibiotics	in	37	C°	humidified	atmosphere	with	5%	
CO2.	 ATCC	 synovial	 sarcoma	 cell	 line	 SW982	 was	 purchased	 from	 by	 American	 type	 Culture	
Collection	and	grown	 in	alfaMEM	10%	FBS,	100	U/ml	penicillin	 and	100	μg/ml	 streptomycin.	 The	
cells	were	maintained	in	a	humidified	incubator	in	5%	CO2	at	37	°C.		
4.2.3	-	Chemicals	and	Reagents	 	
Sunitinib/SUTENT/PF-00262192	is	an	oral	multitargeted	tyrosine-kinase	inhibitor	(including	VEGFR,	
kit	 and	 PDGFR)	 and	 it	 was	 provided	 by	 Pfizer	 Inc,	 NJ,	 USA.	 Axitinib/PF-01367866	 is	 an	 oral	
multitargeted	 tyrosine-kinase	 inhibitor	 (including	 VEGFR,	 kit	 and	 PDGFR)	 and	 it	 was	 provided	 by	
Pfizer	 Inc.,	NJ,	USA.	Nivolumab/Opodo	ia	a	umanized	monoclonal,	 immunoglobulin	G4	antibody	to	
PD-1	and	it	was	provided	by		Bristol	Myers	Squibb	(NYC,	NY,	USA).	
4.2.4	-	Cell	proliferation	assay		
The	 effects	 of	 Sunitinib	 on	 sarcoma	 cell	 lines	 were	 assessed	 using	 a	 CellTiter	 96®	 AQueous	 One	
Solution	Cell	Proliferation	Assay	(MTS)	–	PROMEGA)	(154).	Cells	at	exponential	phase	were	seeded	
in	 96-well	 plates	 at	 a	 density	 of	 5000	 cells/well	 in	 50	µl	 of	 the	 appropriate	 culture	medium	 and	
incubated	 for	 1	 hour	 at	 37°C	 to	 guarantee	 adherence.	Each	well	plate	was	then	added	with	
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medium	containing	 sunitinib	 (50	µl)	 at	 different	 concentrations	 (drug	 final	 concentrations:	 0	µM,	
0.5	µM,	1	µM,	3	µM,	5	µM,	7	µM,	10	µM)	and	 for	a	 total	 volume	of	100	µl.	 Each	condition	was	
repeated	in	3	subsequent	well	plates	(1	well	plate	for	24	hours,	1	for	48	hours,	and	1	for	72	hours).	
After	 24	 h,	 48	 h,	 72	 h	 growth,	 the	 cells	 were	 treated	 with	 20μl	 di	 CellTiter	 96®	 AQueous	 One	
Solution	Reagent.	Following	3	h	incubation	(dark	condition)	the	absorbance	at	490	nm	by	a	96-well	
plate	 reader	 (Multiskan	 EX	 Thermo	 Fisher	 Scientific)	 was	 recorded.	 Each	 day	 a	 standard	 curve	 if	
untreated	cells	was	seeded	and	the	absorbance	was	measured	in	order	to	calculate	cell	number	for	
each	well	plate.	
4.2.5	-	PD-L1	expression	on	sarcoma	cell	lines	by	flow	cytometry	
Flow	cytometry	was	used	 to	evaluate	PD-L1	expression	on	sarcoma	cell	 lines.	Each	osteosarcoma	
and	 synovial	 sarcoma	 cell	 line	 was	 harvested	 with	 brief	 Trypsin-EDTA	 treatment,	 washed	 in	 and	
centrifuged	 (5	 min/2000	 rpm).	 After	 counting	 the	 cells	 number,	 cell	 lines	 were	 washed	 and	
resuspended	in	phosphate-buffered	saline	(PBS)	solution.	For	PD-L1	staining,	the	mAb	anti-human	
CD274	(B7-H1)	APC-conjugated	(clone	MIH1.		Lot.	E12159-1634;	from	eBiosciences,	San	Diego,	CA)	
was	used.	 (155).	 100.000	 cells	were	 supplemented	with	 3	µl	Anti-Human	PD-L1	 antibody	 and	 re-
suspended	 in	PBS	50	µl.	Cell	were	 incubated	at	4	 °C	 for	20	minutes,	washed	and	 resuspended	 in	
PBS.	At	least	10,000	events	were	collected	from	each	sample	at	FACS	Canto	II	cytofluorimeter.	For	
each	 cell	 line,	 100.000	unstained	 cells	 (autofluorescence)	were	used	as	 a	 control.	 The	number	of	
replicates	(cell	lines	at	subsequent	passages)	was	4.		
4.2.6	-	Mixed	lymphocyte	reaction	(MLR)	
Human	 monocyte-derived	 immature	 dendritic	 cells	 (DCs)	 were	 generated	 by	 a	 6-day	 culture	 of	
CD14+	 cells	 in	 complete	 RPMI	 in	 presence	 of	 granulocyte-macrophage	 colony-stimulation	 factor	
(50 ng/mL;	 GM-CSF	 Endogen,	 USA)	 and	 IL-4	 	 (800 U/mL;	Miltenyi),	 as	 previously	 described	 (156,	
157).		
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For	DC	pulsing,	 tumor	 cell	 lysate,	 obtained	after	 three	 cycles	of	 cells	 freeze-thawing	 and	 filtering	
through	an	insulin	syringe,	or	Sunitinib-treated	tumor	cells	(15	m5)	were	cultured	for	24	hours	with	
immature	DCs	 (2:1	ratio)	 in	RPMI	medium.	After	culture,	15	000	tumor	cells-loaded	DCs	were	co-
cultured	with	150	000	CFSE-labeled	allogenic	CD3+	T	cells	in	presence	or	absence	of	Nivolumab	(20	
mg/ml).	Briefly,	allogeneic	CD3+	T	cells	were	labeled	by	CFSE	(CellTrace™	CFSE	Cell	Proliferation	Kit,	
Thermofisher,	USA)	at	the	concentration	of	5	µM	for	20	minutes	at	37°C.	After	incubation,	the	cells	
were	 washed	 with	 PBS	 and	 seeded	 in	 flat-bottom	 96-well	 microplates	 (150	 000/well).	 At	 same	
cases,	MLR	was	performed	by	co-culture	of	150	000	CFSE-labeled	CD3+	T	cells	with	irradiated	tumor	
cell	line	(3000	cGy)	at	ratio	of	1:10.	After	5	days,	T	cells	were	harvested,	washed	with	PBS	and	T-cell	
proliferation	by	 flow	cytometry	was	evaluated.	As	negative	control,	150	000	unstimulated	CD3+	T	
cells	were	used.	Proliferation	index	was	calculated	using	FCS	Express	4	Research	Edition	software.	
4.2.7	-	Flow	cytometry	immunophenotyping		
In	addition	to	proliferation,	after	5	days	of	MLR,	immunophenotype	of	stimulated	CD3+	T	cells	were	
also	 characterized	 using	 following	mAbs,	 according	 to	 manufacturer’s	 instructions:	 	 CD3	 APC-H7	
(SK7,	 BD	 Biosciences,	 USA),	 CD4	 Pe-Cy7(clone	 SK-3,	 Thermofisher,	 USA),	 CD8	 PE	 (SK1,	 BD	
Biosciences)	and	PD-1	APC	(EH12.2H7,	Biolegend,	USA).	Briefly,	150	000	T	cells	were	resuspended	in	
80	ml	of	PBS	and	stained	with	3	ml	of	directly	conjugated	monoclonal	antibodies.	After	incubation	
for	15	min	at	 room	temperature,	 the	samples	were	washed	with	PBS.	As	positive	control,	CD3+	T	
cells	stimulated	for	3	days	with	phytohemagglutinin	(PHA)	(20	ug/ml)	were	used.		
As	negative	control,	150	000	unstimulated	CD3+	T	cells	were	used,	whereas	150	000	unstained	CD3+	
T	 cells	were	used	as	negative	 fluorescence	control.	 For	each	sample,	at	 least	10,000	events	were	
collected	at	BD	FACS	Canto	II	(BD	Biosciences)	and	analysed	by	using	FCS	Express	4	Research	Edition	
software.		
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4.2.8	-	Cell	apoptosis	assay		
The	 effects	 of	 Sunitinib	 on	 the	 osteosarcoma	 and	 synovial	 sarcoma	 cell	 lines,	 apoptosis	 were	
measured	 using	 flow	 cytometry	 assay.	 After	 cultured	 in	 IMDM	 (or	 DMEM	 for	 Syo	 cell	 line),	 the	
adherent	cells	(150	000/well)	were	cultured	in	the	presence	of	0.5,	1,	3,	5,	7,	10,	12,	15,	20	and	30	
mM	 Sunitinib	 for	 24	 hours	 in	 24-well	 plate,	 removed	 from	 culture	 flasks	 using	 0,05%	 trypsin-
ethylenediamine	tetraacetic	acid	(EDTA)	(Life	Technologies,	USA)	and	washed	in	PBS.	After	15	min	
of	staining	with	5	ml	of	APC	Annexin	V	(BD	Pharmingen,	USA)	in	the	dark	at	room	temperature,	the	
percentage	of	apoptotic	cells	were	determined	using	Accuri	C6	(BD	Biosciences)	flow	cytometer	and	
FCS	Express	4	Research	Edition	software.	
4.2.9	-	Statistical	analysis	
Data	 were	 expressed	 as	 mean	 ±	 standard	 error	 of	 mean	 (SEM)	 of	 values	obtained	 in	 the	
experiments.	 Statistical	 analyses	 were	 performed	 with	 GraphPad	 Prism	 6	 software	 (GraphPad	
Software,	 Inc.,	 La	 Jolla,	 USA),	 using	 ANOVA	or	 unpaired	 t-test.	 P	 values	 <	 0.05	 were	 considered	
statistically	significant.	
	
	
4.3	-	Aim	3:	Anti-CXCR4	activity	in	osteosarcoma	and	synovial	sarcoma	 	
4.3.1	-	Cell	lines	and	chemicals	 		
Cell	lines	
Human	 osteosarcoma	 cell	 line	 U2OS	 was	 obtained	 from	 American	 type	 Culture	 Collection	 and	
cultured	 in	 αMEM	 supplemented	 with	 10%	 Fetal	 Bovine	 Serum	 (FBS)	 and	 antibiotics	 in	 37	 C	
humidified	atmosphere	with	5%	CO2.		
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Synovial	sarcoma	cell	lines	SYO-1	bearing	the	pathogenetic	translocation	(X;18)(p11.2;q11.2),	were	
obtained	by	Dr	Akira	Kawai	(National	Cancer	Center,	Tokyo,	Japan)	and	Dr.	Aki	Yoshida	Laboratories	
(Okayama	University,	 Tokyo,	 Japan)	 and	 cultured	 in	 αMEM	 supplemented	with	 10%	 FBS,	 or	 10%	
fetal	calf	serum	(FCS)	and	antibiotics	in	37	C	humidified	atmosphere	with	5%	CO2.	Synovial	sarcoma	
cell	line	SW982	were	purchased	by	American	type	Culture	Collection	and	grown	in	αMEM	10%	FBS,	
100	 U/ml	 penicillin	 and	 100	 μg/ml	 streptomycin.	 The	 cells	 were	 maintained	 in	 a	 humidified	
incubator	in	5%	CO2	at	37	°C.			
Bone	 Marrow	 Mesenchymal	 Stem	 Cells	 (BM-MSCs)	 have	 o	 been	 identified	 as	 pro-active	 tumor	
stroma-	associated	cells	 that	are	 implicated	 in	promoting	cell	survival,	angiogenesis,	 invasion,	and	
metastasis	in	addition	to	the	evasion	of	the	immune	system	(113).	Osteosarcoma	and	synovial	cells	
were	 then	 cultured	 in	 BM-MSCs	 conditioned	 medium	 (BM-MSC–CM),	 containing	 a	 higher	
concentration	of	CXCL12	(SDF-1)	as	compared	to	αMEM	10%FBS,	and	treated	with	CXCR4	inhibitors	
Chemicals	
MDX-1338/	 BMS-936564/	 Ulocuplumab	 s	 a	 fully	 human	monoclonal	 antibody	 specific	 for	 human	
CXCR447Kuhne	MR	and	it	was	provided	by	Bristol	Myers	Squibb	(NYC,	NY,	USA)	(158).	
AMD3100	 (Plerixafor),	 an	 FDA-EMA	 approved	 CXCR4	 inhibitor	 to	 enhance	 mobilisation	 of	
haematopoietic	stem	cells	 for	autologous	transplantation,	was	purchased	by	Sigma	(St	Louis,	MO,	
USA).			
4.3.2	-	Isolation	and	culture	of	human	bone-marrow	mesenchymal	stem	cells	(BM-MSC)		
Bone	marrow	 (BM)	 sample	was	 obtained	 from	 one	male	 patient	 who	 underwent	 surgery	 at	 the	
Rizzoli	 Orthopaedic	 Institute	 after	 informed	 consent	 .The	 isolation	 of	mononuclear	 cells	 and	 the	
expansion	 of	 cultures	 of	 human	 BM-MSCs	 in	 vitro	 were	 performed	 as	 previously	 described,	
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using	 gradient	 separation	 and	 plastic	 adherence	methods	 (159).	BM-MSCs	were	 characterized	 by	
their	 ability	 to	 proliferate	 in	 culture,	 their	 adherent,	 spindle-shape	 morphology,	 their	 ability	 to	
differentiate	 toward	 osteoblastic,	 cartilage	 and	 adipogenic	 lineages	 and	 for	 the	 expression	 of	 CD	
105,	CD73	and	lack	of	CD45	expression.	BM-MSCs,	after	isolation	and	characterization,	were	seeded	
at	 2000	 cells/cm2	 and	 grown	 until	 40-50%	 confluence	 in	 a-MEM	 supplemented	 with	 20%	 FBS.		
Thereafter,	 cells	were	 cultured	 in	 a-MEM	supplemented	with	 FBS	1%	 for	 72	h	 in	order	 to	obtain	
conditioned	medium	(BM-MSC-CM),	cells	were	then	cultured	in	a-MEM	supplemented	with	FBS	1%	
for	72	h.	BM-MSC-CM	were	collected	and	stored	at	-80°C	until	use.		BM-MSC-CM	presented	a	high	
concentration	of	CXCR4	ligand	SDF-1	as	shown	using	ELISA	kit	(R&D	Systems,	USA),	according	to	the	
directions	of	the	manufacturer.		
The	BM-MSC-CM,	after	thawing	at	RT,	was	centrifuged	at	1000	×	g	for	10	min,	and	filtered	through	
0.22-μm	filters	(Millipore,	Billerica,	MA)	before	being	added	to	tumor	cells.	The	BM-MSCs	were	used	
at	passage	3–4	in	this	study.	
4.3.3	-	CXCR4	and	SDF1	expression	in	sarcoma	cell	lines	
RNA	extraction		
Total	 RNA	 was	 extract	 from	 U2OS,	 SW982	 and	 SYO-I	 cell	 lines	 using	 TRizol	 reagent	 (Invitrogen,	
Carlsbad,	CA,	USA),	following	the	manufacturer’s	instructions.	The	concentrations	of	the	total	RNAs	
were	 measured	 using	 a	 spectrophotometer,	 and	 their	 purity	 and	 quality	 were	 checked	 through	
denatured	gel	electrophoresis.	
CXCR4	mRNA	expression	analysis	by	Real	Time	PCR		
mRNA	 levels	 of	 CXCR4,	were	 determined	 in	 osteosarcoma	 cell	 line	U2-OS	 and	 synovial	 sarcomas	
cells	SYO-I	and	SW982	following	TaqMan	Reverse	Transcription	Protocol	 (Applied	Biosystems,	Life	
Technologies,	CA,	USA).	Quantitative	RT-PCR	was	performed	using	Viia7	sequence	detection	system	
(Applied	 Biosystems,	 Life	 Technologies,	 CA,	 USA).		
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CXCR4	 expression	 was	 quantified	 by	 TaqMan	 Expression	 Assays	 (Hs00607978_s1);	 Applied	
Biosystems,	Life	Technologies,	CA,	USA)	according	to	manufacturer’s	protocol.	Expression	of	target	
genes	was	calculated	by	2-∆∆CT	comparative	method	 (Applied	Biosystems,	User	Bulletin	No.	2,	P/N	
4303859)	and	normalized	to	ACTB	housekeeping	gene	(Hs99999903_m1	gene;	TaqMan	Expression	
Assays-Applied	Biosystems).	
Normal	osteoblast	and	mesenchymal	stem	cells	were	used	as	calibrator	for	U2-OS	and	for	synovial	
cell	lines	respectively.	
CXCR4	and	SDF1	(CXCL12)	protein	expression	by	FACS	analysis		
Cells	were	then	stained	with	anti-CXCR4	antibody	(ab2074	AbCam)	(1:100	diluition	in	PBS)	and	with	
SDF1a	antibody	(FL-93-	Sc-28876)	(1:100	diluition	in	PBS).	Following	washes	with	wash	buffer,	cells	
were	incubated	with	a	goat-anti-rabbit	secondary	antibody	FITCH	conjugated	(1:80	dilution	in	PBS)	
for	1	h	in	the	dark.	After	two	additional	washes	in	wash	buffer,	flow	cytometry	were	done	by	FACS	
Calibur	Flow	Cytometer	(Becton	Dickinson).	
SDF1	(CXCL12)	expression	in	culture	medium	by	ELISA	
Osteosarcoma	and	synovial	sarcomas	cells	were	incubated	in	a	humidified	incubator	at	37	C.	When	
the	cells	had	reached	confluence,	the	media	were	collected.	After	centrifugation,	the	supernatant	
was	obtained	for	the	detection	of	SDF-1	levels	using	an	ELISA	kit	(R&D	Systems,	USA),	according	to	
the	directions	of	the	manufacturer.	
4.3.4	-	t(X;18)	SS18(SYT)-SSX1		in	synovial	sarcoma	by	RT-PCR		
2	μg	of	RNA	from	synovial	cell	 lines	was	reverse	transcribed	using	High	Capacity	cDNA	Archive	Kit	
(Applied	Biosystems,	Foster	City,	CA).	The	primers	used	for	detection	of	t(X;18)	SS18(SYT)-SSX1	and	
t(X;18)	 SS18(SYT)-SSX2	 by	 PCR	 amplification	 was:	 forward	 SS18	 5ʹGGA	 CAA	 GGT	 CAG	 CAG	 TAT	
GGA3ʹ;	 reverse	 primers	 for	 SSX1	 5ʹTTG	 GGT	 CCA	 GAT	 CTC	 TTA	 TT3ʹ;	 and	 reverse	 for	 SSX2	
5ʹTTGGGTCCAGATCTCTCGTG3ʹ	
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4.3.5	-	Cell	viability	and	sensitivity		
The	cell	viability	was	performed	before	and	after	MDX1338		(0.001	μg/ml,	0.005	μg/ml,	0.05	μg/ml),	
AMD3100	(5μg/ml,	20	μg/ml,	30	μg/ml).	200,000	cells	were	seeded	in	6-well	plate	in	αMEM	1%	FBS,	
25%	 BM-MSC–CM.	 The	 cell	 suspension	 was	 carried	 out	 during	 the	 normal	 process	 of	 cell	
detachment	from	flask,	which	involves	several	steps	including:	the	removal	of	medium,	the	addition	
of	4-5	ml	of	1	X	PBS	to	wash	cell	monolayer,	the	addition	of	1	ml	of	trypsin-EDTA,	which	acts	at	an	
optimal	temperature	of	37	°C,	and	finally	the	addition	of	4	ml	of	αMEM	10%	FBS	to	inactivate	the	
trypsin.	The	suspension	obtained	was	inserted	into	a	15	ml	tube	and	centrifuged	at	1000	rpm	for	5	
minutes	at	room	temperature	to	allow	the	removal	of	the	supernatant	and	the	pellet	obtained	was	
suspended	in	a	known	volume	of	αMEM.	
The	 number	 of	 adherent,	 viable	 cells	 was	 assessed	 after	 48h	 and	 72h	 microscopically	 using	 an	
improved	Neubauer	haemocytometer	and	proliferation	was	assessed	as	the	percentage	of	cells	that	
excluded	0.2%	trypan	blue.	
Living	cells	were	counted	and	the	number	of	cell/ml	calculated	by	multiplying	the	average	number	
of	cells	for	10,000,	chamber	conversion	factor,	and	then	for	the	volume	of	the	flask,	5ml.	
For	 combined	 treatments,	 cells	 were	 treated	 at	 the	 same	 time	 in	 combination	 with	 AMD3100	
(30μg/ml)	or	MDX1338	(0.005μg/ml)	and	doxorubicin	at	different	concentrations	for	48h	and72h.	
4.3.6	-	Cell	apoptosis	assay		
OS	cells	were	seeded	at	100,000/well	 in	6-well	plates,	allowed	to	attach	overnight,	and	incubated	
with	or	without	MDX1338	(0.005	μg/ml)	or	AMD3100	(30	μg/ml)	for	48	and	72	h.	According	to	the	
protocol	 kit	 (MEBCYTO	 Apoptosis	 kit;	 MBL	 International,	 Woburn,	 MA,	 USA),	 the	 adherent	 cells	
were	 trypsinized,	 detached,	 and	 combined	 with	 floating	 cells	 from	 the	 original	 growth	medium,	
centrifuged	and	washed	twice	with	PBS	1X.	Cells	were	re-suspended	 in	500	μl	of	staining	solution	
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containing	FITC-conjugated	Annexin	V	antibody	and	propidium	iodide	(PI)	for	30	min	and	analyzed	
by	flow	cytometry.	
The	 number	 of	 viable	 (Annexin−/PI−),	 apoptotic	 (Annexin+/PI−)	 and	 necrotic	 (Annexin+/PI+)	 cells	
were	determined	with	 the	Cell	Quest	 Software	 (BD	Biosciences,	 San	 Jose,	CA,	USA),	using	a	peak	
fluorescence	 gate	 to	 exclude	 cell	 aggregates	 during	 cell	 cycle	 analysis	 in	 a	 FACS	 Calibur	 flow	
cytometer	(Becton-Dickinson,	San	Jose,	CA,	USA).	
4.3.7	-	Wound	healing	assays	
Migration	assay	was	performed	on	human	U2OS	and	SW982.	The	cells	were	incubated	at	37	°C	in	
5%	 CO2	 for	 24	 h,	 then	 incubated	 in	 100%	 BM-MSC-CM	 supplemented	 or	 not	 with	 CXCR4	
antagonists,	AMD3100	(30μg/ml)	and	MDX1338	(0.005μg/ml).		
A	sterile	10μl	pipette	tip	was	used	to	make	a	wound	across	a	cell	culture	monolayer.	To	investigate	
cell	migration	the	plate	was	photographed	at	different	time	points	after	wounding	(0h,	4h,	8h,	12h,	
18h)	and	the	area	of	wound	was	measured	by	 ImageJv.1.45r	software	 (160).	The	experiment	was	
repeated	three	times.	The	extent	of	wound	closure	was	determined	as	follows:	wound	closure	(%)	=	
1	−	(wound		width	tx/wound	width	t0)	×	100.	All	experiments	were	performed	at	least	three	times.	
4.3.8	-	Statistical	analysis	
All	data	were	presented	as	mean	±	SE	from	three	independent	experiments.	Statistical	significance	
was	analysed	by	the	Student’s	t-test	and	a	probability	value	of	p<0.05	was	considered	to	indicate	a	
statistically	significant	difference.	
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5	-	RESULTS		
	
5.1	-	Aim	1:	Immune	context	in	osteosarcoma	and	synovial	sarcoma		
5.1.1	-	Osteosarcoma	
5.1.1	-	Tumoral	microenvironment	components	prior	chemotherapy	(bioptic	samples)	
Eighty-six	 out	 of	 129	 patients	 with	 localized	 osteosarcoma	 analysed	 had	 evaluable	 results	 for	 at	
least	7	markers	and	were	included	in	the	present	study.		
Most	 of	 the	 cases	 presented	 TILs	 (CD3+	 77/86,	 90%;	 CD8+	 74/86,	 86%,	 CD20+	 25/86,	 29%)	 and	
FOXP3+	population	(Treg)	were	detected	in	28/86	(33%).	Tia-1	was	detected	in	57/78	(73%)	of	the	
samples.	 TAMs	 (CD163	 positive)	 were	 observed	 in	 the	 microenvironment	 in	 47/70	 (67%)	 of	 the	
patients,	while	31/74	(37%)	patients	presented	also	high	 levels	of	CD68	positivity.	Only	3/78	 (4%)	
and	 16/78	 (21%)	 cases	 presented	 CD303+	 and	 Arginase-1+	 cells.	 PD-L1	 expression	 was	 found	 in	
12/86	(14%)	patients	in	IC	and	0/86	(0%)	in	TC;	19/86	(22%)	showed	PD-1	expression	in	IC	(Table	1;	
Figure	1).	
	
Table	1.	Immunological	characterization	of	tumor	microenvironment	in	86	patients	with	localized	
osteosarcoma.	
		 CD3	n	(%)	
CD8	
n	(%)	
CD20	
n	(%)	
FOXP3	
n	(%)	
Tia1	
n	(%)	
CD68*	
n	(%)	
CD163	
n	(%)	
CD303	
n	(%)	
Arg-1	
n	(%)	
PD-L1	
(TC)	
n	(%)	
PD-1	
(IC)	
n	(%)	
PD-L1	
(IC)	
n	(%)	
Pos	 77	(90)	 74	(86)	 25	(29)	 28	(33)	 57	(73)	 31	(37)	 47	(67)	 3	(4)	 16	(21)	 0	(0)	 19	(22)	 12	(14)	
Neg	 9	(10)	 12	(14)	 61	(71)	 58	(67)	 21	(27)	 53	(63)	 23	(33)	 75	(96)	 62	(79)	 86	(100)	 67	(78)	 74	(86)	
	
Arg-1:	 Arginase-1;	 TC:	 tumor	 cells;	 IC:	 immune	 cells;	 *	 CD-68:	 Pos:	 high	 level	 expression;	 neg:	 low	 level	
expression.	
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Figure	1.	Tumor	microenvironment	components		
	
Immunohistochemical	 expression	 in	 tumor	 microenvironment	 of	 CD3,	 CD8,	 CD20	 (T	 tumor	 infiltrating	 lymphocytes:	
TILs),	 Tia-1	 (cytotoxic	 T	 cell),	 FOXP3	 (T	 regulatory	 lymphocytes:	 T-regs),	 PD-1,	 PD-L1,	 CD68	 (tumor	 associated	
macrophages:	TAM),	BDCA-2/CD303	(plasmacytoid	dendritic	cells:	pDC),	Arginase-1	(myeloid	derived	suppressor	cells:	
MDSC)	proteins.		
	
	
Survival	analysis	
With	a	median	follow-up	of	8	years	(range	1-13),	the	5-year	OS	was	74%	(95%	CI	64-85).		
Univariate	 analysis	 showed	 better	 5-year	 OS	 for	 good	 responders	 (good	 89%	 vs.	 poor	 57%,	 p	 =	
0.0001),	for	cases	with	patients	with	CD8/Tia1	tumoral	infiltrates	(CD8+/Tia1+	81%	vs	CD8+/Tia1-	60%	
vs	CD8-/Tia1-	45%,	p	=	0.002)	and	patients	with	normal	AP	at	baseline	 (AP	normal	85%	vs	AP	high	
44%,	p	=	0.04)	(Table	2,	Figure	2).	
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Figure	 2.	 a)	 5-year	 overall	 survival	 according	 to	 CD8/Tia1	 expression	 at	 diagnosis	 in	 localized	
osteosarcoma;	 b)	 5-year	 overall	 survival	 according	 to	 PD-L1	 expression	 at	 diagnosis	 in	 patients	
with	CD8+	localized	osteosarcoma.	
	
	
	
	
Table	2.	Univariate	Analysis	for	Overall	Survival	(OS)	in	localized	osteosarcoma	
																													
	 Pts	N.	 %	5-year		OS	 95%	CI	 P-value	
Overall	 86	 74.5	 65-84	 	
Age	 	 	 	 0.9	
		 ≥	18	years	 27	 74	 57-90	 	
		 <	18	years	 59	 75	 63-86	 	
Sex	 	 	 	 0.8	
	 Female	 33	 76	 61-90	 	
	 Male	 53	 74	 61-89	 	
Histologic	Response°		 	 	 	 0.0001	
	 Good	 45	 89	 80-98	 	
	 Poor	 40	 57	 42-73	 	
CD8		 		 	 	 0.003		
Positive	 74	 78	 69-88	 	
Negative	 12	 50	 22-78	 	
TIA-1	°°	 	 	 	 0.008	
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Not	available	 in	1	patient;	 °°	non	available	 in	8	patients;	 *	not	 available	 in	2	patients;	 **	not	available	 in	7	patients;	
***not	available	in	16	patients	
	
	
No	 statistically	 significant	 difference	was	observed	 in	 5-year	OS	 according	 to	 PD-1,	 FOXP3,	 CD68,	
CD20,	Arginase-1,	CD303,	CD163	expression	 in	microenvironment,	 and	age,	 gender	or	 LDH,	while	
PD-L1	 (IC)	 positive	 cases	 had	 a	 non-significant	 inferior	5-year	OS	(PD-L1+	58%	vs	PD-L1-	77%,	p	=	
Moderate	 14	 86	 67-100	 	
Focal	 43	 79	 67-91	 	
None	 21	 52	 31-74	 	
CD8/	Tia1	°°	 	 	 	 0.002	
	 Positive	/	Positive	 57	 81	 70-91	 	
	 Positive	/	Negative	 10	 60	 30-90	 	
	 Negative	/	Negative	 11	 45	 16-75	 	
CD3	 	 	 	 0.07	
	 Positive	 77	 78	 69-87	 	
	 Negative	 9	 44	 12-77	 	
FOXP3		*	 	 	 	 0.13	
		 Positive	 28	 75	 54-93	 	
		 Negative	 56	 73	 64-85	 	
PD-1	(IC)	 	 	 	 0.6	
	 Positive	 19	 74	 54-93	 	
	 Negative	 67	 74	 64-85	 	
PD-L1	(IC)	 	 	 	 0.14	
	 Positive	 12	 58	 30-86	 	
	 Negative	 74	 77	 67-87	 	
LDH	°°	 	 	 	 0.15	
	 Normal	 60	 78	 68-89	 	
	 High	 18	 61	 39-84	 	
sAP	 	 	 	 0.04	
	 Normal	 48	 85	 75-95	 	
	 High	 38	 64	 48-80	 	
Arginase-1	**	 	 	 	 0.3	
	 Positive	 16	 81	 62-100	 	
	 Negative	 61	 70	 59-82	 	
CD303	°°	 	 	 	 0.9	
	 Positive	 3	 67	 13-100	 	
	 Negative	 75	 73	 63-83	 	
CD68	*	 	 	 	 0.1	
	 High	 31	 84	 71-99	 	
	 Low	 53	 67	 54-80	 	
CD163	***	 	 	 	 0.17	
	 Positive	 47	 81	 70-92	 	
	 Negative	 23	 56	 36-77	 	
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0.14)	(Table	2).		
After	 multivariate	 analysis,	 good	 histologic	 response	 (p	=	0.007)	 and	 a	 CD8+/Tia1+	 lymphocytic	
infiltrate	(0.05)	were	independently	associated	with	better	survival	(Table	3).	
Table	3.	Multivariate	Analysis	for	Overall	Survival	(OS)		
in	patients	with	localized	osteosarcoma	
	
Since	 PD-L1(IC)	 is	 a	marker	 of	 cytotoxic	 function	 exhaustion,	we	 investigated	 if	 PD-L1	 expression	
could	influence	survival	in	the	subgroup	of	patient	with	CD8+	lymphocytes:	at	univariate	analysis	the	
5-year	 OS	 was	 82%	 (95%CI	 73%-92%)	 in	 case	 of	 PD-L1	 negative	 and	 58%	 (95%	 CI	 34%-78%)	 in	
positive	PD-L1	(p	=	0.03)	(Figure	2).		
At	the	multivariate	analysis	in	this	subgroup,	lack	of	PD-L1	was	and	independent	prognostic	factor	
for	longer	survival	(p	=	0.04)	(Table	4).	
	
Table	4.	Multivariate	Analysis	for	Overall	Survival	in	patients	with		
CD8+	localized	osteosarcoma	
Variable	 RR	 95%	CI	 P	
CD8/Tia1	 	 	 	
Positive/Positive	 reference	 	 0.05	
Positive/Negative	 1.8	 0.7-5.2	 0.2	
Negative/Negative	 3.1	 1.2-7.8	 0.01	
Histologic	Response	 	 	 	
Poor	 reference	 	 0.007	
Good	 0.27	 0.1-0.7	 	
sPA	 	 	 	
Normal	 reference	 	 0.2	
High	 1.75	 0.8-3.9	 	
Variable	 RR	 95%	CI	 P	
PD-L1	 	 	 	
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5.1.2	-	Tumoral	microenvironment	post-induction	chemotherapy	(surgical	samples)	
Based	on	multivariate	 analysis	 results	on	pre-treatment	 samples,	 a	post-hoc	analysis	on	CD8	and	
Tia1	 was	 performed.	 Due	 to	 post-treatment	 changes	 33/86	 patients	 were	 assessable	 after	
treatment	(excluding	53	patients	with	massive	necrosis	and	no	tumor).	
Chemotherapy-induced	changes	of	CD8+	TILs	were	as	follow:	all	patients	with	score	0	(5	cases)	were	
unchanged,	 the	 proportion	 of	 patients	 with	 score	 1	 decreased:	 19/33	 (58%)	 pre-chemotherapy,	
14/33	(42%)	post-treatment;	and	the	proportion	of	patients	with	a	score	2/3	increased:	9/33	(27%)	
to	12/33	(36%)	(p	=	0.5).				
A	survival	analysis	according	to	presence	of	CD8+/Tia1+	infiltrates	presence	in	the	surgical	samples	
after	induction-chemotherapy,	confirmed	their	prognostic	role:	5-	year	OS	was	78%	(CI%	51-100)	for	
CD8+	/Tia1+	(22	patients),	64%	(CI%43-84)	for	CD8+/Tia1-	(9	patients)	and	none	was	alive	with	CD8-
/Tia1-	(2	patients)	(p	=	0.05)	(Figure	3).	
	
	
Negative	 reference	 	 0.04	
Positive	 2.8	 1-7.4	 	
Histologic	Response	 	 	 	
Poor	 reference	 	 0.02	
Good	 0.3	 0.1-0.9	 	
sPA	 	 	 	
Normal	 reference	 	 0.5	
High	 1.4	 0.5-3.8	 	
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Figure	3.	5-year	overall	survival	according	to	CD8/Tia1	expression		
after	induction	chemotherapy	in	localized	osteosarcoma	
	
	
5.1.2	-	Synovial	Sarcoma	
A	 total	 of	 88	 consecutive	 patients	 were	 selected.	 Forty-five	 patients	 were	 female	 and	 43	 male;	
median	age	was	37	years	 (range	11–63);	14	were	adolescents	and	young	adults	 (AYA)	 (<30	years)	
and	 74	were	 adults	 (≥30	years).	 Size	 of	 the	 lesion	was > 5	cm	 in	 60	 patients	 (68%),	 ≤	 5	cm	 in	 24	
(27%)	and	unknown	in	4	patients.	The	tumor	site	was	trunk	in	13	cases	(15%),	lower	extremity	in	64	
cases	(73%),	upper	extremity	in	11	cases	(12%).	Histotypes:	30	patients	(34%)	had	biphasic	synovial	
sarcoma,	51	(58%)	monophasic	synovial	sarcoma	and	7	(8%)	poorly	differentiated	synovial	sarcoma.	
All	patients	underwent	surgery	with	adequate	surgical	margins	in	68	cases,	inadequate	in	18	and	in	
2	 cases	 surgical	margins	were	 unknown.	 Amputation	was	 performed	 in	 24	 patients	 (27%).	 Forty-
seven	patients	(53%)	underwent	adjuvant	radiotherapy	(RT)	and	57	(65%)	received	chemotherapy:	
27	 of	 them	 (47%)	 preoperatively	 (epirubicin/adrymicin	 and	 ifosfamide	 combination	 in	 49	 cases,	
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non-ifosfamide	containing	regimen	in	8	cases	and	in	1	case	the	treatment	was	unknown).	
FISH	and	RT-PCR	Analysis	
By	FISH	analysis,	all	88	SS	presented	SS18	(SYT)	gene	rearrangement	resulting	in	(X;18)(p11.2;q11.2)	
translocation,	thus	confirming	the	histological	diagnosis.	The	presence	of	SSX	fusion	transcripts	was	
assessed	on	46	frozen	tissues	by	RT-PCR:	28	cases	presented	SSX1	variant,	18	had	SSX2	variant.	
Immunohistochemistry		
Most	of	 the	 cases	presented	TILs	 (CD3+	79/82,	 96%;	CD8+	73/84,	 87%),	while	 FOXP3+	population	
(Treg)	were	detected	in	9/84	(11%).	PD-L1	expression	was	found	in	10/82	(12%)	patients	in	IC	and	in	
2/82	patients	(2%)	in	TC.	In	16/85	(19%)	cases	PD-1	expression	in	IC	was	demonstrated	(Table	1).	
	
Table	1.	Immunological	characterization	of	tumor	microenvironment		
in	86	patients	with	localized	synovial	sarcoma	
	 CD3	n	(%)	
CD8	
n	(%)	
FOXP3	
n	(%)	
PD-L1	
(TC)	
n	(%)	
PD-1	
(IC)	
n	(%)	
PD-L1	
(IC)	
n	(%)	
Pos	 79	(96)	 73	(87)	 9	(11)	 2	(2)	 16	(19)	 10	(12)	
Neg	 3	(4)	 11	(13)	 75	(89)	 80	(98)	 69	(81)	 72	(88)	
	
Outcome	and	statistical	correlations	
With	a	median	follow-up	of	6	years	(1–30	years),	the	5-year	overall	survival	(OS)	was	70%	(95%	Cl	
60-81%).	The	5-year	OS	was	significantly	better	for	young	patients	(100%	for	AYA	and	65%	for	adult	
patients,	p = 0.003).	The	5-year	OS	was	not	significantly	different	for	patients	CD8+	TILs.		
Since	patients	were	not	homogenous	for	treatment	we	also	performed	the	analysis	in	the	sub-group	
of	patients	undergoing	surgery	without	adjuvant	chemotherapy.	
Interestling,	while	patients	CD8+	had	a	5	and	10-year-OS	of	62%	and	50%	respectively,	all	patients	
with	no	CD8	were	long	survivors	(all	alive	after	 10-years).	 After	 adjuvant	 chemotherapy	 5-year	
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OS	for	CD8+	and	CD8-	was	67%	and	60%	respectively	(p	=	0.9).	
	
	
Table	2.	Univariate	Analysis	for	Overall	Survival	(OS)	in	localized	synovial	sarcoma	
	 	
	 Pts	N.	 %	5-year		OS	 95%	CI	 P-value	
Overall	 88	 68	 57-70	 	
Age	 	 	 	 0.003	
		 ≥	30	years	(adult)	 74	 65	 50-78	 	
		 <	30	years	(AYA)	 14	 100	 	 	
Size	(uk	in	4)	 	 	 	 0.4	
	 	<	5	cm	 24	 82	 66-98	 	
	 ≥	5	cm	 60	 67	 53-80	 	
Histology	 	 	 	 0.5	
	 	Biphasic		 30	 67	 53-80	 	
	 	Other	 58	 76	 59-93	 	
Chemotherapy	 	 	 	 0.5	
	 	Yes		 60	 68	 54-81	 	
	 	No	 38	 73	 67-85	 	
CD8	(uk	in	4)	 		 	 	 0.4		
Positive	 73	 66	 53-78	 	
Negative	 11	 72	 44-99	 	
CD3		(uk	in	4)	 	 	 	 0.5	
	 Positive	 79	 67	 55-78	 	
	 Negative	 3	 33	 0-87	 	
FOXP3		(uk	in	4)	 	 	 	 0.9	
		 Positive	 9	 76	 47-100	 	
		 Negative	 75	 65	 53-77	 	
PD-1	(IC)	 	 	 	 0.7	
	 Positive	 16	 63	 37-89	 	
	 Negative	 69	 68	 56-80	 	
PD-L1	(IC)	 	 	 	 0.8	
	 Positive	 10	 66	 33-100	 	
	 Negative	 72	 66	 53-78	 	
PD-L1	(TC)	 	 	 	 NV	
	 Positive	 2	 100	 	 	
	 Negative	 80	 65	 53-66	 	
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5.2	-	Aim	2:	Anti-VEGFR	and	anti-PD-1	activity	in	osteosarcoma	and	synovial	sarcoma	
5.2.1	-	Sunitinib	malate	inhibit	proliferation	in	sarcomas		
The	sunitinib	effect	on	proliferation	was	studied	 in	synovial	sarcoma	cell	 lines	(SYO-1	and	SW982)	
and	 in	2	osteosarcoma	cell	 lines	(MG-63	and	osteoblastic	SaOS-2).	Treatment	of	synovial	sarcoma	
cell	 line	 SW982	 for	 24	 h,	 48	 h,	 72	 h	with	 0.5	 μM,	 1	 μM,	 3	 μM,	 5	 μM,	 7	 μM	an	 10	 μM	 sunitinib	
inhibited	proliferation	 in	a	dose-dependent	manner	as	assessed	by	cell	proliferation-assay	 (Figure	
1a),	with	best	result	obtained	after	72	h	with	10	μM	sunitinib.	The	effect	on	synovial	cell	line	SYO-1	
was	very	similar	(Figure	1b),	but	the	greater	inhibition	of	proliferation	was	reached	at	48	h	with	10	
μM	 sunitinib.	 Treatment	 of	 osteosarcoma	 cell	 lines	 MG-63	 and	 SaOS-2	 for	 24	 h,	 48	 h,	 72	 h	 at	
increasing	sunitinib	concentration	was	also	able	to	inhibit	proliferation	in	a	dose-dependent	manner	
(Figure	1c,	1d),	with	best	result	obtained	after	72	h	with	10	μM	sunitinib.	
	
Figure	1.	Sunitinib	significantly	reduce	proliferation	in	sarcomas	
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5.2.2	-	Sarcoma	cell	lines	express	PD-L1	
PD-L1	expression	was	detected	in	all	cell	lines	tested,	with	a	median	expression	(in	4	experiments)	
ranging	from	21.6%	(SYO-1)	al’	81.3%	(SaOS-2)	(Figure	2)	
	
	
Figure	2.	Express	of	PD-L1	in	osteosarcoma	and	synovial	sarcoma	
	
	
	
5.2.3	-	PD-1	blockade	hamper	sarcoma-induced-PD1	expression	on	lymphocytes	
Lympocytes	–	sarcoma	co-culture	
We	 hypothesized	 that	 sarcoma	 cell	 lines	 were	 tolerogenic	 by	 increasing	 PD-1	 expression	 on	
		 79	
lymphocytes.	We	demonstrated	that	mean	 intensity	of	 fluorescence	(MIF)	 for	PD-1	was	 increased	
by	osteosarcoma	cell	line	SaOS-2	(Figure	3).	
	
	
Figure	 3.	 Osteosarcoma	 cell	 line	 SaOS-2	 induced	 increase	 of	 PD-1	 MIF	 (mean	 intensity	 of	
fluorescence)	in	CD4	and	CD8	lymphocytes.	
	
	
	
	
We	also	assumed	that	nivolumab	/PD-1	blockade	might	hamper	sarcoma	tolerance,	by	decreasing	
PD-1	expression.		
As	said,	adding	osteosarcoma	cell	 line	SaOS-2	prior	to	the	functional	assays	significantly	 increased	
PD-1	 expression	 on	 lymphocytes	 (CD3+/CD8+),	 and	 nivolumab,	 was	 able	 to	 decrease	 PD-1	
expression	(Figure	4	a,	c);	similar	effects	were	observed	on	CD4+	gated	lymphocytes	(Figure	4	b,c).	
	
		 80	
Figure	4.	Osteosarcoma	cell	line	SaOS-2	co-cultured	with	lymphocytes	induced	PD-1	up-regulation	
both	 on	 CD3/CD8	 lymphocytes	 (from	 0.5%	 to	 6.7%)	 (a,	 c)	 and	 on	 CD3/CD4	 lymphocytes	 (from	
0.9%	 to	7.5%)	 (b,	 c);	nivolumab	counteracts	PD-1	up-regulation,	0%	expression	after	nivolumab	
exposure,	on	CD3/CD8	lymphocytes	(a,	c),	and		reduction	on	CD3/CD4	lymphocytes,	(b,	c).	
	
	
	
Gated	on	CD8	T	cell	
Gated	on	CD4	T	cell	
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Lymphocytes	-	Dendritic	cell	(DCs)	coculture	(allogeneic	mixed	lymphocyte	reaction	-	MLR)	
The	 ability	 of	 nivolumab	 to	 promote	 T-cell	 response	was	 also	 evaluated	 in	 vitro	 using	 allogeneic	
MLR.	
In	an	allogeneic	MLR,	human	monocyte-derived	immature	dendritic	cells	(DCs)	pulsed	with	SaOS-2	
cell	 line	 lysate	were	 co-cultured	with	 lymphocytes:	 PD-1	 blockade	with	 nivolumab	 systematically	
resulted	 in	a	dramatic	decrease	of	PD-1	expression	on	 lymphocytes,	while	 their	proliferation	was	
unchanged	(Figure	5).	
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Figure	5.	PD-1	up-regulation	 induced	by	dentritic	 cells	 (DCs)	pulsed	with	osteosarcoma	cell	 line	
SaOS;	nivolumab	counteracts	PD-1	up-regulation	both	on	CD3/CD8	and	CD3/CD4	lymphocytes	(a),	
while	the	proliferation	is	not	affected	with	a	proliferation	index	only	slightly	increase	after	SaOS-2	
co-culture	(both	in	presence	of	lymphocytes	only	or	lymphocytes	and	DCs	co-culture)	and	almost	
unchanged	after	nivolumab	supplementation		(b).	
	
	
5.2.4	-	Nivolumab	activity	on	activated	T-lymphocytes		
Lymphocytes	–	sarcoma	co-culture	
After	exposure	of	T	lymphocytes	to	osteosarcoma	cell	line	SaOS-2,	we	observed	the	induction	of	a	
new	subset	of	activated	T-lymphocytes,	distinguished	by	a	morphological	 shift	on	 forward	scatter	
(Figure	6)	
Figure	6.	Induction	of	a	new	subset	of	activated	T-lymphocytes,	
distinguished	by	a	morphological	shift	on	forward	scatter	(red	arrow)	
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The	 effect	 of	 nivolumab	 in	 the	 sub	 group	 of	 activated	 T-lymphocytes	 was	 more	 pronounced,	 if	
compared	with	inactivated	lymphocytes	as	shown	in	Figure	7.	
	
	
	
Figure	7.	PD-1	up-regulation	induced	by	osteosarcoma	cell	line	SaOS-2;		
no	PD-1	expression	can	be	detected	after	nivolumab	both	on	CD4	and	CD8	on	activated	T-cells	(a),	
while	on	non-activated	lymphocytes	PD-1	expression	is	similar	to	baseline	levels	for	CD4	(b),	and	
reduced	but	still	expressed	on	CD8	(a).	
	
	
	
	
	
	
	
After	performing	the	same	analysis	in	the	subset	of	CD8	or	CD4	activated	lymphocytes,	we	observed	
the	ability	of	nivolumab	to	reduce/abort	PD-L1	up-regulation	is	increased,	as	compared	to	the	entire	
group	of	CD8/CD4	lymphocytes	(Figure	8).	
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Figure	8.	PD-1	up-regulation	induced	by	osteosarcoma	cell	line	SaOS-2	in	the	subset	of	activated	
CD4	and	CD8	lymphocytes;	after	nivolumab	PD-1	expression	is	abrogated	both	on	CD4+	activated	
lymphocytes	(PD-1	positivity	from	8.62%	to	0%)	(left	panel)	and	CD8+	activated	lymphocytes	(PD-1	
positivity	from	19.63%	to	0%)	(right	panel)	
	
Lymphocytes	-	Dendritic	cell	(DCs)	co-culture	(allogeneic	mixed	lymphocyte	reaction	-	MLR)	
Similarly,	 in	 allogeneic	 MLR,	 when	 lymphocytes	 were	 co-cultured	 with	 DCs	 pulsed	 with	
osteosarcoma,	PD-1	blockade	with	nivolumab	systematically	resulted	in	a	dramatic	decrease	of	PD-
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1	expression	on	the	subset	of	CD4+	and	CD8+	activated	lymphocytes	(Figure	9).	
Figure	9.	PD-1	up-regulation	 induced	by	dentritic	 cells	 (CDs)	pulsed	with	osteosarcoma	cell	 line	
SaOS-2;	 nivolumab	 counteracts	 PD-1	 up-regulation	 on	 CD4+	 activated	 lymphocytes	 (PD-1	
positivity	from	35.29%	to	0.76%)	(left	panel)	and	on	CD8+	activated	lymphocytes	(PD-1	positivity	
from	21.66%	to	0.49%)	(right	panel)		
	
	
5.2.5	-	Sunitinib	induce	apopotosis	in	sarcoma	
We	 used	 sunitinib	 at	 4	 different	 concentrations	 (10	 μM,	 15	 μM,	 20	 μM	 and	 30	 μM).	 Sunitinib	
induced	 dose-dependent	 cell	 death	 as	 demonstrated	with	 Annexin	 test	 in	 osteosarcoma	 (MG-63	
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and	SaOS-2),	in	synovial	sarcoma	(SYO-1	and	SW982)	(Figure	10).	
Figure	10.	Dose-dependent	 apoptosis	 in	osteosarcoma	 (SaOS-2	 and	MG-63)	 and	 synovial	 sarcoma	
(SW982	and	SYO-1)	cell	lines,	with	red	arrow	showing	for	each	cell	line	a	concentration	of	sunitinib	
sufficient	 to	 obtain	 at	 least	 30%	 of	 apoptotic	 cells,	 after	 24	 hours	 exposure	 to	 different	
concentration	of	sunitinib	
	
	
	
	
5.2.6	–	Sunitinib	and	PD-L1	expression	in	sarcoma	
	
Sunitinb	 was	 able	 to	 immunomodulate	 the	 expression	 of	 PD-L1	 in	 synovial	 sarcoma	 and	 SaOS-2	
osteosarcoma	cell	lines	assessed,	while	MG-63,	an	osteosarcoma	cell	line,	showed	constant	levels	of	
PL-L1	expression	after	sunitinib	5,	7	e	10	μM	(Figure	11).	
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Figure	 11.	A	dose-dependent	PD-L1	up-regulation	was	demonstrated	 in	 osteosarcoma	 cell	 lines	
SaOS-2	and	MG-63	and	in	synovial	sarcoma	cell	line	SYO-1	(A,	C	and	D),	while	an	up-regulation	of	
PD-L1	expression	was	shown	at	concentration	of	30	μM		in	SW982	cell	line	with	no	changes	with	
lower	doses	(B).		
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5.3	-	Aim	3:	Anti-CXCR4	activity	in	osteosarcoma	and	synovial	sarcoma	
5.3.1	-	SYT-SSX	translocation	in	synovial	sarcoma	cell	lines	
Before	 all	 the	 experiments,	 we	 tested	 our	 synovial	 sarcoma	 cell	 lines	 for	 the	 presence	 of	 the	
pathognomonic	 translocation:	 the	 commercial	 sarcoma	 cell	 line	 SW982	 lacked	 SYT-SSX	
translocation,	as	expected,	while	SYO-1	carried	the	SYT-SSX	translocation.		
	
Table	1.	t(X;18)	SS18(SYT)-SSX1	in	synovial	sarcoma	by	RT-PCR	
	
Cell	lines	 SYT-SSX	translocation	
SYO-1	 Positive	(SYT-SSX1,	SYT-SSX2)	
SW982	 Negative	
	
	
5.3.2	-	CXCR4	and	SDF-1	(CXCL12)	expression	in	sarcoma	cell	lines		
To	evaluate	whether	CXCR4	and	 its	corresponding	 ligands	SDF-1	 (CXCL12)	contributed	to	sarcoma	
progression,	we	first	determined	the	mRNA	and	protein	expression	of	CXCR4	in	3	cell	lines	(SW982,	
SYO-1,	U2OS)	using	qRT-PCR	(TaqMan	gene	expression	assay)	and	by	FACS	analysis,	respectively.	
	
CXCR4	mRNA	was	expressed	in	all	3	cell	lines	and	the	highest	expression	level	was	found	in	SYO-1	as	
compared	with	both	commercial	 sarcoma	cell	 line	SW982	 (using	mesenchymal	 cells	as	 calibrator)	
and	osteosarcoma	cell	lines	U2OS	(using	osteoblast	as	calibrator)	(Table	2).		
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Table	2.	CXCR4	(mRNA)	expression	in	sarcoma	cell	lines		
Cell	lines	 CXCR4	expression	(2_DDCT)	
SW982	(synovial	sarcoma)	 4482	
SYO-1	(synovial	sarcoma)	 50012	
U2OS	(osteosarcoma)	 131	
	
Then	 we	 evaluated	 protein	 expression	 of	 CXCR4	 and	 SDF-1	 (CXCR12)	 by	 immunofluorescence	
analysis.	The	three	cell	lines	showed	a	different	distribution	of	expression	(Figure	1-3):		
- Osteosarcoma	U2OS	 cell	 line	 expressed	 CXCR4	 and	 SDF-1	 (CXCR12)	 in	 98%	 and	 80%	of	 cells,	
respectively	
	
Figure	1.	CXCR4	and	SDF-1	(CXCR12)	in	osteosarcoma	U2OS	cell	line	
		 	
	
	
- synovial	 sarcoma	 SW982	 cells	 expressed	 CXCR4	 (left	 panel,	 grey	 spike)	 and	 SDF-1	 (CXCL12)	
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(right	panel,	grey	spike)	in	83.5	and	41%	respectively,	as	compared	with	control	(black	spike)	
	
Figure	2.	CXCR4	and	SDF-1	(CXCL12)	in	SW982	cell	line		
																							 	
- Synovial	 sarcoma	 SYO-I	 cell	 line	 expressed	 CXCR4	 and	 SDF-1	 (CXCL12)	 in	 12.0%	 and	 6.0%,	
respectively.	
	
Figure	3	CXCR4	and	SDF-1	(CXCL12)	in	synovial	sarcoma	SYO-I	cell	line	
																													 	
	
	
5.3.3	-	SDF-1	(CXCL12)	expression	in	different	media	
By	 Elisa	 analysis	 the	 levels	 of	 SDF-1	 (CXCL12)	 was	higher	in	in	BM-MSC-CM,	when	compared	to	
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αMEM	alone,	or	αMEM	supplemented	with	25%	BM-MSC	(Table	3).	
	
Table	3.	SDF1	(CXCL12)	expression	in	αMEM	
Conditions	 SDF-1α/CXCL12	(pg/mL)		
αMEM	1%	FBS	 307,5616	
αMEM	 1%	 FBS	
+25%	BM-MSC	
351.09	
	
BM-MSC	–CM	
(100%	BM.MSC)	
1071,369	
	
	
	
Figure	4.	SDF-1	(CXCL12)	concentration	in	different	media	
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5.3.4	-	Treatment	with	MDX1338	and	AMD3100	reduce	SW983	and	U2OS	proliferation	
MDX	 and	 AMD3100,	 specific	 chemical	 inhibitor	 for	 CXCR4,	 can	 block	 SDF-1/CXCR4	 signalling	
pathway.	 Our	 goal	 was	 to	 investigate	 whether	 MDX1338/AMD3100	 treatment	 can	 reduce	
osteosarcoma	 (U2OS)	and	 synovial	 sarcoma	 (SW982)	 cell	 viability	 (experiments	on	SYO-1	 synovial	
sarcoma	 cell	 line	 are	 ongoing).	 Secondly,	 we	 evaluated	 if	 the	 combined	 use	 of	 doxorubicin	 and	
CXCR4	inhibitors	could	result	in	additive	or	synergistic	inhibition	effect.		
Synovial	sarcoma	(SW982)	cell	viability	after	CXCR4	inhibitor	treatment	
	SW982	 cells	 responded	 to	 different	 MDX1338	 concentrations	 (0.001	 μg/ml,	 0.005	 μg/ml,	 0.05	
μg/ml),	with	a	small	reduction	of	cell	viability,	reaching	a	cell	death	rate	at	72h	of	22%	with	0.005	
µg/ml	drug	concentration	(Figure	5).	
	Similarly,	 AMD3100	 treatment	 (5	 μg/ml,	 20	μg/ml,	 30	μg/ml)	 caused	 a	 cell	 viability	 reduction	 of	
30%	after	72	h	using	a	drug	concentration	of	30	µg/ml		(Figure	6).	
	
Figure	5.		SW982	proliferation	after	treatment	with	MDX1338	
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Figure	6.		SW982	proliferation	after	treatment	with	AMD3100	
	
	
	
Osteosarcoma	cell	viability	(U2OS)	after	CXCR4	inhibitor	treatment		
Several	MDX1338	concentrations	were	tested	(0.001	μg/ml,	0.005	μg/ml,	0.05	μg/ml),	at	48h.	We	
observed	the	best	results	at	using	a	drug	concentration	of	0.005	µg/ml,	with	a	cell	viability	decrease	
of	about	30%	(Figure	7).	
Similarly,	for	AMD3100	we	assessed	different	concentrations		(5	μg/ml,	20μg/ml,	30	μg/ml)	at	48h,	
and	obtained	a	40%	of	reduction	in	cell	viability	with	a	drug	concentration	of	30	µg/ml	(Figure	8).	
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Figure	7.		U2OS-2	proliferation	after	treatment	with	MDX1338			
	
Figure	8.		U2OS	proliferation	after	treatment	with	AM3100	
	
5.3.5	-	Treatment	with	MDX1338	and	AMD3100	does	not	change	CXCR4	expression		
We	 wanted	 to	 verify	 whether	 the	 treatment	 with	 CXCR4	 inhibitors	 might	 be	 able	 to	 change	
(induce/reduce)	 the	 expression	 of	 CXCR4	 protein.	 FACS	 analysis	 demonstrated	 that	 CXCR4	
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expression	in	SW982	(Figure	9)	and	U2OS	(Figure	10)	was	almost	unchanged	after	72h	of	MDX1338	
(0.005	μg/ml)	and	AMD3100	(30	μg/ml	treatment)		(2.93%	and	0.78%	reduction	respectively)			
	
Figure	9.	CXCR4	expression	in	SW982	changes	after	treatment	with	CXCR4	inhibitors	
	
Figure	10.	CXCR4	expression	in	U2OS	changes	after	treatment	with	CXCR4	inhibitor	
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5.3.6	-	Treatment	with	MDX1338	and	AMD3100	reduces	SW982	and	U2OS	cells	migration	
We	explored	whether	MDX1338	and	AMD3100	could	decrease	migration	of	SW982	cells.	CXCL12	is	
a	 potent	 chemotactic	 factor	 and	 can	 induce	 directional	 migration	 of	 hematopoietic	 and	 non-
hematopoietic	 cells.	 Wound	 healing	 assay	 at	 different	 time	 points	 (24h,	 48h,	 72h)	 reached	 the	
complete	wound	closure	after	24	hours	of	 treatment,	with	a	 short-term	slowing	down	up	 to	48h	
with	both	AMD3100	and	MDX1338,	when	compared	to	control	(Figure	11)	
	
Figure	11.	SW982	migration	after	treatment	with	CXCR4	inhibitors:	a)	Image-based	monitoring;	b)	
Wound	closure	expressed	as	a	percentage	of	the	initial	wound	area	that	has	healed.	
	
	
	
	
In	contrast,	U2OS	responded	to	MDX1338	and	AMD3100	treatment	with	an	evident	decrease	of	cell	
motility	up	to	72h	compared	to	control	(Figure	12).	
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Figure	12.	U2OS	migration	after	CXCR4	inhibitor	treatment:	a)	Image-based	monitoring;	b)	Wound	
closure	expressed	as	a	percentage	of	the	initial	wound	area	that	has	healed.	
	
	
	
5.3.7	-Treatment	with	MDX1338	and	AMD3100	promote	SW982	and	U2OS	cells	apoptosis		
The	 effects	 of	MDX1338	 (0.005	 μg	 /ml)	 and	AMD3100	 (30	 μg	 /ml)	 on	 SW982	 cell	 apoptosis	was	
analyzed	by	 flow	cytometry.	 Experimental	 results	 showed	a	 significant	 increase	of	 apoptotic	 cells	
after	CXCR4	inhibitors	treatments	compared	with	the	untreated	cells.	The	percentage	of	apoptotic	
cells	was	3.42%	and	12.9%	at	48h	and	72h	respectively	in	untreated	cells	versus	6.4%	(p=0.006)	and	
22.3%		(p=	0.002)	respectively	for	MDX1338,	and	10.0%		(p=0.003)	and	23%	(p=0.004)	for	AMD	3100	
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(Figure	13).		
Figure	13.	SW982	apoptosis	after	treatment	with	CXCR4	inhibitors	
	
U2OS	cells	responded	similarly	to	CXCR4	inhibitors,	with	an	increase	of	the	apoptotic	rate	1.9%	and	
8.3%	 at	 48h	 and	 72h	 in	 untreated	 cells,	 versus	 3.3%	 (p=	 0.013)	 and	 14.2%	 	 (p=	 0.011)	 after	
treatment	with	MDX1338	and	3.9%		(p=0.019)	and	15.2%	(p=0.022)	after	AMD3100	administration	
(Figure	14).		
Figure	14.	U2OS	apoptosis	after	treatment	with	CXCR4	inhibitors	
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5.2.8	-	Doxorubicin	–	CXCR4	inhibitor	combined	treatments		
Finally,	 SW982	and	U2OS	were	exposed	 to	 increasing	doses	of	doxorubicin	 (0.001,	0.005,0.01,0.1	
μg/ml)	 alone	 and	 combined	with	 sub-toxic	 dosed	 of	MDX1338	 (0.005	 μg	 /ml)	 and	AMD3100	 (30	
μg/ml)	for	72h.	Data	demonstrated	that	both	CXCR4	inhibitors	didn’t	change	doxorubicin	activity	in	
terms	 of	 cell	 vitality	 on	 SW982	 cells,	 with	 overlapping	 IC50	 values	 of	 doxorubicin	 (0.01	 μg/ml,	
0.0075	μg/ml,	0.018μg/ml	respectively),	combined	with	either	MDX1338	or	AMD3100	(Figure	15).	
	
Fig	15.	Cell	vitality	with	combined	treatment	of	doxorubicin	and	MDX1338	/	AMD3100	on	SW982	cells	
	
	
	
Similarly,	 U2OS	 showed	 similar	 IC50	 values	 to	 doxorubicin	 alone	 (IC50=0.04),	 as	 compared	 with	
doxorubicin	(Figure	16).	
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Fig	16.	Cell	vitality	with	combined	treatment	of	doxorubicin		
and	a)	MDX1338	or	b)	AMD3100	on	U2OS	cells	
	
We	 than	 assessed	 if	 there	 was	 synergy	 between	 doxorubicin	 and	 CXCR4	 inhibitors	 in	 term	 of	
apoptosis.	No	 significant	differences	were	 found	 in	U2OS	after	72h	of	 combined	 treatments	with	
respect	 to	 doxorubicin	 alone	 at	 a	 dose	 of	 0.01	 µM,	 while	 when	 the	 dose	 of	 doxorubicin	 was	
increased	 at	 0.05	 or	 0.1	 µM,	 a	 significant	 increase	 of	 apoptosis	 was	 observed	 with	 30	 µM	 of	
AMD3100	 (p	 =	 0.0005),	 but	 not	 significant	 change	was	 observed	 after	 combined	 treatment	with	
MDX1338	(Figure	17).	
	
Figure	17.		Percentage	of	apoptotic	cells	in	U2OS	after	combined	treatment	of	doxorubicin		(blue	
bar)	and	MDX1338	(brown)	or	AMD3100		(green)	as	compared	to	doxorubicin	alone	
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On	 the	 other	 hand,	 when	 synovial	 sarcoma	 SW982	 cell	 lines	 were	 exposed	 to	 doxorubicin	
associated	 with	 either	MDX1338	 or	 AMD3100,	 the	 apoptotic	 fraction	 increased	 as	 compared	 to	
apoptosis	after	doxorubicin	alone	(Figure	18)	(p=0.0005).	
	
	
Figure	18.	Percentage	of	apoptotic	cells	in	SW982	after	combined	treatments	
	 	
	
	
	
Finally,	we	assessed	the	synergy	of	doxorubicin	and	CXCR4	inhibitors	on	migration.		
In	 osteosarcoma,	 wound	 healing	 assay	 at	 different	 time	 points	 (24h,	 48h,	 72h)	 demonstrated	 a	
complete	wound	closure	after	72	hours	 in	osteosarcoma,	with	 similar	 inhibition	with	doxorubicin	
alone	or	combined	treatment	with	CXCR-4	inhibitors	(Figure	19).	
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Figure	19.	U2OS	migration	after	treatment	with	CXCR4	inhibitors	and	doxorubicin:	a)	Image-based	
monitoring;	 b)	 Wound	 closure	 expressed	 as	 a	 percentage	 of	 the	 initial	 wound	 area	 that	 has	
healed.	
	
	
On	the	other	hand,	wound	healing	assay	at	different	 time	points	 (24h,	48h,	72h)	demonstrated	a	
complete	 wound	 closure	 after	 24	 hours	 in	 synovial	 sarcoma,	 with	 synergic	 inhibition	 with	
doxorubicin	or	CXCR-4	inhibitors	at	48	hours,	limited	to	MDX1338	after	72h	(Figure	19).	
	
Figure	20.		SW982	migration	after	combined	treatment	with	CXCR4	inhibitors	and	doxorubicin:	a)	
Image-based	monitoring;	b)	Wound	closure	expressed	as	a	percentage	of	the	initial	wound	area	
that	has	healed.	
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6	-	DISCUSSION		
During	the	past	decade,	work	that	began	with	the	mouse	studies	by	Robert	Schreiber,	Lloyd	Old	and	
collegues	 (161-164),	 and	 that	 culminated	 with	 the	 demonstration	 that	 infiltrating	 T	 cells	 have	 a	
major	effect	on	the	clinical	attributes	of	human	cancer	(165,	166),	has	changed	the	field	of	tumour	
immunology.	 Indeed,	 a	 recent	 review	 by	 Hanahan	 and	 Weinberg	 included	 “avoiding	 immune	
destruction”	as	a	hallmark	of	cancer,	in	addition	to	the	previously	established	hallmark	of	tumour-
promoting	 inflammation	 (113).	 The	 potential	 effect	 of	 a	 patient’s	 immune	 system	 on	 clinical	
outcome	is	not	only	of	academic	interest	but	it	also	has	important	implications	for	the	identification	
of	prognostic	markers,	and	markers	that	predict	responses	to	chemotherapy	and	radiotherapy.		
A	demonstration	of	 the	effect	of	 the	host	 immune	 response	on	 tumour	 invasion,	 recurrence	and	
metastasis	has	come	from	analyses	of	the	in	situ	immune	components	and	how	these	are	organized	
within	human	 tumours	 (25,	27,	29,	30,	33,	34,	37,	39,	42,	44,	46).	 Indeed,	 immune	 infiltrates	are	
heterogeneous	between	tumour	types,	and	are	very	diverse	from	patient	to	patient.		
	
The	 aim	 of	 this	 project	 was	 to	 characterize	 osteosarcoma	 and	 synovial	 sarcoma	 tumor	
microenvironment,	to	assess	how	the	infiltrating	immune	cells	can	affect	the	prognosis	of	patients	
and	 to	 assess	 the	activity	of	 immune	modulating	 (anti-PD-1),	 antiangiogenetic	 (anti-VEGFRs,	 anti-
PDGFRs)	compounds	and	migration	inhibitors	(anti-CXCR4)	in	a	in	vitro	model	of	sarcomas.	
The	 role	 of	 microenvironment	 in	 tumor	 immune	 escape	 is	 well	 recognized.	 Several	 studies	
addressed	 the	 role	 of	 tumor	 microenvironment	 in	 pathobiology	 and	 its	 impact	 on	 survival	 of	
osteosarcoma	(52,	53,	167	–	170),	however	none	is	specific	for	osteosarcoma	in	the	localized	stage,	
nor	compared	the	prognostic	power	of	immune-infiltrate	with	the	other	validate	prognostic	factor	
routinely	used	in	clinical	practice	(147).	
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The	present	study,	including	patients	with	osteosarcoma	in	a	localized	stage,	and	treated	within	the	
same	protocol	(146)	demonstrated	an	independent	prognostic	role	of	CD8+	and	Tia1	lymphocytes.		
The	 first	 study	 demonstrating	 the	 association	 between	 CD8	 infiltrate	 and	 cancer	 specific	 survival	
was	 published	 in	 2001	 (39)	 and	 similar	 findings	 were	 subsequently	 confirmed	 among	 many	
histotypes	(see	paragraph	2.2.2.1,	Table	1,	ref	25,	27,	29,	30,	33,	34,	37,	39,	42,	44,	46).	
	
In	 the	 sarcoma	 field	 both	 a	 series	 of	 33	ostesarcoma,	 including	metastatic	 and	 localised	patients	
(52)	and	a	large	soft	tissue	sarcoma	French	study,	including	several	histotypes	and	also	low	grades	
lesions,	failed	to	demonstrate	a	prognostic	role	for	CD8+	lymphocytes	(51).	The	results	of	our	study	
are	 in	 contrast	with	 those	data	 (51,	52);	 in	 fact	a	 strong	advantage	 in	 terms	of	 survival	has	been	
observed	in	patients	with	CD8+	infiltrate.		
	
To	 investigate	 the	differentiation	state	of	 tumor-infiltrating	T	cells,	 tissues	were	analysed	 for	Tia1	
expression,	which	 is	 a	marker	of	 cytotoxic	 function:	 the	prognostic	 significance	of	CD8+	cells	was	
even	more	 relevant	when	 the	 tumor	 infiltrate	was	 characterized	by	 the	 concomitant	presence	of	
Tia1+	 lymphocytes.	 Tia1+	 lymphocytes	might	 represent	 a	more	 efficient	 subset	 of	 CD8+	 effector	
cells,	playing	an	important	role	in	immune-surveillance	of	osteosarcoma	(67).	
	
The	prognostic	 role	of	 cytotoxic	TILs	CD8/Tia1	was	also	 confirmed	after	 induction	 chemotherapy,	
while	 chemotherapy	 does	 not	 seem	 to	 induce	 significant	 changes	 in	 CD8+	 TILs:	 all	 cases	with	 no	
CD8+	TILs	prior	chemotherapy,	were	confirmed	negative	after	chemotherapy,	while	a	slight	increase	
on	score	severity	(1	to	2/3)	was	observed.	
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In	our	study,	the	rate	of	PD-L1	expression	in	IC	was	14%.	Previous	studies	on	osteosarcoma	samples	
reported	a	higher	rate	of	positive	expression	of	PD-L1(IC)	ranging	from	25%	(49)	to	74%	(70).	This	
difference	 might	 be	 related	 to	 the	 heterogeneity	 of	 the	 cases	 examined,	 being	 many	 of	 them	
metastatic,	 while	 our	 patients	 all	 had	 localized	 disease.	 In	 fact,	 it	 is	 well	 known	 that	 PD-L1	
expression	 increases	 in	 advanced	 stages	 of	 the	 diseases	 as	 reported	 by	 Sundara	 Y	 et	 al:	 13%	 in	
primary	tumours,	25%	in	local	relapses	tissue	and	48%	in	metastatic	(p	=	0.002)	(167).		
	
In	our	study	a	trend	towards	an	inferior	survival	for	positive	PD-L1(IC)	patients	was	observed.	Other	
reports	were	able	to	demonstrate	a	significantly	inferior	event-free-survival	(EFS)	for	osteosarcoma	
patients	with	positive	PD-L1(IC)	(52).	A	prognostic	role	for	PD-L1	was	also	confirmed	by	Kim	et	al,	at	
RNA	level	(67).	Interestingly,	in	our	series,	the	PD-L1(IC)	expression	has	a	prognostic	significance	at	
multivariate	 analysis	 in	 the	 subgroup	 of	 patients	 with	 CD8+	 immune-infiltrate.	 It	 might	 be	
hypothesised	that	“PD-L1”-mediated	immune-suppression	negatively	influences	CD8+	lymphocytes	
function	 (see	 in	 paragraph	2.2.1	 Figure	 1).	 In	 addition,	 it	was	 shown	 that	 tumor	 response	 to	 PD-
L1/PD-1	 inhibition	 is	 directly	 related	 to	 both	 the	 level	 of	 PD-L1	 expression	 and	 lymphocytic	
infiltration	of	the	tumor	(148,	171	–	173).		
None	of	the	patients	had	PD-L1	on	tumor	cells,	as	shown	for	other	histotypes,	such	as	colon	rectal	
and	 gastric	 carcinoma	 (174,	 175).	 About	 7%	 of	 osteosarcoma	 presented	 PD-L1	 in	 the	 neoplastic	
clone	in	the	study	by	Koirala	et	al	(52),	while	head	and	neck	squamous	cell	carcinoma,	melanoma,	
breast	 and	 kidney	 cancer	 frequently	 express	 PD-L1	 on	 the	 surface	 of	 tumour	 (148,	 176).	 Such	
variable	expression	among	different	studies	may	reflect	 the	variable	susceptibility	of	 tumour	cells	
and	 infiltrating	 immune	cells	 to	 cytokines	and	other	 stromal	 factors	 in	 the	 tumour	milieu	 (59).	 In	
fact	there	are	two	distinct	type	of	PD-L1	expression:	the	first	is	a	constitutive	(innate)	expression	on	
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tumoral	cells	membranes,	with	an	homogenous	patter;	the	second	is	adaptative,	and	can	be	found	
both	on	tumoral	cells	or	in	macrophage	(59).	
In	67%	of	the	cases	we	found	CD163+	macrophages	in	microenvironment.		CD163	was	shown	to	be	
a	useful	marker	for	M2-like	macrophages,	which	have	a	“pro-tumoral”	activity,	in	contrast	with	M1-
like	macrophages	characterized	by	a	“tumoricidal”	activity	(26)		
In	 our	 series	 no	 difference	 in	 survival	 according	 with	 presence	 of	 TAMs,	 characterized	 by	 both	
CD163	and	CD68	expression,	was	observed	(CD163+	81%	vs.	CD163-	56%,	p	=	0.17),	while	in	other	
osteosarcoma	series	a	prognostic	role	of	TAMs	was	suggested	(168,	169).	This	might	be	explained	
by	different	statistical	analysis	design	and	different	stages	of	patients	included	(168,	169).		
Our	data	 suggest	a	 role	of	 immune-infiltrate	 in	progression	of	 localized	osteosarcoma,	and	might	
support	 the	 use	 of	 immune-modulating	 agents	 in	 the	 treatment	 of	 this	 tumor.	 Of	 interest,	
mifamurtide,	 a	 modulator	 of	 innate	 immunity,	 which	 increases	 a	 wide	 variety	 of	
immunomodulatory	 molecules	 (177)	 and	 favours	 CD8	 and	 NK	 cell	 activation	 (178),	 has	 been	
approved	by	EMA	for	 the	treatment	of	patients	with	 localized	high-grade	osteosarcoma	based	on	
the	results	of	a	randomized	trial	(179).		
	
Specific	data	on	immune	infiltrate	and	synovial	sarcoma	were	lacking	till	recently	(180,	181),	and	the	
number	of	patient	with	synovial	sarcoma	included,	22	(180)	and	29	cases	(181),	is	relatively	small.	
Our	series,	 including	88	patients	with	 localized	synovial	sarcoma,	demonstrated	low	proportion	of	
cases	 with	 PD-1	 and	 PD-L1	 expression,	 both	 on	 tumor	 and	 on	 immune	 cells,	 and	 high	 CD3/CD8	
expression,	similarly	to	D’	Angelo	et	al.	CD8	TILs	had	not	prognostic	impact	in	our	series,	while	in	the	
sub-group	 of	 patients	 treated	with	 surgery	 and	 no	 adjuvant	 chemotherapy,	 cases	 CD8-	 had	 best	
		 107	
outcome	 (all	 alive	 at	 10-years).	 While	 we	 have	 no	 reason	 for	 this,	 similar	 findings	 on	 synovial	
sarcoma	were	recently	published	(180,	181).	The	presence	of	high	levels	of	CD8+	lymphocytes	in	the	
tumor	correlated	with	a	worse	metastases-free	survival	(MFS)	and	showed	a	trend	towards	worse	
EFS	 in	 a	 report	 on	22	 cases	 by	 van	 Erp	AEM	et	 al.	 (180).	 Furthermore,	Nowicki	 et	 al.	 showed	an	
association	 for	CD8	with	worse	progression-free	 survival	 (PFS),	 in	 addition	 to	worse	PFS	 for	 PD-1	
expression	in	the	tumor-invasive	margins,	in	29	patients	with	synovial	sarcoma	(181).	
	
Overall,	expression	of	 immune	checkpoint	could	be	a	positive	prognostic	marker	in	osteosarcoma,	
and	a	negative	prognostic	marker	 in	synovial	sarcoma.	Further	research	into	the	synovial	sarcoma	
immune	context	might	help	in	immunotherapeutic	approach	to	this	histotype.	
	
Immunotherapy	 for	 treatment	 of	 cancer	 has	 been	 always	 a	 fascinating	 topic.	 Immune	 cells	 are	
initially	 attracted	 to	 tumor	 cells	 by	 the	 presence	 of	 tumor	 specific	 antigens.	 Cancers	with	 higher	
mutational	 loads	 present	 greater	 numbers	 of	 tumor	 specific	 neoantigens	 and	 are	 frequently	
associated	with	robust	immune	infiltration	(182)		
	
Osteosarcoma	demonstrates	significant	genetic	complexity,	with	the	majority	of	tumors	displaying	
loss	 of	 both	 p53	 and	 RB	 (183),	 In	 addition,	 33%	 of	 primary	 osteosarcoma	 shows	 evidence	 of	
chromothripsis,	or	chromosome	shattering	(184)	and	over	50%	exhibit	kataegis,	or	localized	areas	of	
hypermutation	(185).	The	high	mutational	load	in	osteosarcoma,	along	with	the	regular	interaction	
between	 immune	 cells	 and	 bone	 cells	 in	 normal	 tissue,	 suggests	 that	 osteosarcoma	 may	 be	 an	
immunogenic	tumor	and	evasion	of	the	 immune	response	may	be	an	 important	component	of	 its	
pathogenesis.		
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Several	studies	addressed	the	role	of	NY-ESO-1	in	synovial	sacoma	and	recently,	 in	a	panel	of	108	
synovial	 sarcoma	positivity	 for	NY-ESO-1,	 PRAME,	MAGEA4	was	 confirmed	 in	 the	majority	 of	 the	
cases	(186).	
	
Although	 previous	 studies	 have	 suggested	 a	 potential	 role	 for	 immune	 cells	 in	 osteosarcoma,	 to	
date	no	study	has	provided	an	in	vitro	model	to	assess	checkpoint	inhibitors	in	sarcoma.	
	
Vascular	endothelial	 growth	 factor	 (VEGF),	 v-akt	murine	 thymoma	viral	oncogene	homolog	 (AKT),	
platelet-derived	 growth	 factor	 (PDGF),	 mitogen-activated	 protein	 kinase	 (MAPK),	 are	 variably	
expressed	 in	 osteogenic	 sarcoma,	 and	 were	 found	 to	 be	 a	 critical	 signalling	 pathway	 for	
osteosarcoma	growth	(187,188).	In	vitro	and	in	vivo	preclinical	activity	of	multi-TKI	such	as	sunitinib	
and	sorafenib	was	demonstrated	(189,190).	
	
Sunitinib	 might	 exert	 its	 immunostimulatory	 activity	 through	 the	 modulation	 of	 the	 ratio	 of	
immunostimulatory	 versus	 immunoregulatory	 cells.	 In	 fact,	 In	 addition	 to	 its	 pro-angiogenic	
function,	 VEGF	 has	 immunemodulating	 properties,	 which	 include	 increasing	 the	 influx	 of	
lymphocytes	and	DCs	into	the	tumour,	while	decreasing	the	intratumoural	frequencies	of	TReg	cells	
and	myeloid-derived	suppressor	cells	(MDSCs)	(191,192).	
	
We	sought	to	analyse	the	combined	effect	of	sunitinib	and	nivolumab	in	sarcoma	cell	lines.	Sunitinib	
was	able	 to	 inhibit	proliferation	 in	 synovial	 sarcoma	and	osteosarcoma	cell	 lines,	with	best	 result	
obtained	 after	 72	 h	 with	 10	 μM	 sunitinib.	 These	 results	 are	 similar	 to	 those	 observed	 in	 other	
studies	with	gliomas	(193)	and	osteosarcomas	(194).	
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We	addressed	the	expression	rate	of	PD-L1	in	sarcomas	cell	lines:	the	range	of	expression	was	wide,	
from	 20%	 to	 40%	 for	 synovial	 sarcoma,	 and	 from	 20	 to	 80%	 for	 osteosarcoma.	 It	 was	 recently	
reported	 that	 the	 expression	 of	 programed	 PD-L1	 in	 the	 immune	 component	 increased	 with	
pazopanib	therapy,	while	CD8	expression	decreased	(195).	
	
It	 is	 unclear	 if	 the	 same	 happens	with	 sunitinib	 (196,197),	 but	 at	 least	 in	 one	 case	 report	 PD-L1	
tumor	expression	by	immunohistochemistry	was	higher	in	the	post-	sunitinib	tumor	tissue	sample,	
as	compared	with	pre-sunitinib	tumor	tissue	sample,	the	number	of	stained	tumor	cells	(198).	
	
We	showed	that	sunitinb	was	able	to	 immunomodulate	the	expression	of	PD-L1	 in	3	out	of	4	cell	
lines	assessed,	with	a	dose-dependent	up-regulation	for	the	osteosarcoma	cell	line	SaOS-2.	We	also	
demonstrate	 dose-dependent	 cell	 death	 in	 osteosarcoma	 cells	 and	 synovial	 sarcoma	 cell	 lines	
treated	with	 sunitinib,	with	 a	 significant	 increase	observed	with	 lower	 concentration	 (10	μM)	 for	
osteosarcoma	 MG-63	 cell	 line	 and	 100%	 apoptotic	 rate	 at	 30	 μM;	 on	 the	 other	 hand	 synovial	
sarcoma	 required	 higher	 concentration	 (20	 μM)	 and	 were	 only	 partially	 sensitive	 to	 sunitinib	
treatment.	
	
We	than	assessed	the	effect	of	nivolumab	and	we	were	able	to	demonstrate	that	nivolumab	/PD-1	
blockade	might	hamper	sarcoma	tolerance,	by	decreasing	PD-1	expression:	 infact,	coculturing	PD-
L1-positive	 sarcoma	 cell	 lines	 and	 lymphocyte	we	 induced	 PD-1	 expression	 on	 lymphocyte;	 after	
nivolumab	 PD-1	 was	 reduced.	 Notably,	 we	 identified	 a	 subgroup	 of	 activated	 lymphocytes	 and	
found	that	this	sub-population	of	lymphocytes	was	specifically	sensitive	to	nivolumab	PD-1	induced	
immune-modulation,	with	PD-1	expression	 completely	abolished	after	 treatment	with	nivolumab.	
We	are	planning	to	further	characterize	these	activated	lymphocytes	to	assess	their	potential	role	in	
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predicting	response	to	nivolumab	treatment.	
	
Trial	addressing	the	immune-modulator	effect	of	sunitinib	combined	with	nivolumab	in	metastatic	
renal	cell	carcinoma	(mRCC)	were	performed,	and	compared	to	pazopanib	combination	(199)	mRCC	
patients	 (≥1	 prior	 systemic	 therapy)	 received	 nivolumab	 in	 combination	with	 sunitinib	 (50	mg,	 4	
weeks	on,	2	weeks	off)	or	pazopanib	(800	mg	daily),	until	progression	or	unacceptable	toxicity.		
Responses	were	seen,	by	first	assessment	(6	weeks),	in	56%	and	41%	of	pazopanib/nivolumab	and	
sunitinib/nivolumab	respectively	(199).	PFS	rate	at	24	weeks	was	78%	for	sunitinib	arm	and	55%	for	
pazopanib	arm,	while	 in	a	non-inferiority	phase	 II	 trial	 in	 renal	 carcinoma	 (200)	 response	 rates	of	
31%	and	24%	 for	 pazopanib	 and	 sunitinb	 respectively,	were	 reported,	 suggesting	 that	 nivolumab	
might	 me	 synergic	 with	 TKI	 in	 the	 contest	 of	 kidney	 cancer.	 Only	 recently,	 a	 phase	 I-II	 trial	
addressing	the	 impact	of	 immune	modulation	on	the	efficacy	of	sunitinib	via	 its	potential	synergy	
with	anti	PD-1	the	context	of	sarcomas	(https://clinicaltrials.gov/ct2/show/NCT03277924)	and	will	
enrol	soft	tissue	sarcoma	and	bone	sarcomas.	 In	particular,	high	grade	soft	tissue	sarcoma	will	be	
included.	 It	 might	 be	 anticipated	 that	 some	 histotypes	 such	 as	 undifferentiated	 pleomorphic	
sarcoma	 (UPS)	 and	 synovial	 sarcoma	 might	 be	 more	 sensitive	 to	 this	 approach,	 being	 more	
frequently	diagnosed	in	patients	immune-suppressed	due	to	transplant	(201)	and	proven	sensitive	
to	pazopanib	in	the	PALETTE	phase	III	trial	(202).		
The	 rationale	 of	 using	 nivolumab	 in	 bone	 sarcoma	 includes	 anectodal	 report	 of	 spontaneous	
regression	 in	 osteosarcoma	 (203)	 and	 genomic	 instability	 described	 for	 both	 osteosarcoma	 (204)	
and	Ewing	sarcoma	(205,	206).	 It	 is	 in	fact	well	known	that	numeric	alterations	of	the	PD-1	ligand	
loci	 (207),	 higher	 neoantigen	 burden,	 and	 DNA	 repair	 pathway	 mutations	 (208)	 might	 increase	
sensitivity	 to	 immune-treatment.	 Nevertheless,	 data	 of	 the	 SARC28	 trial,	 on	 the	 use	 of	
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pembrolizumab	monotherapy	both	 in	bone	and	 in	soft	tissue	sarcoma	are	disappointing,	with	the	
exception	of	specific	histotypes	such	as	undifferentiated	pleomorphic	sarcoma	or	dedifferentiated	
liposarcoma	 (105).	 Enrolment	 to	 expanded	 cohorts	 of	 those	 subtypes	 is	 ongoing	 to	 confirm	 and	
characterize	the	activity	of	pembrolizumab	in	sarcoma.		
Therefore	 it	 is	 important	 to	 find	way	 to	 enhance	 response	 to	 immune-modulator	 and	 to	 identify	
predictive	factors	of	response.	For	example,	 it	was	demonstrated	that	melanoma	patients	express	
higher	 levels	of	PD-L1	on	circulating	T	 cells	 than	healthy	volunteers,	 and	higher	PD-L1	expression	
together	with	 CD137	 expression	 on	 blood	 CD8+	T	 cells	 predicts	 sensitivity	 to	 the	 combination	 of	
anti-CTLA-4+	anti-PD-1	treatment	(209).	
	
Characterize	 peripheral	 blood	 lymphocytes	 changes	 over	 sunitinb	 and	 nivolumab	 treatment	 and	
studying	 CD8/PD-L1	 co-expression	 might	 help	 to	 guide	 treatment	 in	 this	 difficult	 setting.	 In	 this	
contest,	the	Immune	Biomarkers	Task	Force	of	the	Society	for	Immunotherapy	of	Cancer	(SITC),	an	
international	multidisciplinary	panel	of	 experts,	 proposed	guidelines	on	predictors	of	 response	 to	
immunotherapy,	 focusing	on	 the	complexity	of	 the	 tumor	microenvironment,	with	 its	diversity	of	
immune	genes,	proteins,	and	pathways	naturally	present	at	baseline	and	in	circulation	(210).		
	
In	the	last	experiment	of	our	project,	ongoing,	DCs	pulsed	with	synovial	sarcoma	and	osteosarcoma	
cell	lines	pre-treated	with	sunitinib	will	be	cocultured	with	lymphocytes	and	ability	of	nivolumab	to	
ambrogate	PD-1	expression	will	be	compared	to	that	of	nivolumab	on	lymphocytes	cocultured	with	
DCs	pulsed	with	untreated	cell	lines.	
Last,	 we	 addressed	 the	 role	 of	 stromal	 cell-derived	 factor	 1	 (SDF-1	 or	 CXCL12)	 and	 its	 receptor	
chemokine	 receptor	 4	 (CXCR4)	 in	 sarcoma	 progression.	 Metastasis	 is	 in	 fact	 a	 highly	 organized	
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process	and	various	molecular	 families	are	 involved	 in	 cancer	metastases	and	with	 tumor-storma	
interactions,	 or	 tumor	 microenvironment	 interaction.	 The	 tumor	 microenvironment	 consists	 of	
resident	 non-cancerous	 cells	 (stromal	 fibroblasts,	 endothelial	 cells	 and	 immune	 cells),	 connective	
tissue	and	extracellular	matrix,	altogether	supporting	tumor	structure,	angiogenesis	and	growth.		
	
Mounting	evidence	indicates	that	chemokines	and	their	specific	receptors	play	a	vital	role	in	organ-
specific	metastasis.	SDF-1	or	CXCL12	and	its	receptor	CXCR4	have	been	extensively	studied	and	are	
involved	 in	 tumorigenicity,	 proliferation,	metastasis	 and	 angiogenesis	 in	multiple	 human	 cancers	
(211-215).			
CXCR4	 antagonist	 can	block	 CXCR4/	 SDF-1	 interaction	 and	has	 been	 shown	effective	 in	 inhibiting	
tumor	cell	metastasis	by	targeting	various	pathways	(140-145,216).	But	there	are	few	studies	about	
the	combined	effect	of	CXCR4	antagonist	and	chemotherapy	on	sarcoma	cells	survival	and	growth.			
To	 confirm	 the	 positive	 effect	 of	 SDF-1-CXCR4	 axis	 on	 sarcoma	 survival	 and	metastasis,	 we	 first	
measured	 the	 expression	of	 CXCR4	 and	 SDF-1	 in	 several	 osteosarcoma	and	 synovial	 sarcoma	 cell	
lines.	We	showed	that	the	expression	of	CXCR4	and	SDF-1	were	varying	in	different	cell	lines	and	no	
obvious	correlation	was	found	between	the	expression	of	CXCR4	and	SDF-1	(CXCL12).			
This	is	in	contrast	with	other	studies	on	chronic	lymphocytic	leukemia	(CLL),	showing	no	expression	
of	CXCL12	by	flow	cytometry	and	CXCL12	gene	expression	by	RT-PCR	was	also	negative	in	the	large	
majority	 of	 samples	 (216),	 while	 it	 confirmed	 other	 recent	 findings	 on	 osteosarcoma	 (217).	 This	
difference	might	reflect	histotype-specific	homing	pathway	and	suggests	that,	unlike	in	sarcomas,	in	
CLL	 the	 activation	 of	 CXCR4	 induced	 by	 CXCL12	 occurs	 either	 by	 cell-cell	 interactions	 with	 non-
leukemia	 CXCL12	 expressing	 cells,	 likely	 located	 in	 lymphatic	 tissues,	 or	 mediated	 by	 soluble	
CXCL12.	 Also,	 inverse	 correlation	 for	 CXCR4	 expression	at	gene	and	protein	level	was	noted,	
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with	osteosarcoma	cell	line	U2OS	presenting	low	expression	of	CXCR4	m-RNA	and	98%	positivity	for	
protein	 FACS	 analysis,	 while	 synovial	 sarcoma	 (SYO-1	 cell	 line)	 presented	 high	 levels	 of	 CXCR-4	
mRNA	and	only	12%	protein	expression.	
Several	studies	have	reported	that	BM-MSCs,	which	are	known	to	be	involved	in	tissue	homeostasis	
and	 regeneration	 can	 be	 recruited	 into	 primary	 tumors	 and	 become	 active	 components	 of	 the	
tumor	 microenvironment,	 such	 as	 cancer-associated	 fibroblasts	 (CAFs)	 (218,219)	 BM-MSCs	
contribute	 to	 tumor	 cell	 growth	and	metastatic	 behavior	 in	 a	 variety	of	 cancers,	 including	breast	
(220),	colon	cancer	(221)	and	osteosarcoma	(222-225).		
In	a	 study	by	Fontanella	et	al,	 the	 role	of	BM-MSCs	 in	promoting	growth,	migration	and	 invasion	
was	addressed	 in	osteosarcoma	and	hepatocellular	 carcinoma	cell	 lines	demonstrating	 that	when	
these	cell	lines	were	treated	for	24h	with	conditioned	medium	from	BM-MSCs,	a	significant	increase	
was	observed	in	CXCR4	mRNA	and	protein	levels		was	observed	(226).	We	demonstrated	that	levels	
of	SDF-1	(CXCL12)	protein	was	higher	 in	BM-MSC-CM,	when	compared	to	αMEM	alone,	or	αMEM	
supplemented	with	25%	BM-MSC	(see	in	paragraph	5.3.2	Table	3).	Therefore	we	used	BM-MSC-CM	
to	test	the	activity	of	CXCR4	inhibitors.	
As	 a	 noncompetitive	 CXCR4	 inhibitor,	 AMD3100	 can	 block	 the	 SDF-1-CXCR4	 axis.	 The	 inhibition	
effect	 of	 AMD3100	 on	 migration,	 invasion	 and	 metastasis	 of	 various	 cancer	 cells	 has	 been	
confirmed	by	a	large	amount	of	experimental	researches	(227).	
Ulocuplumab	(BMS-936564)/MDX1338	is	a	first	in	class,	fully	human	IgG4	monoclonal	antibody	that	
has	 been	 engineered	 to	 specifically	 bind	 to	 CXCR4	 (228).	 In	 vitro	 studies	 have	 shown	 that	
Ulocuplumab	 (BMS-936564)	has	 a	potent	 anti-tumor	activity	 in	 established	 tumor	 including	AML,	
NHL,	 and	multiple	 myeloma	 xenograft	 models		 (228).		
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However,	researches	focused	on	the	effect	of	AMD3100	and	MDX1338	on	migration,	and	data	on	
proliferation	and	apoptosis	are	scarce.		
Furthermore,	 CXCR4	 expression	 seems	 to	 play	 a	 role	 in	 resistance	 to	 chemotherapy	 in	 synovial	
sarcoma	(124)	and	this	is	the	first	study	addressing	SDF1-CXCR4	axis	role	in	this	histotypes.	
We	speculated	that	AMD3100	and	MDX1338	may	have	strong	activity	in	osteosarcoma	and	synovial	
sarcoma	 vitro	 and	 that	 the	 activity	 was	 synergic	 with	 chemotherapy.	 The	 results	 of	 our	 in	 vitro	
experiments	showed	that	treatment	with	MDX1338	and	AMD3100	was	able	to	reduce	SW983	and	
U2OS	proliferation,	without	changing	CXCR4	expression	in	sarcoma	cell	lines.	
Also,	this	study	confirmed	that	both	drug	were	able	to	reduce	SW982	and	U2OS	cells	migration.	The	
ability	to	induce	apoptosis	was	confirmed	when	drugs	were	employed	alone	(Figure	13),	especially	
after	72	h.	
Combined	 treatment	 with	 doxorubicin	 and	 MDX1338	 /AMD3100	 was	 not	 synergic,	 with	 over-
imposable	curves	in	terms	of	cell	vitality.	
The	apoptotic	 rate	was	no	 significantly	different	after	72h	of	 combined	 treatments	doxorubicin	+	
MDX1338,	with	 respect	 to	 doxorubicin	 alone,	while	 a	 slight	 increase	 only	 after	 doxorubicin	with	
AMD3100	was	observed,	although	this	difference	was	not	significant.	
In	 conclusion,	 our	 results	 showed	 AMD3100/MDX1338	 could	 effectively	 induce	 apoptosis	 and	
inhibition	of	proliferation	and	invasion	of	osteosarcoma	and	synovial	sarcoma	cells.	
When	 combined	 with	 chemotherapy,	 CXCR4	 inhibitors	 did	 not	 increase	 proliferation	 inhibition,	
while	 AM3100	 combined	 with	 doxorubicin	 (not	 MDX1338)	 was	 able	 to	 increase	 apoptosis	 as	
compared	 to	 doxorubicin	 monotherapy	 in	 osteosarcoma	 cell	 lines.	 Also,	 both	 AM3100	 and	
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MDX1338,	 demonstrated	 synergic	 activity	 in	 synovial	 sarcoma	 cell	 line	 SW982,	when	doxorubicin	
was	employed	at	a	dose	of	0.1	µM.		
Last,	in	synovial	sarcoma,	inhibition	of	migration	was	significantly	increased	when	doxorubicin	was	
combined	with	CXCR4	inhibitors,	as	compared	to	doxorubicin	alone.	
Among	 several	 CXCR4	 inhibitors,	 Plerixafor	 (AMD3100),	 already	 approved	 for	 poor	 mobilizer	
patients	in	bone	marrow	transplant	program,	has	reached	clinical	testing.		
For	instance,	phase	I-II	trial	with	chemotherapy	combined	with	Plerixafor,	or	other	CXCR4	inhibitors	
are	 ongoing	 (Table	 1),	 and	will	 confirm	 the	 potential	 chemosentitizing	 effect	 of	 this	 approach	 in	
several	hematologic	and	solid	tumors,	including	Ewing	sarcoma.	
	
	
Table	 1.	 Ongoing	 clinical	 trials	 with	 CXCR4	 inhibitors	 in	 hematologic	malignancies	 and	 in	 solid	
tumors	
	
Chronic	lymphoid	leukaemia;	MM	multiple	myeloma,	NHL	Non	Hodgkin	lymphoma	
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7	-	CONCLUSIONS	
In	 conclusion,	 CD8/Tia1	 cytotoxic	 T-lymphocytes	 emerge	 as	 an	 important	 mediator	 of	 the	 anti-
tumor	immune	response.	Also,	this	study	highlights	the	prognostic	role	of	tumor	microenvironment	
in	the	setting	of	localized	osteosarcoma.	The	data	are	intriguing,	but	a	clinical	application	requires	
confirmations	 in	 other	 series	 in	 order	 to	 use	 immune-stratification	 to	 plan	 treatment	 strategy	
(Figure	4).		
Figure	4.	Proposal	for	‘Immune-infiltrate	based	treatment	algorithm’	for	localized	osteosarcoma.	
	
Effort	to	standardize	immune-infiltrate	scoring	system,	including	PD-L1	thresholds,	CD8	density	and	
location	 (invasive	margin	versus	 central	 tumor)	are	ongoing,	 and	an	 international	 consortium	has	
been	 initiated	 to	 validate	 and	 promote	 the	 Immunoscore	 in	 routine	 clinical	 settings	 (229).	 The	
results	of	this	international	consortium	may	result	in	the	implementation	of	the	Immunoscore	as	a	
prognostic	tool,	designated	TNM-I	(TNM-Immune),	and	might	also	serve	to	guide	design	predictive	
study	to	immunotherapeutics.		
In	 the	 era	 of	 immunotherapy,	modulation	 of	 immune	 response	with	 chemotherapy	 or	 anti-VEGF	
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targeted	compound	represent	an	important	area	of	research.		
Tumor	-	stroma	interaction	has	emerged	has	an	important	player	of	chemotherapy	resistance	and	
possibly	with	immune-resistance,	since	the	administration	of	a	CXCR4	inhibitor	was	synergic	with	α-
PD-L1	antibody	in	a	mice	model	of	pancreatic	cancer	(230).	
Effort	 to	 better	 combine	 tumor-targeted	 agent	 with	 microenvironment	 target	 drugs	 might	
represent	 the	 key	 to	 increase	 the	 survival	 plateau	 reached	 for	 many	 aggressive	 solid	 tumors,	
including	sarcomas.	
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